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There is mounting evidence that implicates reactive oxygen species (ROS) as an 
important signaling molecule in various physiological processes. In contrast to the 
wealth of information on gene up-regulation by ROS, little attention has been paid to 
the down-regulation of gene expression by ROS. In this thesis, we have studied how 
two important genes, estrogen receptor alpha (ERα) and sodium hydrogen exchanger 
1 (NHE1) were redox-regulated by H2O2. 
In the first part of the study, the regulation of ERα by oxidative stress induced by the 
exposure of MCF7 cells to H2O2 was investigated. The data supported that ERα 
protein is down-regulated when exposed to oxidative stress. The down-regulation of 
ERα protein occurs not through proteosomal degradation pathway, but via the 
decrease in ERα mRNA level. We found that Akt, MAPK and caspases were not 
involved in the down-regulation of ERα by H2O2. Instead, H2O2 inhibition of ERα 
expression involves an oxidation event that is reversible by the addition of reducing 
agent, DTT. We also demonstrated that 15d-PGJ2 suppressed ERα expression via the 
production of ROS. ERα down-regulation resulted in decreased ERα-responsive gene 
expression and impaired estrogen signaling. These effects could have contributed to 
the growth arrest observed in H2O2 treated MCF7 cells. 
In the second part of the study, the down-regulation of NHE1 by H2O2 was examined. 
We found that the minimal promoter region required for full transcription activation 
lies on the 0.15kb of NHE1 promoter. This region is also regulated by H2O2. The 
regulation of NHE1 by H2O2 is similar to the regulation of ERα. H2O2 targets NHE1 
at the mRNA level in a reversible manner. The down-regulation involves an oxidation 
mechanism which is reversible by reducing agents DTT and BME. The drug 15d-
iv 
 
PGJ2 was also shown to down-regulate NHE1 promoter activity via the production of 
ROS. Finally, the data suggested that AP2 is not the transcription factor for NHE1 and 
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CHAPTER 1: INTRODUCTION 
1.1 FREE RADICALS, REACTIVE SPECIES AND REDOX BALANCE 
1.1.1 Reactive oxygen species 
Reactive oxygen species (ROS) are a group of molecules generated in the cell from 
the partial reduction of oxygen (O2) as byproducts of aerobic metabolism. The radical 
species includes superoxide anion (O2·-) and hydroxyl radical (OH·), while hydrogen 
peroxide (H2O2) is the main non-radical species. The O2·-, the precursor of most other 
ROS, is formed from the reduction of triplet-state molecular oxygen (3O2) in a process 
mediated by membrane NADPH oxidase (Nox), xanthine oxidase, or leakage from the 
mitochondria electron transport chain (Dröge, 2002). In the cells, superoxide 
dismutase (SOD) dismutates O2·- into H2O2 (Deby and Goutier, 1990), and H2O2 can 
be converted into highly reactive OH· in the presence of reduced transition metal such 
as ferrous iron (Fe2+) through the Fenton reaction : 
Fe2+ + H2O2  Fe3+ + OH· + OH 
OH· is highly reactive and is toxic to the cell due to its propensity to react and cause 
damage to a wide range of cellular components, including DNA, proteins, and lipids 
(Stinefelt et al., 2005). Other than forming OH·, H2O2 can also be converted to water 
(H2O) through catalase, glutathione peroxidase (GPx) or peroxiredoxins (Prx) (Day, 
2009). In addition to forming H2O2 and OH·, O2·- also reacts with nitrite oxide (NO·) 
to from a highly reactive oxidant, the peroxynitrite (ONOO-) (Jourd'heuil et al., 2001). 





Figure I: Pathways of reactive oxygen species (ROS) production and clearance. 
Glutathione (GSH), glutathione disulfide (GSSG). Adapted from (Dröge, 2002). 
 
 1.1.1.1 Mitochondria electron transport chain 
The mitochondria electron transport chain (ETC) is an important source of ROS 
production in most mammalian cells (Turrens, 2003; Balaban et al., 2005; Andreyev 
et al., 2005). The ETC, found at the inner membrane of the mitochondria, is a multi-
complex system which utilizes oxygen to generate energy in the form of adenosine 
triphosphate (ATP). It is composed of a series of electron carriers (flavoproteins, iron-
sulfur proteins, ubiquinone and cytochromes) arranged into four complexes (Liu et al., 
2002). The ETC complex I accepts electrons from NADH and passes them through 
flavin and iron-sulfur centers to ubiquinone (Buchanan and Walker, 1996). Complex 
II uses succinate as substrate and provides electrons to ubiquinone. Complex III 
accepts electrons from ubiquinone and passes them on to cytochrome c (Trumpower, 
1990). Complex IV transfer electrons from cytochrome c to O2, producing H2O. In the 
mitochondria, O2·- is produced by the one-electron reduction of O2 and O2·- mediates 
oxidative chain reactions (Turrens, 2003). Figure II shows the sites of O2 production 
at the ETC.  Approximately 2% of O2 is converted into O2·- through the ETC (Chance 
3 
 
et al., 1979). Complex I and III are shown to be the major sites of O2·- production by 
the ETC (Turrens and Boveris, 1980; Turrens et al., 1985; Liu et al., 2002). While 
complex II has been shown to be capable of producing O2·- under certain 
circumstance of dysfunction, complex IV is not known to release ROS (Senoo-
Matsuda et al., 2001; Lemarie et al., 2010). The ROS produced by the ETC 
contributes not only to damage in the mitochondria but is also crucial in the redox 
signaling of the cell.  
 
 






1.1.1.2  NADPH oxidase 
Another important contributor of ROS in the cells is the membrane bound NADPH 
oxidase complex. Initially discovered in phagocytic cells, the NADPH oxidase (Nox2) 
is found to be responsible for oxidative burst to fight against invading microorganisms 
(Nauseef, 2004). In phagocytes, the complex is made up of a membrane-spanning 
heterodimeric protein (flavocytochrome b588) which comprises pg91phox and 
p22phox; and cytosolic proteins p47phox, p67phox, p40phox and small GTP-binding 
protein Rac (Rac1 and Rac2) (Babior, 1999). Upon stimulation, the cytosolic 
components of the complex are recruited to the flavocytochrome b588 to catalyze the 
conversion of O2 to O2·- (Groeger et al., 2009). Some of this O2·- is converted to H2O2 
by Cu/Zn SOD in the cytosol. Figure III shows the assembly of Nox 2 in phagocytic 
cell. Similar NADPH oxidase systems have also been found in non phagocytic cells. 
Nox1 is the homolog of gp91phox and is found to be expressed in colon epithelial and 
other various cell types (Takeya et al., 2006). Noxo1 and Noxa1 are homolog of 
p47phox and p67phox respectively (Bánfi et al., 2003; Geiszt et al., 2003; Cheng and 
Lambeth, 2004). Nox1 complexes with p22phox and interacts with Noxo1 and Noxa1 
to produce O2·- (Ambasta et al., 2004; Sumimoto et al., 2004).  Other forms of non-
phagocytic NADPH oxidases that exist include three Nox complexes (Nox3-Nox5) 
and two dual oxidases (Duox1 and Duox2) (Groeger et al., 2009). The exact 
composition of these non-phagocytic NADPH oxidases and the mechanism of ROS 
production have not yet been completely elucidated. However, it is known that the 
activation of signaling pathways involving cytokine receptors, G-protein coupled 
receptors, receptor tyrosines and serine/threonine kinases can lead to ROS production 
from these Nox complexes (Sauer et al., 2001). Nox-produced ROS can also play a 
role in pathologies such as nephropathy, cardiovascular diseases, liver fibrosis and 
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pulmonary diseases (Li and Shah, 2003; Dworakowski et al., 2006; Minicis and 
Brenner, 2007; Pantano et al., 2007). 
 
 
Figure III: Assembly of Nox2 in phagocytic cell. Adapted from (Groeger et al., 2009). 
 
1.1.2 The antioxidant system 
The amount of reactive species in the cell is determined by the rate of their production 
and the rate of clearance by various antioxidant enzymes and compounds in the cell 
(Dröge, 2002). Antioxidants are defined as substances that are able to compete with 
other oxidizable substrates at a relatively low concentrations, thus slowing down or 
preventing the oxidation of those substrates (Halliwell and Gutteridge, 2007). While 
transient increase in ROS plays a role in redox signaling, excessive level or chronic 
production of ROS will lead to oxidative stress (Jones, 2008). High level of ROS in 
the cell can cause damage to a wide range of molecules including lipid peroxidation, 
DNA adduct formation or strand breaks, and oxidation of proteins which inhibits their 
functions. In mammalian cells, antioxidant defense systems are present to maintain 
the redox balance and reduce the damage caused by ROS. The SOD system plays a 
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key role in the removal of excessive O2·- from the cell. It converts O2·- into H2O2. 
There are three SOD isoforms found in mammalian cells: cytosolic Cu/Zn SOD 
(SOD1), mitochondria Mn SOD (SOD2), and extracellular SOD (EC SOD) (Choung 
et al., 2004). H2O2 in the cells are in turn removed mainly by three groups of enzymes: 
glutathione peroxidase (Gpx) system, thioredoxin peroxidase (peroxiredoxins) system 
and catalase (Dringen and Hamprecht, 1997) . While catalase catalyses the direct 
decomposition of H2O2 to O2 and H2O, Gpx removes H2O2 by coupling its reduction 
to H2O with the oxidation of glutathione (GSH) to glutathione disulfide (GSSG). 
GSSG is reduced back to GSH by NADPH-dependent glutathione reductase. The 
thioredoxin peroxidase removes H2O2 by coupling its reduction to H2O with the 
oxidation of thioredoxin (Trx). Oxidized form of Trx is reduced back by NADPH 
dependent thioredoxin reductase (Veal et al., 2007). Figure IV illustrates the removal 
of H2O2 by glutathione peroxidase and thioredoxin peroxidase systems. Several other 
non-enzymatic compounds also participate in the removal of ROS in the cell and they 





Figure IV: The redox-cycling reactions involved in the catalytic removal of hydrogen 
peroxide by the glutathione peroxidase and thioredoxin peroxidase systems. Glutathione 
peroxidases (Gpx), peroxiredoxins (Prx) selenocysteine (SeH), cysteine (SH), glutathione 
(GSH) disulphide glutathione (GSSG), thioredoxin (Trx), sulfenic acid (SOH), and sulfinic 
acid (SOOH). Adapted from (Veal et al., 2007). 
 
1.1.3 Hydrogen peroxide as a signaling molecule 
It has been established in recent years that H2O2 is an important regulator of signal 
transduction in addition to its cytotoxic activity. H2O2 is produced in response to a 
variety of extracellular stimuli and the inhibition of H2O2 production leads to the 
attenuation of downstream cell signaling of the stimuli (Rhee, 2006; D'Autréaux and 
Toledano, 2007). Stimulation of human epidermoid carcinoma cells with epithelial 
growth factor (EGF) transiently increased H2O2 in the cells. This H2O2 production is 
important for the EGF-induced tyrosine phosphorylation of various cellular proteins 
including EGF receptor and phospholipase C-γ1(Bae et al., 1997). Scavenging of 
H2O2 produced in response to platelet-derived growth factor (PDGF) inhibits cellular 
signaling such as tyrosine phosphorylation, mitogen-activated protein kinase 
stimulation, DNA synthesis, and chemotaxis in rat vascular smooth muscle cells 
(Sundaresan et al., 1995).  
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Upon oxidative stress or stimulation with growth factors there is an increase in 
tyrosine phosphorylation level of numerous proteins (Schieven et al., 1993; Schieven 
et al., 1993; Nakamura et al., 1993; Hardwick and Sefton, 1995; Rhee, 2006). (Woo et 
al., 2010). H2O2 can promote tyrosine phosphorylation by activating protein tyrosine 
kinases (PTKs). One such example is the activation of the tyrosine kinase Src through 
oxidation at two cysteine residues by H2O2 upon cell attachment to extracellular 
matrix (Giannoni et al., 2005). The activation of PTKs alone is however insufficient 
to increase steady-state protein tyrosine phosphorylation level in the cells. The 
concurrent inhibition of protein tyrosine phosphatases (PTPs) is required (Woo et al., 
2010). H2O2 can inactivate PTPs by oxidizing the catalytic cysteine residue of these 
enzymes, thus inhibiting their activities (Chiarugi and Cirri, 2003; Tonks, 2005; Rhee 
et al., 2005). It was recently shown that the high level of H2O2 required in the cell to 
inhibit PTPs was achieved by the transient phosphorylation and inactivation of 
peroxiredoxin I at tyrosine-194 following stimulation of growth factor or immune 
receptors  
H2O2 is also known to be involved in the activation of MAPK cascade. Angiotensin II 
induces the production of H2O2 and activates ERK 1/2 and p38 MAPK to promote 
hypertrophy in vascular smooth muscle cells (Ushio-Fukai et al., 1998). More recently, 
H2O2 have been shown to activate p38 MAPK to regulate the translocation of 
fibroblast growth factor 1 (FGF1) into the cytosol and nucleus (Sørensen et al., 2008). 
The serine/threonine kinase protein kinase C (PKC) can be activated by H2O2 through 
tyrosine phosphorylation of the PKC catalytic domain (Konishi et al., 1997; Lin and 
Takemoto, 2005). The cytosolic Ca2+ level also plays an important role in signal 
transduction in the cell (Clapham, 2007). The level of Ca2+ can be modulated by H2O2 
through mobilization of intracellular Ca2+ store or through the influx of extracellular 
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Ca2+ (Roveri et al., 1992; Doan et al., 1994; Hecquet et al., 2008; Giambelluca and 
Gende, 2008). In summary, H2O2 fulfils five criteria to act as a signaling molecule or 
second messenger in cells and this is summarized in Table I. 
 
Table I: Characteristics of H2O2 as second messenger. Summarized from (Forman, 
2007) 
Characteristics of second messenger H2O2 as second messenger 
Increases in concentration occur through: 
 
1) enzymatic generation 
 
2) regulated release into the cytosol from 
sites of higher concentration through 
channels 
 
H2O2 increases in concentration through 
enzymatic generation by oxidoreductases and 
DuOXs and from dismutation of O2•− 
Decreases in concentration through: 
 
1) enzymatic degradation 
 
2) restoration of the concentration gradients 
by the action of pumps 
 
3) diffusion from the cell enhanced by 
reaction or binding of the second messenger 
in another cell 
 
H2O2 decreases through enzymatic 
degradation catalyzed by catalase, 
glutathione peroxidases and peroxiredoxins 
Intracellular concentration rises and falls 
within a short period 
 
H2O2 concentration rises and falls within a 
short period from a steady state of nanomolar 
 
Specific in action 
 
Specific in action 
Gradients of their concentration from their 
origin to where they are either degraded or 
sequestered determines where they are 
effective 
 
H2O2 react within a few molecular diameters 
of its site of production with its target effecter 
due to high distribution of glutathione 







1.2 REDOX REGULATION OF GENE EXPRESSION 
The regulation of gene expression is the control of the level and timing of appearance 
of the functional product of a gene. A shift in the redox balance in the cell due to 
either increase in ROS production or diminished antioxidant capacity can affect 
cellular components. Redox system can regulate the expression of a gene through its 
transcription, mRNA stability, posttranslational modifications, and protein stability 
(Trachootham et al., 2008). 
 
1.2.1 Transcriptional regulation 
The regulation of gene expression starts at the transcriptional level, and is a tightly 
regulated process. In response to changes in the redox environment, various genes are 
up-regulated to enable the cells to cope with the changes. This is mediated through 
redox control of transcription factors. Some of the better studied redox responsive 
transcription factors are NFκB, AP1 and Nrf2.  
 
1.2.1.1  NFκB 
Nuclear factor kappa B (NFκB) is a redox sensitive factor that is involved in 
immunity, inflammation, cell proliferation, development, and cell survival 
(Trachootham et al., 2008). In mammals, the NFκB consist of five members: p50, p52, 
p65 (RelA), c-Rel, and Rel-B. These members can form various combinations of 
homo- and heterodimers. Normally, NFκB is sequestered in the cytosol by inhibitors 
of kappa B (IκB) (Hayden and Ghosh, 2004). Upon oxidative stress, IκB kinase (IKK) 
is activated and phosphorylates IκB, which leads to the release of NFκB from IκB. 
NFκB can then translocate to the nucleus and bind to the promoter region of target 
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genes. In response to oxidative stress, NFκB up-regulates anti-apoptotic genes such as 
Bcl-xL, A1/Bfl-1, FLIPL, IAPs and TRAF1. It also up-regulates Gadd45, which 
inhibits JNK-induced cell death and it activates antioxidants genes such as MnSOD 
and ferritin heavy chain (Karin and Lin, 2002). 
 
1.2.1.2  AP-1 
The AP-1 transcription factor belongs to the leucine zipper domain family of protein 
that includes Fos and Jun (Curran, 1992). AP-1 proteins form heterodimers and bind 
to their DNA target sequence-12-O-tetradecanoyl phorbol-13-acetate (TPA) response 
element (TRE) (Risse et al., 1989). AP-1 controls the expression of large number of 
genes by binding to the TRE in the promoters regions of these genes (Vollgraf et al., 
1999; Toualbi et al., 2007). AP-1 activation could lead to either cell 
survival/proliferation or cell death depending on the circumstance of activation 
(Shaulian and Karin, 2002). The activity of AP-1 is controlled at the transcriptional, 
posttranscriptional and posttranslational level (Hunter and Karin, 1992; Karin, 1995). 
The activity and expression of AP-1 are both inducible by H2O2 (Li and Spector, 1997; 
Chung et al., 2002). Oxidative stress can activate c-Jun via phosphorylation at Ser63 
and Ser73 by activated JNK (Karin, 1995; Li et al., 2004). Oxidative stress can also 
promote the activation of AP-1 through histone acetylation by inhibiting histone 





1.2.1.3  Nrf2  
Nrf2 is a key transcription factor involved in the protection against oxidative stress. 
Activation of Nrf2 induces transactivation of many antioxidant genes, phase II 
detoxification enzymes, heat shock proteins and glutathione-synthesis enzymes (Itoh 
et al., 1997; Kobayashi and Yamamoto, 2005). Under normal conditions, Nrf2 is 
found in the cytosol where it interacts with Kelch-like ECH-associating protein 1 
(Keap1) (Itoh et al., 1999). During oxidative stress, multiple cysteine residues of 
Keap1 are oxidized which results in the dissociation of Keap1 from Nrf2 (Dinkova-
Kostova et al., 2002). Other than oxidizing Keap1, oxidants can also activate Nrf2 
through phosphorylation of PKC and PERK. The free Nrf2 translocates into the 
nucleus and forms heterodimer with small Maf proteins (Motohashi et al., 2004). This 
complex then binds to antioxidant response element (ARE) of target genes promoter 
to initiate their transcription (Tanito et al., 2007). 
 
1.2.1.4  Regulation of transcription by redox modulation of DNA binding 
domain  
Many transcription factors contain redox-sensitive cysteine residues at their DNA 
binding domains (Haddad, 2002). The oxidation of these critical cysteine residues 
often leads to the inactivation of their DNA binding activity, thereby inhibiting target 
gene transcription (Turpaev, 2002). The reduced form of NFκB is required for its 
binding to DNA. Oxidation of Cys62, a redox sensitive site on p50 abolishes its DNA 
binding ability and inactivates downstream gene transcription (Toledano and Leonard, 
1991; Mitomo et al., 1994). NFκB has also been shown to be inactivated by 
glutathionylation (Pineda-Molina et al., 2001) and S-nitrosylation (Marshall and 
Stamler, 2001). Nitric oxide has been shown to inhibit DNA binding of AP-1 through 
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S-glutathionylation (Klatt et al., 1999). Hypoxia inducible factor-1 (HIF-1) DNA-
binding activity is shown sensitive to oxidizing reagents diamide and H2O2 and the 
alkylating agent N-ethylmaleimide (Wang et al., 1995; Nikinmaa et al., 2004). Other 
transcription factors that are modulated by redox regulation at their DNA binding 
domain include estrogen receptor (ER) (Hayashi et al., 1997);Weitsman et al., 2009), 
Activating Protein 2 (AP2) (Huang and Domann, 1998), and Specificity Protein (SP1) 
(Bloomfield et al., 2003; Ammendola et al., 1994). 
 
1.2.2  mRNA stability 
The regulation of mRNA stability is a major control point in gene expression. The 
stability of mRNA can be regulated through redox-mediated mechanisms. The 
stability of an mRNA depends on the interaction between RNA-binding proteins and 
structural elements of the mRNA (Guhaniyogi and Brewer, 2001). RNA binding 
protein human antigen R (HuR) is found mainly in the nucleus. However, upon 
exposure to oxidative stress triggers such as H2O2, arsenite, or UV radiation, it 
translocates to the cytoplasm, and binds to AU-rich elements in the 3' untranslated 
regions (UTR) of mRNA. This increases the half-life of many mRNA encoding 
stress-response genes (Brennan and Steitz, 2001). Snail is a protein that plays a 
fundamental role in the induction of a phenotypic change called epithelial to 
mesenchymal transition (EMT). It has been shown that H2O2 can increase Snail 
protein level by stabilizing Snail mRNA (Dong et al., 2007). The association of HuR 
to Snail mRNA was suggested to play a major role in H2O2-induced Snail mRNA 
stability. H2O2 can also stabilize MKP-1 mRNA and increase the association of MKP-
1 mRNA with the translational machinery (Kuwano et al., 2008). It does so by 
increasing the association of MKP-1 mRNA with RNA binding proteins HuR and 
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NF90 and decreasing the association of MKP-1 mRNA with translation repressor 
TIAR and TIA-1. Macrophage inflammatory protein-1a (MIP-1a) mRNA half-life 
was markedly increased after H2O2 treatment (Shi et al., 1996). H2O2 has also been 
implicated in increased activity of macrophage scavenger receptor (MSR) by 
stabilizing MSR-I mRNA (De et al., 1998).  
Conversely, ROS has also been shown to decrease mRNA stability. Resistin was 
reported to decrease endothelial nitric oxide synthase (eNOS) mRNA stability through 
production of superoxide in the cells (Chen et al., 2010). H2O2 and intracellular 
oxidative stress can destabilize the mRNA of ceruloplasmin (Cp), a copper-containing 
protein, by affecting the RNA protein complex formation at the 3’-UTR of Cp mRNA 
(Tapryal et al., 2009). H2O2 has recently been shown to decrease mRNA stability of 
transcription factor atf1 in Schizosaccharomyces pombe cells (Day and Veal, 2010). 
 
1.2.3 Direct oxidative modification 
Oxidative modification of proteins is an important redox regulation of protein 
function at the posttranslational level (England and Cotter, 2005). Mild to moderate 
levels of oxidative stress can induce reversible modifications such as glutathionylation 
(Ghezzi, 2005), S-nitrosylation (Sun et al., 2006) and disulfide bond formation 
(O'Brian and Chu, 2005) on cysteine residue of proteins. These modifications by mild 
oxidative stress lead to structural and functional changes of the proteins. 
Glutathionylation is the formation of mixed disulfides between GSH and proteins. In 
most incidences, glutathionylation leads to the inactivation of a protein’s function. For 
example, glutathionylation of transcription factors such as Jun and NFκB inhibit their 
DNA binding ability (Klatt et al., 1999; Pineda-Molina et al., 2001). Glutathionylation 
could be a way to protect the protein from more irreversible forms of oxidation that 
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would lead to permanent inactivation. S-nitrosylation is the attachment of an NO 
moiety to the cysteine residue of a protein (Sun et al., 2006). S-nitrosylation has also 
been proposed as a way to protect proteins from further oxidation during oxidative 
stress. The activity of proteins may either be enhanced by S-nitrosylation (eg. p21ras, 
Akt1, and thioredoxin) (Lander et al., 1997; Haendeler et al., 2002; Lu et al., 2005) or 
suppressed by it (eg. caspase and methioine adenosyl) (Mannick et al., 1999; Pérez-
Mato et al., 1999). The cysteine residue of some protein tyrosine phosphatases (PTPs) 
such as PTEN, Cdc25 and low molecular weight-PTPs can form disulphide bond with 
a nearby cysteine when oxidized by H2O2 (Caselli et al., 1998; Savitsky and Finkel, 
2002; Kwon et al., 2004). Severe oxidative stress can result in more damaging 
modifications, such as the formation of sulfenic acid, sulfinic acid, and sulfonic acid 
(Poole et al., 2004). Besides cysteine residue, tyrosine residue is also a target for 
redox modification. The oxidation of tyrosine to nitrotyrosine by reactive nitrogen 
species (RNS) causes the protein to lose its phosphorylation site (Trachootham et al., 
2008). Kinases such as PI3K, PKC and p38 MAPK are targets of tyrosine nitration, 
leading to their inactivation (Hellberg et al., 1998; Knapp et al., 2001; Webster et al., 
2006).  
Another more severe form of modification is the carbonylation of proteins which can 
occur either directly through the oxidation of amino acid side chains (lysine, arginine, 
threonine and proline) or indirectly through amino acid interacting with oxidation 
products of lipids and sugars (Stadtman and Berlett, 1991; Schneider et al., 2001). 
Carbonylation of proteins is a form of irreversible modification which often leads to 
loss of protein function (Dalle-Donne et al., 2006). Examples of such proteins are 
ANT, Hsp and Bcl2 (England and Cotter, 2005). As carbonylated protein is easily 
detectable, it is frequently used as an indicator of the oxidative damage to the cell. 
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While moderately carbonylated proteins are degraded via the proteosomal pathway, 
heavily carbonylated proteins form aggregates that can inhibit proteosome function 
(Dalle-Donne et al., 2006). 
 
1.2.4 Regulation of protein turnover 
The half-life of the protein affects the duration it can execute its function in the cell. 
The more stable a protein is, the longer its effects are in the cell. The rate of protein 
turnover can also be subjected to redox regulation. The Rac1 protein is involved in the 
production of superoxide via NADPH oxidase. One study found that as a way to 
control ROS production in the cell, Rac-1-induced superoxide production activates a 
feedback loop where Rac-1 protein turnover is enhanced via increased degradation by 
the proteosome (Kovacic et al., 2001). Superoxide has also been shown to promote 
apoptosis in cells by increasing the turnover of anti-apoptotic protein Bcl2 through 
ubiquitin-proteosomal pathway (Azad et al., 2008). HIF is a transcription factor that 
controls the transcription of a number of genes during hypoxia (Brahimi-Horn and 
Pouysségur, 2007). Under normoxia, HIFα, the subset of HIF protein is continuously 
synthesized but is also rapidly degraded via the ubiquitin, proteosomal system. ROS 
generated at the mitochondria have been shown to stabilize HIFα under hypoxic 
conditions by decreasing protein turnover (Chandel et al., 2000). In some cell types, 
growth factors have also been shown to stabilize HIFα during normoxia through the 





1.3 ESTROGEN RECEPTOR 
 
1.3.1 Estrogen and estrogen receptors: Introduction 
Estrogens are steroid hormones produced primarily in the ovaries of pre-menopausal, 
non-pregnant women. They are converted from testosterone to estradiol (E2) by an 
enzyme aromatase, a member of the cytochrome P450 superfamily. Although E2 is 
the primary estrogen in the body, it can be broken down into its less potent 
metabolites estrone and estriol. In post-menopausal women and men, estrogen is 
synthesized in mesenchymal cells of adipose tissue, osteoblasts and chondrocytes of 
bone, the vascular endothelium and aortic smooth muscle cells, and numerous sites in 
the brain (Simpson and Davis, 2001). Other than playing important roles in the 
monthly estrus cycle of pre-menopausal women, estrogens are essential for various 
physiological processes in tissues and organs such as bone, urinary tract, brain, uterus, 
prostate and breast. 
Estrogen exerts its effects primarily via binding to estrogen receptor (ER) which 
consist of two members, ERα and ERβ. The DNA coding for ERα was cloned in 1985 
(Walter et al., 1985). In the following decade, this receptor was thought to be the only 
receptor mediating the physiological effect of estrogens. It was only in 1996 that a 
second and novel estrogen receptor, ERβ was discovered in rat prostate (Kuiper et al., 
1996). ERβ was subsequently identified in human and mouse tissues (Mosselman et 
al., 1996; Tremblay et al., 1997). Human ERα and ERβ contains 595 and 530 amino 
acids respectively and are coded by different genes (Green et al., 1986; Ogawa et al., 
1998). ERα gene is found on chromosome 6q25.1 while ERβ gene is found on 
chromosome 14q23.2. ERα is the major form of estrogen receptor in uterus, liver, 
adipose, skeletal muscle, pituitary gland and hypothalamus while ERβ is the major 
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form in ovary, testis, prostate, lung and other parts of the brain. ERα and ERβ 
colocalize in mammary glands, bone, uterus, central nervous system and 
cardiovascular system (Nilsson et al., 2001). 
Estrogen receptor belongs to a class of nuclear receptors which are transcription 
factors targeted by small lipid-soluble molecules such as steroid hormones, thyroid 
hormones, retinoids, vitamin D3 and bile acids (Mangelsdorf et al., 1995). Like all 
nuclear receptors, ER can be divided into five functional domains. The A/B domain of 
the estrogen receptor, which is also known as activation function (AF-1) activates 
gene transcription of target genes through the recruitment of co-regulators 
(Tzukerman et al., 1994).  C domain is the DNA-binding domain (DBD) which is rich 
in basic amino acids. It recognizes specific DNA sequence known as estrogen 
response element (ERE) and binds to ERE via its two zinc-stabilized DNA-binding 
fingers (Kumar et al., 1987). D domain, which also harbors the nuclear localization 
signal, acts as a hinge between C and E domains. E domain is a hydrophobic domain 
that binds to ligands. Embedded within E domain is the dimerization region and a 
second transcriptional activation function (AF-2). F domain exerts a complex 
modulatory role on activity of the receptor and interaction with other proteins 
(Montano et al., 1995; Koide et al., 2007). Human F domain contains a PEST region 
which is enriched in proline (P), glutamic acid (E), serine (S) and threonine (T).  
PEST sequence had been suggested to be a signal for rapid degradation of proteins 
(Rogers et al., 1986; Hirai et al., 1991). Thus, the F domain might also play a role in 
ER turnover.  
Structurally, the two ER receptors are very similar to each other particularly in the 
DNA-binding domain (97% homology) and the c-terminal ligand-binding domain (47% 
homology). The major difference is at the A/B and F domains with only 18% 
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homology. This is an indication that the two receptors most likely interact with 
different set of co-factors upon activation (see Figure V for structure of ERα and 
ERβ). Despite considerable variation in sequence of the ligand-binding domain, both 
ERα and ERβ bind to estrogen with similar high affinity with dissociation constant of 
0.1 nM (Kuiper et al., 1998). The major difference in the ligand binding of these two 
receptors lies in having different affinities for various compounds. In addition, one 
compound could also evoke differential transcriptional response in the two receptors. 
For example, tamoxifen it is a mixed agonist and antagonist for ERα but is an 
antagonist for ERβ (Watanabe et al., 1997; Barkhem et al., 1998). Phytoestrogens 
such as genistein, coumestrol and zearalenon, and environmental estrogenic 
compounds for instance nonylphenol, bisphenol A, o, p'-DDT, and 2',4',6'-trichloro-4-
biphenylol have also been shown to compete with E2 in their binding to ER, abide 
with lower affinities (Kuiper et al., 1998). 
 
 
Figure V: Domain structure representation of human ERα and ERβ isoforms. Domains 
(labeled A–F), amino acid sequence numbering, AF-1 and AF-2, and percentage homology 
between the two isoforms in different regions, including the DBD and LBD, are shown. 





1.3.2 Estrogen receptor and genomic signaling  
There are several pools of ER that exist in the cell. They can be found in the cytosol, 
nucleus, plasma membrane and mitochondria (Nadal et al., 2001; Ivanova et al., 2009; 
Jazbutyte et al., 2009). In the non-ligand bound state, ER is found to complex with 
heat shock proteins, immunophiline and p23. (Pettersson and Gustafsson, 2001). For 
genomic signaling, ER dissociates from chaperone proteins and dimerizes upon 
binding to its ligand. The ligand-receptor complex moves into the nucleus and binds 
to ERE of target genes. The ERE consensus sequence contains a palindromic 
sequence which is an inverted repeat 5'GGTCAnnnTGACC-3' where n represents any 
nucleotide. It should be noted that many EREs contain variations from the consensus 
sequence (Klein-Hitpass et al., 1986; Klinge et al., 1997; Cheskis et al., 2007). The 
binding of different ligands cause ER to assume different conformations. The LBD is 
formed by a 12 α-helices (Helices 1-12) with a hydrophobic ligand-binding pocket. 
The AF-2 in the LBD of ER is composed of amino acids in helix 3, 4, 5 and 12. The 
position of helix 12 changes when ER binds to ligands and therefore is the key in 
discriminating between agonists and antagonists of ER. For instance, when E2 binds 
to ER, helix 12 is positioned over the ligand pocket and forms the surface for 
recruitment and interaction with cofactors. In contrast, when ER binds to an 
antagonist, such as tamoxifen, helix 12 occupies the hydrophobic groove formed by 
helix 3, 4 and 5. This position prevents the recruitment of co-activators but 
encourages the recruitment of co-repressors instead. (Dickson and Stancel, 2000). 
Besides binding directly to DNA and activating gene transcription, ER could activate 
gene transcription indirectly via interacting with other transcription factors. The 
interaction between ERα and the c-rel subunit of NFκB prevents NFκB from binding 
to interleukin-6 (IL-6) promoter and thus inhibiting the expression of IL-6 (Galien and 
21 
 
Garcia, 1997). ERα physically interacts with SP1 to activate retinoic acid receptor α-1 
(RAR-1) gene transcription through the binding of ER-SP1 complex on SP1 site on 
RAR-1 promoter (Sun et al., 1998; Zou et al., 1999). ER also interacts with the fos/jun 
transcription complex on AP1 sites to modulate gene transcription depending on the 
ligand and ER subtypes (Webb et al., 1995; Paech et al., 1997; Webb et al., 1999). For 
instance, in the presence of ERα, typical agonists such as E2 and antagonist tamoxifen 
function as agonists in the AP1 pathway. Raloxifene acts as a partial agonist. In the 
presence of ERβ, tamoxifen and raloxifene behave like agonist while E2 acts as an 
antagonist, inhibiting the actions of tamoxifen and raloxifene (Paech et al., 1997). 
ER can also be activated in a ligand-independent manner through phosphorylation of 
the various serine and tyrosine residues in the AF-1 and AF-2 domains. Downstream 
signaling pathway of peptide growth factor, PKA-activating agents, neurotransmitters, 
and cyclins can mediate ligand-independent transcription of ER through 
phosphorylation (Cenni and Picard, 1999). The phosphorylation regulates the 
dimerization of the ER and recruitment of various co-activators to the AF-1 and AF-2 
domains depending on the phosphorylation sites. 
 
1.3.3 Membrane and cytoplasmic ER signaling 
Rapid estrogen signaling from the plasma membrane was first identified forty years 
ago (Szego and Davis, 1967; Pietras and Szego, 1977). Other than binding to nucleus 
ER and activating transcriptional activities, estrogens can modulate intracellular 
signaling through secondary messengers. Approximately 5-10% of the total ER is 
found at the plasma membrane (Levin, 2009). This include both ERα and ERβ, 
however, the localization of the different subtypes depends on cell type. The nature of 
22 
 
the plasma membrane located ER is found to be the same as the classical nuclear ERα 
and ERβ. Endothelial cells from mice that are knockout of the classical ERα and ERβ 
also lost of all estrogen binding at the plasma membrane (Pedram et al., 2006). 
Membrane proteins that bind to estrogen-conjugated beads in affinity chromatography 
were identified by mass spectrometry to be the classical ERα, and were identical to 
the nuclear ERα. (Pedram et al., 2006).  
Many signaling cascades have been described for membrane ER and estrogen. These 
include activation of MAPK (Endoh et al., 1997; Song et al., 2002; Mize et al., 2003) 
and PI3K/Akt pathway (Haynes et al., 2000; Haynes et al., 2003), induction of ion 
channel fluxes (Rosenfeld et al., 2000; Coiret et al., 2005), GPCR-mediated second 
messenger generation of cAMP and calcium  (Stefano et al., 2000; Wyckoff et al., 
2001; Wade and Dorsa, 2003), as well as stimulation of growth factor receptors 
(Razandi et al., 2003). When E2 binds to membrane ER, the initiation of signal 
transduction triggers downstream signaling cascades that contribute to important 








1.3.4 Regulation of Estrogen Receptors 
 
1.3.4.1  Phosphorylation 
ERα has been shown to be phosphorylated at multiple sites upon either binding to E2 
or through the actions of second messenger signaling pathways (Washburn et al., 
1991; Denton et al., 1992; Joel et al., 1995). Phosphorylation sites are located at both 
amino- and carboxy-terminals of ERα.  There are four serine located at the AF-1 of 
ERα, (Ser104, Ser106, Ser118 and Ser167) that can be phosphorylated. The 
phosphorylation of these serine residues in the AF-1 domain influences the 
recruitment of co-activators (Lavinsky et al., 1998; Endoh et al., 1999; Tremblay et al., 
1999). Ser118 is the major site phosphorylated in response to E2; although Ser104 
and Ser106 are also phosphorylated to a lesser extent (Joel et al., 1995). Upon 
activation of MAPK by EGF, Ser118 is preferentially phosphorylated in ERα but 
Ser104 and Ser106 remain unphosphorylated (Joel et al., 1998). TFIIH cyclin-
dependent kinase has also been shown to phosphorylate Ser118 (Chen et al., 2000). 
On the other hand, cyclin-dependent kinase 2 (Cdk2) complex can phosphorylate 
Ser104 and Ser106 but not Ser118 (Rogatsky et al., 1999). The downstream kinase of 
MAPK, p90 ribosomal S6 kinase (Rsk) has been shown to phosphorylate Ser167 (Joel 
et al., 1998; Frödin and Gammeltoft, 1999). Ser167 can also be phosphorylated by 
casein kinase II and Akt (Arnold et al., 1995; Martin et al., 2000; Campbell et al., 
2001). In the presence of E2, ERα is phosphorylated by protein kinase A (PKA) on 
Ser236 within the DNA binding domain which facilitates the dimerization of the 
receptor (Campbell et al., 2001). Two Scr tyrosine kinases, p60c-src and p56lck are 
shown to phosphorylate ERα at tyrosine-537 located in the LBD (Arnold et al., 1995). 
The phosphorylation of tyrosine is however not required for the binding of E2 or 
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activation of transcription. Instead, it is important in the conformational change of the 
LBD that can affect the ligand binding kinetics and the stability of ligand-bound 
receptor (Yudt et al., 1999). Phosphorylation of ERβ is less well studied. One study 
suggested that Ser60 of mouse ERβ is phosphorylated in response to activation of 
MAPK pathway (Joel et al., 1995). 
 
1.3.4.2  Glycosylation 
A large number of proteins in the cells such as transcription factors, cytoskeletal 
proteins, nuclear pore proteins, oncogene product, and tumor suppressors can be 
modified by O-linked N-acetylglucosamine (O-GlcNAc) (Hart, 1997; Haltiwanger et 
al., 1997). Glycosylation, like phosphorylation, is a dynamic process with O-GlcNAc 
displaying features essential for a role in signal transduction in the cell. For instance, 
the attachment and removal of O-GlcNAc from proteins are tightly regulated 
processes and the half-life of O-GlcNAc moiety has been shown to be much shorter 
than that of the modified protein backbone (Roquemore et al., 1996). ERα from 
murine, bovine, and human sources is shown to be modified by O-GlcNAc and that a 
major O-GlcNAc site (Thr575) occurs within a PEST sequence of the F domain 
(Jiang and Hart, 1997). Additional glycosylation sites have been found where are 
Ser10 and Thr50 in the AF-1 domain near the N-terminus of murine ERα (Cheng and 
Hart, 2000). O-GlcNAc glycosylation has also been found for murine ERβ at Ser16 
which is in the proximity of the AF-1 domain and within a region with a high PEST 
score (Cheng et al., 2000). The O-GlcNAc glycosylation may play a role in ER 




1.3.4.3  Acetylation 
Modification via acetylation provides another layer of regulation of the estrogen 
receptor. ERα can interact with co-activators that modify histone acetyl groups. It had 
been shown that ERα can interact with p300 which acetylates the receptor directly at 
the lysine residues Lys266 and Lys268. Acetylation of ERα by p300 enhances the 
DNA binding activity of the receptor, leading to increase in ligand-dependent 
transcriptional activity (Kim et al., 2006). However, in another study, the acetylation 
of ERα within the hinge/ligand binding domain could attenuate estrogen-dependent 
transregulation (Wang et al., 2001). Acetylation appears to act as a modulation of 
ligand-dependent gene regulatory activity of ERα. 
 
1.3.4.4  Ubiquitination 
The ubiquitination-proteosomal pathway is a major system for the degradation of 
proteins with short half-life in eukaryotic cells (Haas and Siepmann, 1997; Pickart, 
1997). The covalent attachment of ubiquitin proteins, to lysine residues of targeted 
proteins to form polyubiquitin is necessary for the subsequent proteosomal 
degradation. Ubiquitination involves three classes of enzymes: E1 ubiquitin-activating 
enzyme (UBA), E2 ubiquititin-conjugating enzyme (UBCs) and E3 ubiquiting-protein 
ligases. Other than targeting proteins for degradation, ubiquitination also serves to 
direct cellular localization of proteins (Chen et al., 1996; Kim and Maniatis, 1996). 
Ubiquitination of ER has been observed in rat uterus (Pakdel et al., 1993), and the 
stability of ER is affected by ligand binding.  In the absence of E2, the half-life of ER 
is about 5 days. Upon binding to E2, the half-life of ER shortens to 3-4 hours (Pakdel 
et al., 1993; Nirmala and Thampan, 1995). Ubiquitin-proteosomal degradation of 
ligand bound ER allows the E2-ER signal to be rapidly turned off once its desired 
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effects on the cells is achieved. Misfolded ER has also been shown to undergo 
ubiquitination and proteosomal degradation to safeguard the quality of ER in the cells 
(Tateishi et al., 2004). 
 
1.3.4.5  Oxidation 
Many cellular processes such as protein phosphorylation and binding of transcription 
factors to promoters are driven by oxidation and antioxidant homeostasis (Sen and 
Packer, 1996). Redox regulation of transcription factors had been identified for AP-1, 
NFκB, SP1 and glucocorticoid receptor. The transcriptional activity of ER is 
influenced by its redox state which could be regulated by cellular antioxidant 
thioredoxin (Trx) (Hayashi et al., 1997). ER dependent gene pS2 and ERE-driven 
acetyltransferase (CAT) activity were found to be down-regulated in presence of 
H2O2 and were recovered by the increasing intracellular Trx (Hayashi et al., 1997). 
Cancer cells often have high levels of ROS and this altered redox homeostasis have an 
impact on the transcription activity of ER. ER extracted from a third of ER positive 
primary breast tumors are unable to bind to the consensus sequence of ERE (Liang et 
al., 1998). Treating the tumor extract with reducing agent could partially restore the 
ER binding suggesting that these ERs were in the oxidized form in the primary tumors. 
The DBD of ER contains two (Cys)(4)-liganded zinc finger motifs which function to 
stabilize the DNA-binding recognition helix and flexible helix-supported dimerization 
loop. The oxidation of the zinc finger in the DBD of ER prevents dimerization and 
hence DNA binding leading to down-regulation of ER downstream genes (Whittal et 
al., 2000; Atsriku et al., 2007). The redox state in cells may be an important 
mechanism for post-transcriptional regulation of ER function, thereby playing a 
critical role in regulating the transcriptional activity of ER. 
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1.3.5 Estrogen and estrogen receptors in human breast cancer  
Breast cancer or malignant breast neoplasm is cancer originating from breast tissue, 
most commonly beginning either in the milk ducts (ductal carcinoma) or in the milk 
producing glands (lobular carcinoma). Breast cancer is the most common cancer 
found in women from industrialized countries and is the second biggest killer after 
lung cancer (Jemal et al., 2009). The importance of estrogen in regulating breast 
cancer growth was demonstrated more than a hundred years ago through the 
inhibitory effects of ovariectomy on patients with metastatic breast cancer (Beatson, 
1896). Estrogen has been suggested to be important in breast cancer through non-
receptor- and receptor-mediated mechanisms. The non-receptor-mediated mechanism 
includes a cytochrome P450 (CYP)-mediated metabolic activation, which elicits 
direct genotoxic effects by increasing mutation rate and inducing aneuploidy (Russo 
et al., 2003). Estrogen is metabolized in body by several cytochrome P-450 enzymes 
in phase I metabolism. Estrogen can be metabolized in the body to form catechol 
estrogen. Normally, catechol estrogen is detoxified by phase II enzyme catehol O-
methyltransferase (COMT). Insufficient metabolism by COMT can generate estrogen 
3,4-qinone, a electrophilic reactive intermediate that can form unstable adducts with 
adenine and guanine in the DNA, leading to depurination and mutations (Chakravarti 
et al., 2001; Devanesan et al., 2001; Yue et al., 2003). Mismatch repair or mis-
replication of depurinated sites could lead to carcinogenesis. The reduction of 
estrogen quinones involves redox cycling with ROS generation that could further 
damage cellular lipids and DNA leading to carcinogenesis (Nutter et al., 1994; Seacat 
et al., 1997; Lavigne et al., 2001).  
Deregulation of expression and activity of estrogen receptor contribute to the 
development and progression of breast cancer (Nilsson et al., 2001). High levels of 
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ER promote growth of estrogen-dependent tumors by increasing ER-dependent gene 
transcription and non genomic functions of ER that promotes cell proliferation. 
Although ERβ is important in estrogen functioning, ERα appeared to play a more 
predominant role in mammary tissues. While ERα is found only in 6 to 10% of 
normal breast epithelial cells; 60% of primary breast cancer are ERα-positive and 
their growth is often stimulated by estrogen (Dickson and Lippman, 1988; Jacquemier 
et al., 1990). The over-expression of ERα in breast cancer is suggested to be due to 
amplification of the ERα gene. A tissue microarray analysis of more than 2,000 
clinical breast cancer samples showed ERα gene amplification in 20.6% of breast 
cancers (Holst et al., 2007). ERα gene amplication was also found in benign and 
precancerous breast disease, suggesting that amplification of ERα gene is a common 
and early genetic alteration in proliferative breast disease and breast cancer. Gene 
amplification alone, however, cannot explain all cases involving high ERα protein 
levels. Other possible mechanisms include altered regulation of ERα transcription, 
mRNA stability or protein turnover (Fowler and Alarid, 2007). 
ERα status is important in the clinical setting as a prognostic tool as well as a 
therapeutic target. Currently, biopsy samples from breast cancer patients are routinely 
screened for the presence of estrogen receptor (ER), progesterone receptor (PR) and 
oncoprotein HER2. ERα status is the most important biomarker in breast cancer, 
because it provides clinicians with information on whether the patient will respond to 
endocrine treatment (Weigel and Dowsett, 2010). ERα-positive cells generally have a 
better prognosis. ERα-positive tumor uses E2 as its main growth stimulus thereby 
making ERα a direct target for endocrine therapy. 
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1.4 THE SODIUM HYDROGEN EXCHANGER 1  
 
1.4.1 pH regulation in the cells 
Intracellular pH (pHi) is a tightly regulated parameter in the cell as many cellular 
processes function within a narrow range of pH. Large fluctuations of pHi can affect 
the normal structure and functioning of proteins, gene expression, ion channels and 
other processes. The normal cytosolic pHi in the cells is in the range of 6.99-7.2 
(Gillies et al., 2002). Cells constantly produce H+ ion through its metabolic activity or 
leakage from acidic compartments in the cells. Several transport proteins are located 
on the plasma membrane to transport the acids or bases across the cell. Two 
mechanisms are employed: either H+ ion is transported out of the cell or HCO3- is 
imported into the cell to neutralize the H+ ions in the cytosol. There are three main 
families of exchangers that are present at the plasma membrane of cells. The first is 
Na+/H+ exchanger (NHE) which extrude H+ ion out of the cell and import a Na+ ion in. 
The second family of membrane transporters imports HCO3- into the cell. They 
include Na+/ HCO3- cotransporter (NBC), Cl-/ HCO3- exchanger (AE), Na+ driven Cl-/ 
HCO3- exchanger (NDAE), and Na+ independent Cl-/ HCO3- exchanger. The third 
family of membrane transporters is the H+-ATPase (Putney et al., 2002). With the 
exception of H+-ATPase, none of the membrane transporters has a direct requirement 
for ATP. Of all the membrane transporters, the NHE family plays a key role in 
maintaining the pHi of cells upon acidification in virtually all cell types (Malo and 
Fliegel, 2006). The first member, NHE1 is found to be expressed ubiquitously and is 




1.4.2 Mammalian Na+/H+ exchanger  
In 1982, Pouyssegur and his group identified a “Na+/H+ exchanger system (NHE)” 
that played an important role in the regulation of pHi (Pouyssgur et al., 1982). NHE is 
a family of glycoproteins that exchanges a H+ ion out of the cell for a Na+ ion across 
the membrane in a 1:1 stoichiometry. In mammalian cells, the NHE family consists of 
9 members (NHE1 – NHE9). The gene coding for first member, NHE1, was cloned in 
1989 by Sardet et al and was found to be expressed ubiquitously on the plasma 
membrane of virtually all cell types. NHE1 is referred to as the “housekeeping” 
isoform while the other isoforms have more restricted localization (Sardet et al., 1989; 
Malo and Fliegel, 2006). The specific localization of NHE1 on the plasma membrane 
varies depending on cell type. In fibroblast, NHE1 is mostly found on the 
lamellipodia where it is involved in migration and anchoring (Denker et al., 2000; 
Denker and Barber, 2002). In epithelial cells, NHE1 is distributed to the basolateral 
membrane (Biemesderfer et al., 1992; Orlowski and Grinstein, 2004). In the 
myocardial tissue, NHE1 is found in the intercalated discs and along the transverse 
tubular system (Petrecca et al., 1999). The rest of the NHE members are more 
restricted in their tissue and subcellular distribution. NHE2 – NHE5 are located at the 
plasma membrane but they are more tissue specific. NHE2 is an apical membrane 
protein that shares 42% sequence identity with NHE1 (Wang et al., 1993). NHE2 is 
found in the epithelial tissue of the intestinal tract (mainly in the jejunum, ileum and 
colon), kidney (cortical thick ascending limbs, distal convoluted tubules, connecting 
tubules and macula densa cells), skeletal muscle and testis (Malakooti et al., 1999). 
NHE3 and NHE4 have 39% and 42% identity with NHE1 respectively (Orlowski et 
al., 1992). Both NHE3 and NHE4 are highly expressed in the kidney and 
gastrointestinal tract. In kidney, NHE3 is found in the proximal tubule and thick 
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ascending limb (Amemiya et al., 1995) whereas NHE4 has a more basolateral 
epithelial distribution in the inner medullar (Bookstein et al., 1994). In the 
gastrointestinal tract, NHE3 appears predominantly in the intestines while NHE4 is 
found in the stomach. NHE5 which shares 39% sequence identity with NHE1 is found 
exclusively in the brain. NHE6 to NHE9 are found in the membrane of intracellular 
organelles where they are involved in the maintenance pH in these compartments. 
NHE6 is expressed in the early recycling endosomes, NHE7 in the trans-Golgi 
network, NHE8 in the mid- to trans-Golgi, and NHE9 in the late recycling endosomes 
(Nakamura et al., 2005). 
 
1.4.3 NHE1: Basic structure  
NHE1 isoform is the best characterized amongst the NHE family members. NHE1 
protein is made up of 815 amino acids. The first 500 amino acids makes the 12 α-
helices transmembrane (TM) spanning segment while the remaining residues 
constitute the cytoplasmic tail which is the intracellular regulatory domain (Sardet et 
al., 1989). Both the N- and C- terminals of NHE1 are found in the cytosol. Two forms 
of NHE1 are consistently observed: a plasma membrane protein of 110 kDa that 
contains N- and O-linked oligosaccharide, and an 85 kDa protein that is found 
intracellularly which contains only the N-linked high-mannose oligosaccharides 
(Malo and Fliegel, 2006). The TM domain of NHE1 is responsible for the exchange 
of intracellular H+ for extracellular Na+ in a 1:1 stoichiometry. (See Figure VI for the 
topological model of NHE1). Several TM domains of NHE1 are important for its 
function. The TM IV is critical for the function of NHE1; it is involved in the affinity 
of NHE1 for Na+ and overall NHE1 activity. TM VI and VII are crucial for NHE1 
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activity while TM IX is important in conferring sensitivity to antagonists. TM XI, on 
the other hand, is essential in targeting NHE1 to the cell surface (Fliegel, 2005).  
The recombinant C-terminal of human NHE1 have been expressed and purified from 
Escherichia coli. It is found to be made of 35% α-helix, 16% β-turn, and 49% random 
coils. Using circular dichroism to analyze the various C-terminal fragments, the 
membrane proximal region was predicted to be more structured and compact. The 
more distal region has a more flexible and unstructured feature, possibly to allow for 
the association with various kinases and regulatory proteins (Gebreselassie et al., 
1998; Li et al., 2003). 
  
 
Figure VI: Topology of NHE1 isoform and its regulatory elements. Extracellular loops 1-
6 (EL1-EL6), intracellular loops 1-5 (IL1-IL5), amino acids glutamic acid (E) and aspartic 
acid (D). Regulatory elements and their approximate location of binding: calmodulin (CaM), 
calcineurin homologus protein (CHP), ezrin/radixin/moesin proteins (ERM), carbonic 
anhydrase isoform II (CAII), phosphatidylinositol bisphosphate (PIP2). Putative protein 
kinase that phosphorylate the Na+/H+ exchanger are indicated: ERK 1/2, p90rsk, NIK, 
p160ROCK, p38. Figure adapted from (Malo and Fliegel, 2006) 
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1.4.4 Physiological and pathological roles of NHE1 
 
1.4.4.1  pHi and volume regulation 
The major function of NHE1 in the cell is the regulation of pHi and cell volume. 
NHE1 activity is activated by the decrease in intracellular pH. When the pHi of the 
cell reach a certain threshold, NHE1 will be activated to extrude H+ ion out of the cell 
for a Na+ ion into the cell, leading to intracellular alkalinization (Malo and Fliegel, 
2006). This process is dependent on extracellular Na+, and the cell uses the energy 
gradient of Na+ to catalyze the electro-neutral exchange. NHE1 also regulates cell 
volume during osmotic shrinkage. During hypertonic stress, NHE1 is activated; 
bringing more Na+ into the cell resulting in intracellular alkalinization.  The increase 
in Na+ in cells will draw more water into the cells due to obligatory osmosis 
(Bianchini et al., 1995). 
 
 1.4.4.2 Cell proliferation and differentiation 
It has been long established that the activation of NHE1 and increase in pHi are early 
response to mitogens (Pouysségur et al., 1984). NHE1 has a permissive, but not an 
obligatory role in cell proliferation. Although NHE1 deficient cells were able to 
proliferate in the presence of serum, the rate of proliferation was markedly increased 
in cells with NHE1 expression (Kapus et al., 1994). Inhibition of NHE1 activity with 
pharmacological inhibitors such as EIPA or HOE694 also attenuated growth factor 
induced cell proliferation (Delvaux et al., 1990; Horvat et al., 1992; Benedetti et al., 
2001).  Although NHE1 has been associated with proliferation, the mechanism by 
which NHE1 exerts this function is less known. It has been shown that NHE1 and pHi 
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regulates the G2/M entry and transition. Cells that have a defective NHE1 which 
prevents ion translocation have impaired G2/M transition and delayed entry into S 
phase (Putney and Barber, 2003). 
NHE1 also play a role in cellular differentiation. The inhibition of NHE1 with 
pharmacological inhibitor prevented the differentiation of P19 embryonal carcinoma 
(Wang et al., 1997). NHE1 has recently been shown to be important in the 
differentiation of embryonic stem cells into cardiomyocytes where inhibition of 
NHE1 prevented such differentiation (Li et al., 2009). 
 
1.4.4.3  Cell migration 
NHE1 is important in cell shape and cell migration by acting as a structural anchor for 
organization of cytoskeleton. In some cell types NHE1 is located at the lamellipodia 
where its C-terminal binds ezrin, radixin and moesin (ERM) protein to interact with 
actin filaments (Fliegel, 2005). Actin filaments play a pivotal role in determining the 
shape and motility of a cell and also associate with the dynamic extensions such as 
lamellipodia. Cells that express NHE1 which is defective in the C-terminal and cannot 
interact with ERM proteins have reduced actin organization, irregular shape, and 






1.4.4.4  NHE1 in heart disease 
NHE1 is the main isoform found in myocardiocytes. It is responsible for half of total 
proton efflux and plays a critical role in maintaining pHi homeostasis and contractility 
(Fliegel et al., 1991; Grace et al., 1993). Although it plays an important role in cardiac 
cell functioning, NHE1 has also been implicated in heart diseases. During ischemia, 
where cardiac cells are cut off from oxygen, anaerobic glycolysis occurs, resulting in 
the accumulation of H+ in the cells. In the subsequent reperfusion, NHE1 is activated 
to pump out H+ in exchange for Na+ into the cells (Avkiran, 2001; Allen and Xiao, 
2003). This large influx of Na+ activates Na+/Ca2+ exchanger and drives the exchange 
Na+ out of the cell for Ca2+ into the cell. The built up of Ca2+ in the cells is damaging 
as it triggers various pathways leading to cell death. Inhibition of NHE1 using 
pharmacological drugs such as cariporide, amiloride and EMD 85131 have been 
shown to have a cardioprotective effect in animal models (Karmazyn, 1988; Scholz et 
al., 1995; Gumina et al., 1998).  
 
1.4.4.5  NHE1 and Cancer 
NHE1 has also been found to play a role in the development and progression of 
cancer. One hallmark of transformed cells is intracellular alkalinization where tumor 
cells have a pHi of 7.12-7.65 as compared to 6.99 -7.2 for normal tissue (Gillies et al., 
2002). This intracellular alkalinization occurs early in the cancer formation. NHE1 
was shown to be responsible for the increase in pHi as blocking NHE1 with amiloride 
could reverse both pH change and transformed phenotype (Rich et al., 2000; McLean 
et al., 2000; Reshkin et al., 2000). The activation of NHE1 in tumor cells is a result of 
higher affinity of NHE1 for H+ (Reshkin et al., 2000). This causes the set point of 
NHE1 in the cells to be higher than the resting pHi leading to a constitutively active 
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NHE1 in tumor cells. The development of intracellular alkalinization is accompanied 
by increased DNA synthesis (Hagag et al., 1987; Ober and Pardee, 1987), cell cycle 
progression (Doppler et al., 1987; Siczkowski et al., 1994), substrate- and serum- 
independent growth (Reshkin et al., 2000). 
In addition to establishing an alkaline intracellular environment, NHE1 has also been 
implicated in cancer cell migration. The acidic extracellular environment of tumor 
increases metastatic ability of cancer cells by promoting neoangiogenesis (Kurschat 
and Mauch, 2000), anchorage-independent growth (Gillies et al., 2002), genetic 




1.4.5 Regulation of NHE1 
 
1.4.5.1  Phosphorylation 
The cytosolic domain of NHE1 regulates the TM domain by being the target region of 
kinases and binding site of regulatory proteins. Phosphorylation of the residues in the 
cytoplasmic domain stimulates the activity of NHE1, causing it to be more active at a 
higher pH. Kinases that have been shown to phosphorylate NHE1 include 
extracellular-signal-regulated kinase 1/2 (ERK 1/2) (Denker et al., 2000; Denker and 
Barber, 2002), p90 ribosomal S6 kinase (p90rsk) (Takahashi et al., 1999) Rho 
associated kinase p160ROCK (Tominaga et al., 1998), Nck-interacting kinase (NIK) 
(Yan et al., 2001) and Ca2+/calmodulin-dependent kinase II (CaMKII) (Fliegel et al., 
1992). The p38 kinase of the MAPK family can also phosphorylate NHE1 directly 
(Khaled et al., 2001). Protein kinase C and D regulate the exchanger via mechanism 
other than direct phosphorylation (Haworth et al., 1999; Sauvage et al., 2000). Protein 
phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) have been shown to 
dephosphorylate NHE1 (Misik et al., 2005; Snabaitis et al., 2006). 
 
1.4.5.2  Regulatory Proteins 
The cytoplasmic tail of NHE1 interacts with a variety of signaling molecules. Three 
calcium binding proteins have been shown to interact with NHE1: calmodulin (CaM) 
and calcineurin homologous protein (CHP) stimulate NHE1 activity while tescalcin 
acts to inhibit NHE1 activity. Other molecules that can bind to the cytoplasmic tail 
include carbonic anhydrase II (CAII), adaptor protein 14-3-3, PIP2, HSP70 and ERM. 
CaM binds to the cytoplasmic tail at two sites: a high affinity site located at amino 
acids 636-656 and a low affinity site at amino acids 657-700 (Bertrand et al., 1994). 
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The high affinity site function as auto-inhibitory domain for NHE1 and binding of 
CaM/Ca2+ to this site can abolish this inhibition (Wakabayashi et al., 1994). CHP 
binds to the amino acids located at 510-530. The association between CHP and NHE1 
is crucial for NHE1 functioning, as NHE1 or CHP mutant that prevents their 
association drastically reduces NHE1 activity (Pang et al., 2004). Tescalcin is a 
protein structurally homologous to CHP, where it interacts with the final 180 amino 
acids of cytoplasmic tail of NHE1 to inhibit its activity (Mailänder et al., 2001; Li et 
al., 2003). CAII binds to amino acids 790-802 of NHE1 to enhance the activity of 
NHE1 (Li et al., 2002; Li et al., 2006). Phosphorylation within amino acids 634-789 
region increases the association between NHE1 and CAII, resulting in a more 
efficient proton removal from the cell. The binding of 14-3-3 to NHE1 tail is also 
dependent on phosphorylation of NHE1. The protein 14-3-3 prevents the 
dephosphorylation of Ser703, thereby stabilizing the active conformation of NHE1 
(Lehoux et al., 2001). PIP2 binds to NHE1 at two PIP2 binding motifs at amino acids 
513-520 and 556-564 and is required for optimum activity of NHE1 (Aharonovitz et 
al., 2000). HSP70 binds to the cytoplasmic domain of NHE1 to play a role in the 
folding and processing of the exchanger (Silva et al., 1995). The binding of ERM 
proteins to the cytoplasmic tail of NHE1 allows NHE1 to interact with actin filaments. 
This is important for the localization of NHE1 to the lamellipodia and for NHE1-





1.4.6 Regulation of NHE1 gene transcription 
The human NHE1 gene is located on chromosome 1 p35-p36.1 and is approximately 
70 kilo-bases (kb). The coding region is divided into 12 exons and 11 introns. The 
promoter region of human NHE1 has been described. The promoter region is 1377 
bases and is made of a TATA box, four GC boxes, two CAAT boxes, three AP-1 sites, 
and a cyclic AMP response element (Miller et al., 1991). The regulation of NHE1 
gene transcription in mouse has been widely studied. The analysis of mouse NHE1 
promoter revealed several important regions that are binding sites for transcription 
factors of NHE1. Mitogens, in addition to regulating NHE1 activity also regulate 
NHE1 promoter activity (Besson et al., 1998). Addition of serum to serum-starved 
cells was able to activate a 1.1kb proximal fragment of the mouse NHE1 promoter. 
Other growth factors such as insulin, thrombin and EGF also increase the activity of 
NHE1 promoter (Besson et al., 1998). Promoter analysis and gel mobility shift assays 
showed that a region between 0.9 and 1.1 Kb from the start site of the mouse NHE1 
promoter is involved in mitogen stimulation of NHE1 transcription (Besson et al., 
1998). The chicken ovalbumin upstream promoter-transcription factors (COUP-TFs) 
are found to be involved the transcription of mouse NHE1 at the distal end of NHE1 
promoter (Fernandez-Rachubinski and Fliegel, 2001). Nucleotides at −841 to 
−800 base pair (bp) upstream of the start site bind to COUP-TFs and were protected 
in footprint analysis of the mouse promoter. Further study showed that nucleotides at -
829 to -824 are critical for COUP-TF binding. Thyroid hormone was found to 
stimulate mouse NHE1 transcription in addition to stimulating the activity of the 
protein. The −838 to −832 region is crucial for the binding of thyroid hormone to 
NHE promoter (Li et al., 2002). A highly conserved poly(dA dT)-rich region at −155 
to −169 bp appears to be important in regulation of expression of the NHE1 gene 
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(Yang et al., 1996). AP2 transcription factor was found to bind to the proximal 
promoter end at −95 to −111 bp from the start site of mouse NHE1 promoter (Dyck et 
al., 1995). Deletion of distal promoter sequence up to the AP2 binding site decreased 
promoter activity by 25% in both NIH 3T3 and p19 embryonal carcinoma (Dyck et al., 
1995; Dyck and Fliegel, 1995). Deletion of the AP2 site abolishes most of the 




1.5 AIM OF STUDY 
There is mounting evidence that implicates ROS as an important signaling molecule 
in various physiological processes. Our lab have previously established that the 
regulation of tumor cell sensitivity to death stimulus is linked to the ratio of 
superoxide (O2·-) and hydrogen peroxide (H2O2) (Clément and Pervaiz, 1999; Clément 
and Pervaiz, 2001; Pervaiz and Clément, 2002; Pervaiz and Clement, 2004). ERα 
over-expression in breast tumor cells confers cells proliferative advantages and 
resistance to apoptosis. ERα had been shown to be a redox regulated gene. Its 
transcriptional activity and DNA binding capacity were shown to be modulated by 
thioredoxin (Hayashi et al., 1997). Thiol-reacting oxidants (diamide, iodosobenzoate, 
H2O2) or alkylator (iodoacetamide) produce a concentration-dependent loss in ER 
DNA-binding capacity in MCF7 cells which is fully reversible by dithiothreitol (DTT) 
reduction (Liang et al., 1998). One study using glucose oxidase system suggested that 
ERα protein itself might be redox regulated (Weitsman et al., 2009). The mechanism 
of this regulation is however unclear. The first aim of this project is to investigate the 
mechanistic role of H2O2 in regulating ERα expression. The understanding of how 
ERα is effected by ROS may have an impact on the development of new strategies for 
treatment and prevention of breast cancer. This involves analyzing the protein level of 
ERα in H2O2 treated MCF7 cells and establishing at which level ERα expression is 
being affected. The molecular mechanism of regulation together with the effects of 
altered ERα expression on downstream targets will be explored. Concluding the first 
section is the study of how 15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2), 
affects ERα expression through the production of ROS intermediate. 
Our group has shown that the redox regulation of cell survival in tumor could also be 
associated with regulation of intracellular pH (pHi) (Pervaiz and Clément, 2002). 
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Central to this is the regulation of NHE1 expression. An increase in intracellular O2·- 
increases NHE1 promoter activity and protein expression which enhance cells’ 
resistance to apoptosis whereas addition of exogenous H2O2 represses NHE1 promoter 
activity, protein expression and sensitizes cells to death triggers (Akram et al., 2006); 
(Kumar et al., 2007). Further studies have shown that H2O2 mediates down-regulation 
of 1.1kb mouse NHE1 promoter via an oxidative and caspase dependent mechanism 
(Kumar et al., 2007). The second aim of this project is to further investigate the 
regulation of NHE1 expression by H2O2. This involves identifying the response 
element of H2O2 within the NHE1 promoter and studying how H2O2 affects the 
promoter activity. The role of caspase in H2O2 down-regulation of NHE1 promoter 
activity will be explored. In addition, the effects of 15d-PGJ2 on NHE1 promoter 
activity will be investigated. Finally, we will attempt to identify the transcription 








2.1.1 Chemicals and reagents 
Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park Memorial Institute-
1640 (RPMI-1640), Fetal Bovine Serum (FBS), Charcoal-stripped Fetal Bovine 
Serum (CS-FBS), Phosphate Buffered Saline (PBS), Trypsin, and L-glutamine were 
from Hyclone (UT, USA). Gentamicin Sulphate was purchased from BioWhittaker 
(Walkersville, MD). Geneticin (G418) and Phenol-free RPMI-1640 were supplied by 
GIBCO (MD, USA). Aprotinin, Pepstatin A, Phenylmethanesulfonyl Fluoride 
(PMSF), Leupeptin, Sodium Vanadate, Dimethylsulfoxide (DMSO), 1,10-
Phenanthroline monohydrate, LY294002, U0126, SP600125, MG132, GW9662, 
Cycloheximide, Buthionine Sulfoximine (BSO), N-Acetyl-L-cysteine (NAC), 
Estradiol (E2), Diamide, Dithiothreitol (DTT), β-mercaptoethanol (BME), 
Dimethylthiourea (DMTU), Crystal Violet and Bovine Serum Albumin (BSA) were 
supplied by Sigma-Aldrich (LO, USA). Peroxynitrite (ONOO-) was purchased from 
Upstate (Temecula, CA, USA). Methanol, Hydrogen Peroxide (H2O2) and Sodium 
Dodecyl Sulphate (SDS) were purchased from Merck (Darmstadt, Germany). Caspase 
tetra-peptide inhibitor, z-VAD-FMK was bought from R&D Systems (MN, USA). 
15d-PGJ2 and Caspase Fluorogenic Substrates: Ac-VDVAD-AFC, Ac-DEVD-AFC, 
Ac-VEID-AFC, Ac-IETD-AFC and Ac-LEHD-AFC were from Alexis Biochemical 
(Lausen, Switzerland). 5-(and-6)-chloromethyl-2´,7´-dichlorodihydrofluorescein 
diacetate acetyl ester (CM-H2DCFDA) was purchased from Molecular Probes 
(Eugene, OR, USA). Coomassie PlusTM Protein assay reagent, RestoreTM Western 
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Blot Stripping Buffer, Supersignal West Pico Chemiluminescent Substrate are from 
Pierce Biotechnology Rockford (IL, USA). 
 
2.1.2 Antibodies 
Antibodies for ERα (D-12), ERβ (H-150), AP2α (3B5) and Cu/Zn SOD (FL-154) 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies 
for Akt (C67E7), Phospho-Akt (S-473), p44/42 MAPK (ERK 1/2), Phospho- p44/42 
MAPK (ERK 1/2), SAPK/JNK, Phospho-SAPK/JNK (T183/Y185) (81E11), c-Myc 
(D84C12) XP (TM), and Progesterone Receptor A/B (C89F1) were purchased from 
Cell Signaling Technology Inc (Beverly, MA). PARP antibody was purchased from 
Clontech Laboratories (CA, USA). V5 tag antibody (E10) was purchased from 
Abcam (MA, USA). NHE1 antibody was purchased from Chemicon International Inc 
(CA, USA). SP1 antibody was purchased from Active Motif (CA, USA). β-actin 
monoclonal antibody was purchased from Sigma (LO, USA). Secondary antibodies: 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody was obtained from 
DakoCytomation (Glostrup, Denmark) and HRP-conjugated goat anti-mouse was 
from Pierce Biotechnology (IL, USA).  
 
2.1.3 Plasmids 
Estrogen response element (ERE) reporter construct was bought commercially from 
Clontech Laboratories (CA, USA). The luciferase reporter plasmid constructs of 
mouse NHE1 promoter: pXP-1.1, pXP-0.9, pXP 0.5, pXP-0.2, pXP-0.18, pXP-0.15, 
and pXP-0.12 were kindly provided by Dr. Larry Fliegel, Department of Biochemistry, 
University of Alberta, Canada. Luciferase reporter plasmid constructs of human 
NHE1 promoter: -1374/+16, -252/+16, and -92/+16 were kindly provided by Dr. 
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Alexey Kolyada, Department of Medicine, Tufts University School of Medicine, 
Boston, USA. The mouse AP2 plasmid constructs: AP2α, AP2β, AP2γ, AP2δ and 
AP2ε were kindly provided by Dr. Bruce D. Gelb, Center for Molecular Cardiology, 
Mount Sinai School of Medicine, USA. The AP2 dominant negative construct was 
kindly given by Dr. Frederick B. Domann, Department of Radiation Oncology, and 
Holden Comprehensive Cancer Center, The University of Iowa, USA. 
 
2.1.4 Cell lines and cell culture 
All cell lines used in this project are adherent cells. Cells were grown in 37 οC 
incubator supplied with 5 % CO2. Cells were replenished with fresh medium every 3 
to 4 days and split 1:5 whenever they reached 80 % confluency. For use in 
experiments, cells were detached from the flask using 0.125 % trypsin and pelleted by 
centrifugation at 1,600 rpm before resuspension in fresh medium. Cells were counted 
using haemocytometer prior to seeding. 
Human breast cancer cells lines MCF7 and T47D were maintained in RPMI-1640 
medium supplemented with 10 % fetal bovine serum (FBS), 2 mM L-glutamine and 
0.05 mg/ml gentamycin sulfate. For experiments that test the effects of estrogens, 
cells were grown for one day in complete medium as above before changing to 
phenol-free RPMI 1640 supplemented with required concentration of charcoal-
stripped FBS. 
Wild type L6 rat myoblast cells were maintained in DMEM medium supplemented 
with 10 % FBS, 2 mM L-glutamine and 0.05 mg/ml gentamycin sulfate. L6 cells 
stably transfected with 1.1 kb of NHE1 promoter and NIH 3T3 mouse embryonic 
fibroblast stably transfected with 0.15 kb of NHE1 promoter were obtained from Dr. 
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Larry Fliegel, Department of Biochemistry, University of Alberta, Canada. These 
cells were grown similarly to L6 wild type cells with the addition of 0.25 mg/ml of 





2.2.1 Treatment of cells with hydrogen peroxide (H2O2) and other compounds 
A stock solution of 10 mM H2O2 was first prepared by diluting 30 % (v/v) H2O2 
solution with 1X PBS. Various concentrations of H2O2 were prepared by diluting the 
stock solution of 10 mM H2O2 with 1X PBS. The H2O2 solutions were then added to 
medium to attain the indicated final concentrations. In general, seeding density of 
0.08 x 106 cells/ well was used for 12-well plate, 0.25 x 106 cells/ 60 mm dish and 1.0 
x 106 cells/ 100 mm dish.  
Stock solutions of zVADfmk, U0126, LY294002, SP600125, MG132, GW9662 
cycloheximide, and E2 were prepared in DMSO. 15d-PGJ2 was dissolved in ethanol. 
Stock solutions of diamide, DTT, DMTU, BSO, and NAC were dissolved 1X PBS.  
 
2.2.2 Morphology studies 
The morphology of the cells was analyzed by taking photo using the Olympus 
camedia digital camera attached to the light microscope (Olympus CK2) at the 
magnification of 10X. 
 
2.2.3 Crystal violet assay 
Cells were seeded at 0.08 x 106 cells/ well in a 12-well plate for 2 days. After drug 
treatment the medium was removed from the wells and cells were washed with 1X 
PBS. Five hundred microliters of crystal violet solution (0.75 % crystal violet, 50 % 
ethanol, 1.75 % formaldehyde and 0.25 % NaCl) was added to stain the cells in each 
well for 10 min. The wells were washed with deionized water a few times to remove 
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any traces of the crystal violet solution and left to air dry. The cells were lysed with 
500 µl of 1 % SDS in PBS to release the crystal violet into solution. Fifty microliters 
of the cell lysate from each well was transferred into separate wells of a 96-well 
microtitre plate. Cell density was assessed by measuring cell associated crystal violet 
at 595 nm using Spectrofluoro Plus plate reader (TECAN, GmbH, Grodig, Austria). 
 
2.2.4 Plasmid transfection 
For promoter activity studies, 0.08 x 106 cells/ well were seeded in a 12-well plate. 
For western blot analysis, 0.17 x 106 cells/ 60 mm dish were seeded. Cells were 
seeded for 18 h to 24 h prior to transfection. Overexpression transfection was carried 
out using SuperFect® Transfection Reagent (Qiagen, GmbH, Hilden, Germany) 
according to manufacturer’s instruction. Briefly, for one 60 mm tissue culture dish, 
plasmid DNA was mixed with 150 µl of serum-free, antibiotics-free DMEM and 15 µl 
of SuperFect Reagent and incubated at room temperature for 10 min to allow for 
SuperFect-DNA complex formation. Another 600 µl of DMEM, supplemented with 
serum and antibiotic was then added to the mixture before introducing to cells. Cells 
were exposed to the transfection mixture for 3h in the incubator. After 3 h, cells were 
washed with 1X PBS and provided with fresh medium. Cells were normally harvested 
at 48 h post transfected, unless stated otherwise. 
 
2.2.5 Small interfering RNA (siRNA) transfection 
For promoter activity studies, 0.08 x 106 cels/ well were seeded in a 12-well plate. For 
western blot analysis, 0.17 x 106 cells/ 60 mm dish were seeded. Cells were seeded for 
18 h to 24 h prior to transfection. siRNA transfection was carried using 
Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, CA, USA) 
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according to the manufacturer’s instructions. For 60 mm tissue culture dish, siRNA 
duplex was diluted with 375 µl of Opti-MEM® I Reduced Serum Medium. 
Lipofectamine RNAiMAX was also diluted with 375 µl of Opti-MEM® I Reduced 
Serum Medium. siRNA was combined with RNAiMAX and incubated at room 
temperature for 20 min before adding to cells. Cells were transfected with the 
transfection mixture overnight, after which cells were washed with 1X PBS and 
replenished with fresh medium. Cells were normally harvested at 48 h post 
transfection. 
siRNA for ERα (sc-29305), AP2α (sc-29697)  and SP1 (sc-29488) were purchased 
from  Santa Cruz Biotechnology (Santa Cruz, CA, USA). siRNA for SP1 was also 
purchased from (Thermo Scientific, IL, USA). A control siRNA that is non-
homologous to any known gene sequence was used as a negative control from 
QIAGEN (Valencia, CA, USA). 
 
2.2.6 Protein concentration determination 
Protein concentration of cell lysate was determined by comparing absorbance reading 
of samples with protein standards of known dilutions. Briefing, 200 µl of Coomassie 
Blue (PIERCE, IL, USA) was added to 2 µl of cell lysate in a 96-well plate and 
incubated at room temperature for 5 min. Absorbance was read at 595 nm using 
Spectrofluoro Plus spectroflurometer (TECAN, GmbH, Grodig, Austria). Protein 
standards of 2.5, 5, 10 and 20 µg/ml were prepared using bovine serum albumin 
(PIERCE, IL, USA) and treated similarly to obtain a standard graph from the 
absorbance readings. Protein concentration of the cell lysates were estimated from the 
standard graph.  
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2.2.7 SDS-PAGE and western blot 
After treatment, the medium was removed and cells were washed once with 1X PBS 
before they were removed from the tissue culture plate by scrapping method and 
resuspended in PBS. The cells were pelleted down by centrifugation at 12,000 rpm for 
5 min and lysed in RIPA buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 1% v/v 
deoxycholic acid, 0.1% v/v SDS and 1 mM EDTA) containing protease inhibitors (1 
mM PMSF, leupeptin, pepstain A, aprotinin) and 1 mM phosphatase inhibitor 
Na3VO4. Fifty microgram of protein was incubated at 95 οC for 5 min and resolved by 
8 % sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at 100 
V in a Bio-Rad Mini-PROTEAN 3 Cell (CA, USA). For detection of NHE1 protein, 
samples were heated at 37 οC instead. Kaleidoscope standard (Bio-Rad, Ca, USA) 
was loaded to estimate protein size. Resolved proteins were transferred to a 
nitrocellulose membrane (Pall Corporation) by wet transfer method using Bio-Rad 
Mini Trans-Blot Electrophoretic Transfer Cell (CA, USA) at 370 mA for 1 h. The 
membrane was blocked in 5 % (w/v) non-fat milk in Tris-buffered saline/ 0.1 (v/v) 
Tween 20 (TBST) for 1 h. The membrane was washed three times with TBST and 
probed with the respective 1o antibody dissolved in BSA overnight at 4 οC. After 
washing off the primary antibody with TBST, respective horse radish peroxidase 
(HRP) conjugated 2o antibody in 5 % fat-free milk was incubated with the membrane 
for 1 h. Membranes were washed three times with TBST, specific protein-antibody 
interactions were detected by enhanced chemiluminscence using SuperSignal 
Chemiluminescent Substrate (PIERCE, IL, USA) with Kodak Biomax MR X-ray film. 
For re-probing of the same membrane for different proteins, blots were stripped with 
Restore Western Blot Stripping Buffer and re-probed for another protein of interest. 
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The bands obtained were scanned in with EPSON Perfection 1250 and analyzed by 
FujiFilm Multigauge V3.0. The band density for proteins was normalized against the 
band density of β-actin. 
 
2.2.8 Caspase assay 
After treatment with H2O2 for specific period of time, cells were scraped off the dish 
and transferred to a 15 ml falcon tube together with the medium. Cells were pelleted 
down by centrifugation at 2500 rpm for 5 min at 4 οC. Cells were washed once with 
PBS and pelleted. The supernatant was removed and cells were resuspended with 100 
µl of Cell Lysis Buffer (BD Pharmigen). The lysate was incubated on ice for 10 min 
and transferred to a 1.5 ml eppendorf tube. For caspase assay, cell lysates were 
centrifuged at 12000 rpm for 5 min at 4 οC to remove cell debris. Forty microliters of 
each sample was transferred into a 96-well plate and mixed 50 µM of specific caspase 
substrate (caspase 2 substrate: Ac-VDVAD-AFC, caspase 3/7 substrate: Ac-DEVD-
AFC, caspase 6 substrate: Ac-VEID-AFC, caspase 8 substrate: Ac-IETD-AFC, and 
caspase 9 substrate: Ac-LEHD-AFC) and 40 µl of 2X reaction buffer (10 mM HEPES, 
pH 7.4, 2 mM EDTA, 6 mM DTT, 10 mM KCl and 1.5 mM MgCl2) supplemented 
with protease inhibitors (1 mM PMSF, 10 µg/ml Aprotinin, 20 µg/ml pepstatinA, 10 
µg/ml leupeptin). Samples were incubated at 37 οC for 1 h and AFC fluorescence was 
read at an excitation wavelength of 400 nm and an emission wavelength of 505 nm 
using Spectrofluoro Plus spectroflurometer (TECAN, GmbH, Grodig, Austria).  
Caspase activity was normalized against protein concentration of each sample and 




2.2.9 Single and dual luciferase assay 
NHE1 promoter activity of stably transfected cells was assessed with a single-
luciferase assay kit (Promega, Madison, WI) according to manufacturer’s instructions. 
Cells were grown in 12-well plate and subjected to treatment. After treatment, cells 
were washed with 1X PBS and lysed with 100 µl of reporter lysis buffer at 4 ˚C and 
stored at -80 ˚C before assay. For the assay, 10 µl of the cell lysate was added to 50 µl 
of the luciferase substrate. Bioluminescence generated was measured using a Sirius 
luminometer (Berthold, Pforzheim, Germany). The luminescence readings obtained 
were then normalized with the protein concentration of the cell extract using the 
Coomassie PlusTM Protein assay reagent. 
Dual luciferase assay was used to measure promoter activity of cells transiently 
transfected NHE1 promoter-luciferase construct. Fifty thousand cells/ well were 
seeded overnight in 12-well plate and 1 µg of NHE1 promoter linked to luciferase 
gene construct was transfected into cells using SuperFect Transfection Reagent for 3 h. 
As a transfection control, 0.1 µg of Renilla plasmid was co-transfected. After 
transfection, cells were washed with 1X PBS and given fresh medium and allowed to 
recover. Forty-eight hours post-transfection, cells were washed with 1X PBS and 
lysed with 100 µl of passive lysis buffer.  
For transfection of ERE, MCF7 cells were seeded at 0.05 x 106 cells/well in 12-well 
plate overnight. One microgram of ERE plasmid construct was transfected in each 
well using SuperFect Transfection Reagent for 3 h. As a transfection control, 0.1 µg 
of Renilla plasmid was co-transfected. After transfection, cells were recovered 
overnight in phenol-free RPMI-1640 supplemented with 10 % CS-FBS. Cells were 
then treated with 100 µM of H2O2 for 16h before 10 nM of E2 was added for 2, 4, or 6 
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h. After treatment, cells were washed with 1X PBS and lysed with 100 µl of passive 
lysis buffer.  
Dual-Luciferase® reporter assay system (Promega, Madison, WI, USA) was used 
measure the promoter activity of cells transiently transfected with luciferase plasmid 
constructs, according to the manufacturer’s manual. 
 
2.2.10 Chloramphenicol acetyl transferase (CAT) assay 
NHE1 promoter activity of the transiently transfected cells with CAT reporter plasmid 
constructs was assessed using an enzyme immunoassay to determine the expression of 
the CAT. For transfection, cells were seeded at 0.05 x 106 cells/ well in 12-well plate 
overnight. One microgram of human NHE1 plasmid construct was transfected in each 
well using SuperFect Transfection Reagent for 3 h. As a transfection control, 0.1 µg 
of Renilla plasmid was co-transfected. Cells were washed with 1X PBS and given 
fresh medium and allowed to recover. Forty-eight post-transfection, cells were 
harvested and the promoter activity was analyzed by CAT ELISA assay (Roche) 
according to manufacturer’s protocol. The levels of CAT protein were quantified 
using a CAT antigen capture enzyme-linked immunosorbent assay (ELISA) (Roche 
Molecular Biochemicals).  
To measure the renilla luciferase activity, 50 µl of stop and glow substrate was added 
to 10 µl of cell lysate. The bioluminescence generated was measured using Sirius 





2.2.11 RNA isolation 
Total RNA was isolated by using RNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany) 
according to manufacturer’s instructions. RNA concentration and purity was 
determined using Nanodrop-1000 (Thermo Scientific, Wilmington, DE, USA). 
 
2.2.12 Reverse transcription (RT) and real-time chain polymerase reaction 
(PCR) 
Two hundred nanogram of total RNA was reverse transcribed with 1.1U/ µl 
MultiScribe™ reverse transcriptase in the presence of 1X RT buffer, 5mM MgCl2, 
425 µM of each dNTPs, 2 µM random hexamers, 0.35U/ µl RNase inhibitor, made up 
to 10 µl with sterile water. RT reaction was carried out in Mastercycler gradient 
(Eppendoff, USA) at 25 οC for 10 min, followed by 37 οC for 60 min and a 
terminating step of 95 οC for 5 min. 
 For real time PCR, 200 ng of total RNA was transcribed as described above. For a 50 
µl reaction, 5 µl of RT product was mixed with 1X TaqMan® Universal PCR Master 
mix, 2.5 µl of 20x specific TaqMan probe, 2.5 µl of 18S rRNA TaqMan probe, topped 
up to 50 µl with sterile water. A negative control for RT in which sterile water 
replaced the RNA template was included. Another control where RT mix was 
replaced with sterile water was included to check for DNA contamination. Real-time 
PCR was carried out using 7500 Fast Real-Time PCR System (Applied Biosystems, 
USA) with a protocol that consists of 50 οC for 2 min, 95 οC for 10 min, followed by 
40 cycles of denaturing at 95 ο C for 15 sec and extension at 60 οC for 1 min. Results 
were analyzed using Sequence Detection Software version 1.3 provided by Applied 
Biosystems. Relative gene expression was obtained after normalization with 
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endogenous 18S and determination of the difference in threshold cycle (Ct) between 
treated and untreated cells using 2-∆∆Ct method.  
 
2.2.13 Intracellular ROS assessment by CM-H2DCFDA 
Intracellular concentration of ROS was determined by staining cells with the redox 
sensitive dye CM-H2DCFDA, which fluoresces under oxidation by H2O2 and its free 
radical products. Briefly, cells were washed with PBS once and detached off the 
tissue culture dish by incubating with 0.125 % trypsin at 37 οC for 10 min. Trypsin 
was neutralized with 500 µl of medium and the cell pellet was collected by pulse-spin 
centrifugation. The cells were incubated with 5 µM of CM-H2DCFDA at 37 οC in the 
dark for 20 min. Cells were then pelleted and washed with PBS to remove excess dye. 
Cells were resuspended in 500 µl of PBS and filtered through a 41 µm filter before 
injected into the Coulter Epics Elite ESP Flow Cytometer. Ten thousands events were 
collected with the excitation wavelength of 495 nm and emission wavelength of 525 
nm. No dye treatment and 300 µM of H2O2 were used as negative and positive 
controls respectively.  
 
2.2.14 Nuclear-cytoplasmic fractionation 
Fractionation of the nucleus and cytosol was carried out using NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (PIERCE, Thermo Fisher Scientific Inc, Rockford, 
USA) according to manufacturer’s instructions. Briefly, cells were washed with 1X 
PBS and scrapped off the plate with the help of a scrapper and transferred to a 15 ml 
falcon tube. The amount of the various buffers added and duration of lysis was 
performed according to manufacturer’s instructions. 
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2.2.15 Electromobility shift assay (EMSA) 
The synthetic biotin-labeled oligonucleotide of the sequence 5’-bCGC GAT ACT 
TCT TTC CCT CGG CGA CAG GGG CCG CTG CGC T-3’ and non-labeled reverse 
complement 5’-AGC GCA GCG GCC CCT GTC GCC GAG GGA AAG AAG TAT 
CGC G-3’ were made corresponding to the 5’ 0.15kb of human NHE1 promoter. The 
oligonucleotides were heated up to 95 οC for 5 min and allowed to cool to room 
temperature for annealing. EMSA was performed using LightShift Chemiluminescent 
EMSA Kit (Thermo Scientific, IL, USA). Five microgram of MCF7 nuclear extracts 
was incubated with H2O2 for 20 min at room temperature. For treatment with reducing 
agent, the protein reaction samples were further incubated with various concentrations 
of DTT for another 20 min. The protein reaction mixtures were subsequently 
incubated with biotin-labeled DNA oligonucleotides in the presence of 1 µg poly 
dIdC and 1X binding buffer (10 mM Tris, 50 mM KCl, 1 mM DTT, 2.5 % glycerol, 5 
mM MgCl2, 0.05 % NP-40) for 20 min at room temperature. The bound DNA-protein 
was separated from free oligonucleotides by gel electrophoresis in 5 % native 
polyacrylamide gels in 0.5X TBE buffer (45 mM Tris-borate, 1 mM EDTA). 
Electrophoresis was conducted at a constant current of 100 V for 45 min. The protein-
DNA complex was transferred to a nylon membrane using by wet transfer method 
using Bio-Rad Mini Trans-Blot Electrophoretic Transfer Cell (CA, USA) at 380 mA 
for 30 min. The DNA was cross-linked to the nylon membrane at 120 mJ/ cm2 using a 
commercial UV-cross-linker instrument equipped with 254 nm bulk. The membrane 
was treated according to the manufacturer’s instructions to prepare it to be detected by 
chemiluminescence with Kodak Biomax MR X-ray film. 
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2.2.16 Statistical analysis 
Statistical analysis was performed using algorithm of unpaired Student’s t-test from 
Microsoft Excel software to compare between means of relevant conditions. P-value 




CHAPTER 3A: RESULTS – REDOX REGULATION OF ERα 
 
3A.1 H2O2 AND THE EXPRESSION OF ERα PROTEIN  
Depending on its concentration, H2O2 can have a plethora of effects on cells. Low 
amount of H2O2 has been shown to increase cell proliferation while moderate amount 
of H2O2 regulates cellular processes such as redox regulation of reactive cysteine on 
transcription factors and protein kinases. On the extreme end, H2O2 causes cell death 
either by apoptosis or necrosis. Different types of cells also have different resistance 
or antioxidant capacity against ROS challenge.  
 
3A.1.1  Morphology and growth of MCF7 cells upon exposure to H2O2 
MCF7 is a breast cancer cell line derived in the Michigan Cancer Foundation in 1973 
from a pleural effusion of a 69 year old Caucasian woman (Soule et al., 1973). MCF7 
cell line was chosen to study the redox regulation of ERα as it expresses high level of 
the receptor and has been used as a model of ERα action in large number of reports 
(Pinzone et al., 2004). 
Here, we tested the effects of increasing concentrations of H2O2 on the morphology 
and growth of MCF7 cells. There were some morphological changes in MCF7 cells 
treated with H2O2 for 24 h. Starting from 50 µM of H2O2, cells appeared flatter and 
less clustered from one another (Fig. 1a). Cell density also decreased with increasing 
concentrations of H2O2. Notably, density of cells treated with 200 µM of H2O2 looked 
similar to cells at the time of trigger. 
To assess the effects of H2O2 challenge on the growth of MCF7 cells, the cells were 
treated with increasing concentrations of H2O2 for 24 and 48 h. Cell density was 
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estimated by crystal violet staining. The time at which H2O2 was added was regarded 
as time 0 h. Cell growth was expressed as percentage relative to the time of treatment. 
At lower concentrations, cells showed a decreased proliferation starting from 50 µM 
of H2O2. H2O2 induced a concentration-dependent inhibition of cell growth with total 
inhibition seen at 200 µM of H2O2 treatment (Fig. 1b). There was no statistical 
difference in the cell density when cells were treated with 200 µM of H2O2 and 








*: p-value<0.05 (relative to time of treatment) 
Figure 1: MCF cell survival upon H2O2 treatment. a) Morphology of MCF7 upon H2O2 
treatment. MCF7 cells were seeded for 2 days before being treated with increasing 
concentrations of H2O2 for 24 h. b). Cell density and survival were estimated by staining the 
cells with crystal violet 24 h and 48 h after the treatment. Results were obtained from mean of 
3 independent experiments done in duplicates +/- SE. 
25 µMTime of trigger Control












































3A.1.2  Effect of H2O2 on the expression of ER protein 
ERα had been shown to be a redox regulated gene. Its transcriptional activity and 
DNA binding capacity could be modulated by oxidants such as diamide, 
iodosobenzoate and H2O2. Next, the effects of oxidative stress in the form of H2O2 on 
the expression on ER protein itself were investigated. The effects of H2O2 on ER 
subtypes were examined through a 48 h time-course period. Cells were treated with 
increasing concentrations of H2O2 (0 to 200 µM) for 24 and 48 h. The total cell 
lysates were subjected to western blot using specific antibodies against ERα and ERβ. 
As with the inhibition of cell growth, H2O2 exerted its effects on ERα in a 
concentration-dependent manner (Fig. 2a). Figure 2b shows that treatment of MCF7 
cells with H2O2 decreased ERα protein level to 73, 26 and 5 % of untreated cells with 
50, 100 and 200 µM of H2O2 respectively in the first 24 h. A statistically significant 
decrease in the expression of ERα protein was observed with 100 and 200 µM of 
H2O2. After 48 h of treatment, ERα level returned to 95, 69 and 8 % of untreated cells 
with 50, 100 and 200 µM of H2O2 respectively. The restoration of ERα is statistically 
significant for 100 µM of H2O2. The result suggests that the down-regulation of ERα 
is reversible at concentration of 100 µM of H2O2 or less. ERβ level on the other hand 
was unaffected by H2O2 treatment and stayed constant regardless of the concentration 










*: p-value < 0.05 (relative to no H2O2 control) 
**: p-value < 0.05 
 
Figure 2: H2O2 induces concentration dependent down-regulation of ERα. a) MCF7 cells 
were treated with increasing concentrations of H2O2 for 24 h and 48 h. Cell extracts were 
analyzed by western blot. b) Densitometry of ERα protein level (% relative to no H2O2 



















































An experiment was carried out to ascertain whether the ERα protein was specifically 
recognized by the antibody. MCF7 cells were transfected with either 50 nM control 
(scrambled) siRNA or different concentrations of ERα specific siRNA. Results from 
Figure 3 show that the ERα band disappeared when treated with ERα specific siRNA 




Figure 3: Specificity of ERα antibody. MCF7 cells were grown overnight and transfected 
with ERα siRNA at different concentrations using Lipofectamine RNAiMAX reagent as 



































To determine that the effect of H2O2 is not limited to one single cell line, another ERα 
positive breast cancer cell, T47D was challenged with H2O2. Similar to MCF7 cells, 
the ERα level of T47D was down-regulated by H2O2 in a concentration-dependent 
manner in 24 and 48 h (Fig. 4a and 4b). Thus, the result indicates that the repression 







Figure 4: H2O2 down-regulates ERα in both MCF7 and T47D cells. a) MCF7 and b) T47D 
cells were treated with increasing concentrations of H2O2 for 24 h and 48 h. Cell extracts were 




















When ERα is not bound to its ligand, it resides in the cytosol. It migrates into the 
nucleus once it binds to its ligand and homodimerizes. In a normal growing cell, ERα 
can be found both in the cytosol and nucleus (Jazbutyte et al., 2009) as there will be 
some estrogenic ligands found in the cell culture medium. As the results in Figure 2a 
came from total cell lysates, the observed decrease in ERα is from a pool of both the 
cytosolic and nucleus fractions. In order to understand which fraction of ERα was 
affected by H2O2 treatment, a cytosolic and nuclear fractionation was carried out with 
cells treated with or without 200 µM of H2O2. Figure 5 shows that without treatment, 
MCF7 cells indeed have both cytosolic and nucleus pools of ERα. When cells were 
treated with H2O2, both pools of ERα protein were down-regulated. The results 





Figure 5: H2O2 induces down-regulation of both nucleus and cytosolic fractions of ERα. 
MCF7 cells were seeded for 2 days and treated with or without 200 µM of H2O2 for 24 h. 
Cells were subjected to fractionation of the nucleus and cytosol using NE-PER nuclear-
cytoplasmic extraction reagents. C: cytosolic fraction, N: nucleus fraction. PARP is the 











3A.1.3  Effects of estrogen on H2O2 down-regulation of ERα 
Estrogen has been shown to be involved in the feedback mechanism in the down-
regulation of ERα. Stimulation of cells with E2 will lead to rapid degradation of 
intracellular ERα (Tateishi et al., 2004; Alarid et al., 1999; Nawaz et al., 1999). To 
determine if estrogen or estrogen-like compounds play any role in the repression of 
ERα by H2O2, we tested the down-regulation of ERα by H2O2 in different regular 
serum conditions and also in phenol-free medium supplemented with charcoal-
stripped serum. Regular serum contains many growth factors including estrogens, and 
the phenol added to medium also has estrogen-like functions (Berthois et al., 1986). 
Treating regular serum with charcoal/ dextran removes steroid hormones and growth 
factors including most of the estrogen (Cao et al., 2009). Thus, growing the cells in 
phenol free medium supplemented with charcoal-stripped serum will deprive the cells 
of exogenous estrogen and estrogen-like molecules. Figure 6a shows the effects of 
100 µM of H2O2 on cells grown in regular RPMI containing phenol-red supplemented 
with 10 %, 0.5 % and 0 % fetal bovine serum (FBS). Figure 6b shows the effects of 
100µM of H2O2 on cells grown in phenol-free RPMI supplemented with 10 %, 0.5 % 
and 0 % charcoal-stripped FBS. In all the conditions, H2O2 was able to down-regulate 
ERα protein in 24 h but the expression of the protein was recovered by 48 h. The 
basal levels of ERα when cells were grown in regular medium and in estrogen 
deprived condition were also similar. These results show that the down-regulation of 
ERα by H2O2 is independent of estrogen present in the medium and precluded the 











Figure 6: ERα is down-regulated in all serum conditions. MCF7 cells were seeded 
overnight. On day two, the medium was changed to either a) regular RPMI containing 
different percentage of regular serum (FBS) or b) phenol-free RPMI containing different 
percentage of charcoal-stripped serum (CS-FBS). On day three, cells were treated with 
100µM of H2O2 for 24 and 48 h. Cell extracts were analyzed by western blot. 
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3A.1.4  Time-dependent regulation of ERα protein by H2O2 
Using 100 and 200 µM of H2O2, the study was extended to cover a wider time course 
to determine when ERα protein level starts to decrease. Figure 7a shows that 4 h 
following the exposure of MCF7 cells to H2O2, ERα of treated and untreated cells 
were similar. However, at 8 h after treatment, ERα protein level was decreased from 
100 % to 71 % and 40 % in the presence of 100 and 200 µM of H2O2 respectively 
(Fig. 7b). Consistent with Figure 2, the ERα protein level of cells treated with 100 µM 
of H2O2 was higher at 48 h as compared to 24 h. At 24 h after 100 µM of H2O2 
treatment, ERα protein level of treated cells was at 16 % compared to untreated cells 
while the level increased to 70 %, 48 h after treatment. ERα protein level of cells 
treated with 200 µM of H2O2 remained low even at 48 h. This data suggests that the 
down-regulation of ERα by H2O2 is a reversible event. To determine if ERα down-
regulation is reversible with 200 µM of H2O2, cells were incubated for a longer period 
of time, up to 96 h after H2O2 treatment. Results show that the down-regulation of 
ERα by 200 µM of H2O2 is also reversible. ERα level of cells treated with 200 µM of 







*: p-value < 0.05 (relative to no H2O2 control) 
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Figure 7: H2O2 induces a time-dependent down-regulation of ERα. a) MCF7 cells were 
treated with increasing concentrations of H2O2 for various time-points. Cell extracts were 
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Figure 8: H2O2-induced down-regulation of ERα is reversible. MCF7 cells were treated 
with 0, 100 and 200 µM of H2O2 for various time-points. Cell extracts were analyzed by 
western blot. Results shown are representative of 3 independent experiments. 
 
 
3A.1.5  Chronic ROS leads to continuous suppression of ERα 
Deregulation of the ROS production system in cells and antioxidant defense 
mechanism is a common characteristic of cancer cells (Burdon, 1995). ERα negative 
breast cancer cells were found to have elevated amount of ROS (Choi et al., 2010). 
We have previously shown that H2O2 can induce down-regulation of ERα protein (Fig 
2a). This repression of ERα expression is reversible when the cells were treated with a 
one-time dose of H2O2 (Fig 8). Here, we hypothesize that chronic presence of H2O2 
could lead to ERα expression being suppressed for a prolonged period of time. To test 
the hypothesis, one set of MCF7 cells were treated with 100 µM of H2O2 once and 
harvested at every 24 h to monitor the ERα protein level. Another set of cells was 
treated with 100 µM of H2O2 every 24 h. Results in Figure 9 show that treating cells 
with one bolus concentration of H2O2 led to a transient decrease in ERα at 24 h which 
started recovering at 48 h after treatment. The set of cells treated with the periodic 
addition of H2O2 maintained low ERα level throughout the 96 h tested.   
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Figure 9: Chronic oxidative stress lead to ERα-negative phenomenon. MCF7 cells were 
treated with 100 µM of H2O2 once or every 24 h for 96 h. Cells were harvested at 24 h time 
interval. Cell extracts were analyzed by western blot analysis. Results shown are 
representative of 3 independent experiments. 
 
3A.1.6   ROS involved in the down-regulation of ERα expression 
H2O2 in the presence of iron can undergo Fenton Reaction to form a more reactive 
molecule known as hydroxyl radical (OH·). 
Fe2+ + H2O2 → Fe3+ + OH· + OH− 
This hydroxyl radical is very potent as it can oxidize various cellular components 
including DNA, proteins, and lipids (Stinefelt et al., 2005). To determine if hydroxyl 
radical 
 
is the agent down-regulating ERα, MCF7 cells were pretreated for 2 h with 
different concentration of DMTU, a scavenger of hydroxyl radicals and also H2O2 to a 
lesser extent (Fox, 1984). Cells were then treated with 200 µM of H2O2 for another 
24h. Figure 10a shows that there was slight restoration of the ERα protein in cells 
preincubated with DMTU. As DMTU scavenges mainly hydroxyl radicals, the 
inability of DMTU to completely restore ERα protein level suggested that hydroxyl 
radicals are not the main effecter molecule in the down-regulation of ERα by H2O2. 
To form hydroxyl radical, Fe2+ is required. 1, 10-phenanthroline, a potent scavenger 
of Fe2+ was used to scavenge iron in the cells. MCF7 cells were preincubated for 1 h 
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200µM of H2O2 for another 24 h. Scavenging iron, the co-factor required for 
formation of hydroxyl radical, was unable to prevent the down-regulation of ERα by 
H2O2 (Fig. 10b). The results again suggest that hydroxyl radicals are not involved in 















Figure 10: Hydroxyl radical not involved in down-regulation of ERα by H2O2. a) MCF7 
cells were seeded for 2 days. Cells were left untreated or pretreated with increasing 
concentrations of DMTU for 2 h before exposure to 200 µM of H2O2 for 24 h. b) Cells were 
pretreated with various different concentrations of 1,10-phenanthroline for 1 h before exposed 




3A.1.7  Effect of peroxynitrite on the expression of ERα protein 
Peroxynitrite is an anion formed in vivo by the reaction of NO with superoxide and is 
a powerful oxidizing agent that can induce lipid peroxidation, oxidize sulfhydryls, and 
nitrates the aromatic residues of proteins (Koppenol et al., 1992; Beckman and 
Koppenol, 1996). Although more reactive than H2O2, it is also more unstable. The 
anion is stable at basic conditions but is protonated at physiological condition and has 
a half-life of about 1 second. Here, we tested whether extracellularly added 
peroxynitrite could also down-regulate ERα protein. Figure 11 shows a concentration-




Figure 11: Peroxynitrite down-regulates ERα. MCF7 cells were treated with various 
concentrations of peroxynitrite for 24 h. Cell extracts were analyzed by western blot. Results 










3A.2 DOWN-REGULATION OF ERα DOES NOT INVOLVE THE 
PROTEOSOMAL DEGRADATION PATHWAY 
ERα has been shown to be actively degraded via proteosomal pathway upon 
activation by E2 (Liang and Nilsson, 2004). Unliganded ERα has also been shown to 
undergo proteosomal degradation in the absence of E2 (Tateishi et al., 2004). Hence, 
the decrease in the expression of ERα upon exposure of the cells to H2O2 could be due 
to the activation of proteosomal degradation pathway. To test this hypothesis, we 
utilize MG132, a proteosomal inhibitor, to prevent active degradation of ERα by 
proteosome upon H2O2 treatment. An experiment was set up to determine the effective 
concentration of MG132 required for effective proteosomal inhibition in MCF7. The 
c-Myc protein, which has a short half-life due to rapid and continuous degradation by 
proteosome, was used as a marker of proteosomal inhibition. MCF7 cells were 
preincubated with various concentrations of MG132 for 2 h, after which protein 
synthesis was stopped by adding 100 µg/ml of cycloheximide for another 2 h.    
Figure 12a shows that the degradation of c-Myc was inhibited by as low as 1 µM of 
MG132. Maximum c-Myc inhibition was however seen with 2 µM of MG132. Thus, 
2 µM of MG132 was used to determine the role of proteosome in H2O2 down-














Figure 12: Effective concentration of proteosomal inhibition by MG132. a) MCF7 cells 
were seeded for 2 days before preincubation with different concentrations of MG132 for 2 h. 
Protein synthesis was subsequently blocked with 100 µg/ml cycloheximide for 2 h. Cell 
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To determine whether the early down-regulation of ERα protein was due to 
proteosomal degradation, MCF7 was treated with or without H2O2 for 8 h in the 
presence or absence of 2 µM MG132. The western blot analysis reveals that although 
the MG132 was effective in blocking proteosomal degradation, as shown by the 
accumulation of c-Myc protein in the MG132-treated only control, H2O2 was still able 
to induce a down-regulation of ERα protein in the presence of the proteosome 
inhibitor (Fig. 13a). MG132 treatment was unable to reverse H2O2-mediated early 
down-regulation of ERα protein, which suggests that H2O2 does not alter early ERα 
protein degradation. To determine whether sustained down-regulation of ERα protein 
by H2O2 involves the proteosomal pathway, MCF7 cells were first treated with either 
0 or 200 µM of H2O2 for 16 h. Two micromolar of MG132 was then added to one set 
of the cells for 6 h while another set received DMSO as vehicle control. Figure 13b 
shows that H2O2 was still able to strongly down-regulate ERα protein in the presence 












Figure 13: H2O2-induced decrease in ERα is not due to proteosomal degradation. a) 
MCF7 cells were seeded for 2 days before co-treated with or without 2 µM proteosome 
inhibitor MG132 and exposed to either 0 or 200 µM of H2O2 for 8 h. b) MCF7 cells were 
seeded for 2 days before treatment with either 0 or 200 µM of H2O2 for 16 h. Cells were then 
treated with 2 µM of proteosome inhibitor MG132 for another 6 h. Cell extracts were 























3A.3 THE DOWN-REGULATION OF ERα BY H2O2 IS VIA DECREASE IN 
ERα mRNA LEVEL 
 
3A.3.1  Effects of H2O2 on the expression of ERα mRNA level 
Since H2O2-mediated down-regulation of ERα does not involve the proteosomal 
degradation pathway, we examined whether the effects could be due to the inhibition 
of ERα mRNA transcript level. MCF7 cells were treated with increasing 
concentrations of H2O2 for 24 h and the level of ERα mRNA was monitored by real-
time PCR analysis of total RNA using specific TaqMan primer probe for ERα. 18S 
RNA was used as a loading control. As shown in Figure 14a, there was a 
concentration-dependent reduction in the level of ERα mRNA in cells treated with 
H2O2. Cells treated with 50, 100 and 200 µM of H2O2 showed a statistically 
significant difference in the mRNA transcript level as compared to untreated control. 
Given that ERα protein level was shown to decrease as early as 8 h after H2O2 
treatment, the time when ERα mRNA level started to decline was assessed. Figure 
14b shows that as early as 4 h into H2O2 treatment, ERα mRNA level reduced 
significant when compared to its untreated control. The decrease in ERα mRNA level 
accelerated from 8 h and the repression was sustained for up to 24 h after H2O2 
addition. At 48 h post-treatment, ERα mRNA level started to increase slightly. The 
western blot in Figure 14b shows that the decline in ERα mRNA level preceded the 
down-regulation of ERα protein. 
As shown earlier, the ERα protein level of cells treated with 100 and 200 µM of H2O2 
was restored by 48 h and 72 h respectively (Fig. 8). To determine if it is due to 
recovery of the ERα mRNA level, we treated the cells with H2O2 and observed the 





































level of cells treated with 100 µM of H2O2 was significantly increased at 48 h (Fig.15). 
And at 72 h, the ERα mRNA level of these cells was similar to that of untreated 
control. For cells treated with 200 µM of H2O2, mRNA level of ERα was still low at 
48 h after treatment. This is consistent with the low ERα protein expression observed 
at 48 h post-treatment (Fig. 8). In line with the restoration of protein expression at 72h, 
there was significant increase in mRNA level for cells treated with 200 µM of H2O2 
after 72 h (Fig. 15). This set of results provides strong evidence that the down-































































*:p-value < 0.05 (relative to no H2O2 control) 
 
Figure 14: H2O2 induces time dependent down-regulation of ERα mRNA level. a) MCF7 
cells were seeded for 2 days before treated with increasing concentrations of H2O2 for 24 h. 
ERα mRNA level was measured using realtime-PCR. b) MCF7 cells were treated with 
200µM of H2O2 for different time-points. ERα mRNA level was measured using realtime-
PCR and ERα protein level was determined by western blot analysis. Results are obtained 




*:p-value < 0.05 
Figure 15: H2O2 induces reversible down-regulation of ERα mRNA level. MCF7 cells 
were treated with various concentrations of H2O2 for 24, 48 and 72 h.  ERα mRNA level was 
measured using realtime-PCR. Results are obtained from the mean of 3 independent 




















































3A.3.2  New protein synthesis is not required for H2O2-induced down-
regulation of ERα mRNA  
To determine if the effect of H2O2 requires de novo protein synthesis, we assessed the 
ability of H2O2 to repress ERα mRNA level in the presence or absence of protein 
synthesis inhibitor cycloheximide. MCF7 cells were treated with either 0 or 200 µM 
H2O2 with or without 100 µg/ml of cycloheximide co-incubation for 24 h. After 24 h 
of treatment, total RNA was extracted and ERα mRNA was monitored by real-time 
PCR analysis. The results in Figure 16 show that the inhibition of protein synthesis by 
cycloheximide did not prevent H2O2-mediated decrease in the ERα mRNA level. This 
indicates that the down-regulation of ERα mRNA does not require new protein 
synthesis. Blocking protein synthesis with cycloheximide alone led to a sharp 
decrease in the mRNA level of ERα in MCF7 cells. The result shows that continuous 
protein synthesis is required to maintain basal levels of ERα mRNA. 
 
Figure 16: Protein synthesis is not required in H2O2 down-regulation of ERα mRNA 
level. MCF7 cells seeded for 2 days before treated with either 0 or 100 µg/ml cycloheximide 
in the presence of 0 or 200 µM of H2O2 for 24 h. ERα mRNA level was measured using 





































Medium H2O2 200 µM +chx +chx/H2O2 00 µM
82 
 
3A.4 MECHANISM INVOLVED IN H2O2-INDUCED DOWN-REGULATION 
OF ERα 
 
3A.4.1  Role of Akt activation in H2O2 down-regulation of ERα 
Keratinocyte growth factor (KGF) had been reported to down-regulate ERα protein 
and mRNA expression level in MCF7 cells (Chang et al., 2009). The authors 
identified that Akt was phosphorylated at Ser473 early upon KGF treatment. Blocking 
the phosphorylation with PI3K inhibitor, LY294002, could prevent the down-
regulation of ERα protein and mRNA level by KGF. Thus, their results demonstrated 
that KGF regulated ERα expression through the PI3K/Akt pathway. 
Many researchers have reported that H2O2 treatment could also induce 
phosphorylation of Akt (Martin et al., 2002; Hand and Craven, 2003; Urata et al., 
2006). We asked whether H2O2-mediated down-regulation of ERα could be via a 
similar PI3K/Akt pathway. First, MCF7 cells were tested for Akt phosphorylation at 
Ser473 residue upon exposure to H2O2. Figure 17a shows that Akt was rapidly 
phosphorylated at Ser473 following the treatment of the cells with 200 µM of H2O2. 
Within 5 min of H2O2 addition, Akt phosphorylation could be detected. The 
phosphorylation peaked at 15 min before it started decreasing and became 
undetectable at 60 min post-treatment. LY294002 is an inhibitor of PI3K, a kinase 
upstream of Akt phosphorylation (Furuya et al., 2007). Pre-incubation of cells with 
different concentrations of LY294002 for 30 min followed by treatment with 200 µM 
of H2O2 for 15 min resulted in inhibition of Akt phosphorylation in a concentration 
dependent manner (Fig. 17b). Twenty micromolar of LY294002 was deemed 
sufficient to completely inhibit phosphorylation of Akt caused by H2O2. Figure 17c 









this inhibition was unable to reduce the down-regulation of ERα by H2O2 (Fig. 17d). 
Taken together, the results suggest that the repression of ERα by H2O2 is not via the 
PI3K/Akt pathway. 
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Figure 17: Inhibition of Akt activation does not prevent ERα down-regulation by H2O2. 
a) MCF7 cells were seeded for 2 days before being treated with 200 µM of H2O2 for 5 to 60 
min. b) MCF7 cells were pre-incubate with PI3K inhibitor LY294002 for 30 min prior to 
treatment with 200 µM of H2O2 for 15 min. c) MCF7 cells were preincubated with LY294002 
for 30 min prior to the treatment with 200 µM of H2O2 for 15 min d) 24 h. Cell lysates were 
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3A.4.2  Role of MAPK activation in H2O2 down-regulation of ERα 
Hyperactivation of MAPK has been shown to induce loss of ERα expression in breast 
cancer cells (Oh et al., 2001). As part of the attempt to define which signal 
transduction pathways might be involved in down-regulation of ERα mediated by 
H2O2, we examined the phosphorylation status of the MAPK members ERK and JNK 
in MCF7 cells when exposed to 200 µM of H2O2. Figure 18 shows that the two 
members of the MAPK were activated early upon the exposure of the cells to H2O2. 
ERK 1/2 was activated as early as 10 min upon H2O2 treatment while JNK was 
starting to be activated after 30 min. Both the MAPK were strongly phosphorylated at 
2 h after H2O2 addition.  
 
To determine if their activation are involved in the down-regulation of ERα, 
pharmacological inhibitors were used to inhibit their phosphorylation. To block ERK 
1/2 activation, U0126 was used. U0126 blocks ERK’s upstream kinase MEK 1/2, thus, 
preventing ERK phosphorylation. Twenty micromolar of U0126 was able to 
completely inhibit H2O2 activation of ERK 1/2 at 2 h (Fig. 19a). However, blocking 
ERK 1/2 activation could not prevent down-regulation of ERα by H2O2 (Fig. 19b & 
19c). Next, SP600125 was used to inhibit activation of JNK. Figure 20a shows that 
20µM of SP600125 effectively inhibited phosphorylation of JNK. The inhibition of 
JNK was also unable to prevent down-regulation of ERα by H2O2 (Fig. 20b & 20c). 
These results show that the activation of the MAPK by H2O2 was not involved in the 
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Figure 18: H2O2 activates MAPK. a) MCF7 cells were seeded for 2 days before treated with 
200 µM of H2O2 for 5 to 120 min. Cell lysates were analyzed by western blot. Results shown 

















Figure 19: The inhibition of ERK 1/2 activation does not prevent ERα down-regulation 
by H2O2. a) MCF7 cells were seeded for 2 days and preincubated with various concentrations 
of MEK inhibitor U0126 for 30 min before treated with 0 or 200 µM of H2O2 for 2 h. b) 
MCF7 cells were treated with 0 or 20 µM U0126 for 30 min. Cells were then treated with 0 or 
200 µM of H2O2 for 2 h and c) 24 h. Cell lysates were analyzed by western blot. Results 
shown are representative of 2 independent experiments. 
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Figure 20: Inhibition of JNK activation does not prevent ERα down-regulation by H2O2.  
a) MCF7 cells were seeded for 2 days and preincubated with various concentrations of JNK 
inhibitor SP600125 for 30 min before treated with 0 or 200µM of H2O2 for 2 h. b) MCF7 cells 
were treated with 0 or 20 µM SP600125 for 30 min Cells were then treated with 0 or 200µM 
of H2O2 for 2 h and c) 24 h. Cell lysates were analyzed by western blot. Results shown are 
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3A.4.3  Role of caspases in H2O2 down-regulation of ERα  
Caspases are cysteine proteases traditionally known for their role in apoptosis and 
inflammation (Launay et al., 2005; Li and Yuan, 2008).  They can also be involved in 
immune response, cell proliferation, cell differentiation, cell migration and cell shape 
(Kuranaga and Miura, 2007). The activation of caspases has been shown to be 
involved in the down-regulation of gene expression (Guilherme et al., 2009). H2O2 
has also been reported to activate caspases to repress gene expression (Ma et al., 2003; 
Kumar et al., 2007). Here, we ask if caspase could be involved in the down-regulation 
of ERα by H2O2. Executioner caspases mainly caspase 2, caspase 6 and caspase 7 
were tested for their activity in MCF7 upon treatment with H2O2. Results from Figure 
21a show that there was no activation of caspase 2, in fact, H2O2 induced a down-
regulation of caspase 2 activity at 24 h after treatment. H2O2 treatment of MCF7 also 
led to a lower caspase 6 activity than the untreated control (Fig. 21b). There is no 
caspase 3 in MCF7 due to a 47-base-pair deletion in exon 3 of the CASP-3 gene in 
this particular cell line (Jänicke et al., 1998). Caspase 7 is however present in MCF7. 
Since caspase 3 and 7 have been reported to share similar substrate cleavage site 
(Chandler et al., 1998), caspase 3 substrate was used to measure caspase 7 activity. 
There was a slight activation of 0.2 fold compared to untreated control (Fig. 21c). 
However, this increase was small and statistically insignificant. Taken together, the 
results show that H2O2 does not induce the activation of executioner caspases, 
therefore the role of caspase activation in the down-regulation of ERα protein and 










*: p-value < 0.05 
 
Figure 21: H2O2 does not activate caspase activity. Cells were seeded for 2 days before 
exposed to 200 µM of H2O2 for various time points. Capase activity assay for a) caspase 2, b) 
caspase 6 and c) caspase 7 was carried out using the cell extracts according to the Materials 

















































































































3A.4.4  Oxidation is involved in the down-regulation of ERα by H2O2 
3A.4.4.1  H2O2 mediates down-regulation of ERα through reversible oxidation 
H2O2 is a mild oxidizing agent which does not normally react with DNA, lipids and 
most proteins. However, H2O2 can act on downstream targets to modulate the activity 
of enzymes (e.g. phosphatase and kinases) and transcription factors through selective 
oxidation of the thiol (SH) group of cysteine residues (Poole and Nelson, 2008). The 
oxidized cysteine residues can be reduced back by intracellular antioxidants such as 
glutathione (GSH) or thioredoxin (Trx), or by reducing agents such dithiothreitol 
(DTT) or β-mercapthoethanol (BME) (Halliwell and Gutteridge, 2007).   
To study whether oxidation is part of the signaling mechanism involved in the down-
regulation of ERα expression by H2O2, MCF7 were preincubated with different 
concentrations of reducing agent DTT. DTT is a strong reducing agent capable of 
reducing oxidized proteins intracellularly, due to its propensity to form a six-
membered ring with an internal disulfide bond. MCF7 cells were preincubated with 
various concentrations of DTT for 2 h before being treated with 100 or 200 µM of 
H2O2 for 24 h. Results show that DTT was able to reverse the down-regulation of 
ERα protein by H2O2 at 0.5 mM (Fig. 22a and 22b). The experiment was repeated 
with 0.5 mM of DTT (Fig. 22c) and mRNA level of ERα was determined. Figure 22d 
shows that pretreating cells with DTT prevented the repression of ERα mRNA level 
by H2O2. The results indicate that the down-regulation of ERα by H2O2 is mediated 
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Figure 22: Reducing agent DTT prevents the down-regulation of ERα by H2O2. MCF7 
cells were seeded for 2 days before preincubation with various concentrations of reducing 
agent, DTT for 2 h. Cells were then treated with a) 100 µM and b) 200 µM of H2O2 for 
another 24 h before harvesting. Cell lysates were analyzed by western blot. MCF7 cells were 
preincubated with 0.5 mM of DTT for 2 h before treated with 200 µM of H2O2 for another 24 
h before harvesting for c) western blot analysis and d) realtime PCR analysis. Results shown 












































3A.4.4.2  Thiol-oxidant diamide mimics the effects of H2O2 in down-regulating 
ERα expression 
Diamide is a thiol-oxidizing agent that modifies or cross-links cysteine sulfhydryl 
groups to form cysteine disulfide bridges in proteins (Kosower et al., 1969; Kozlova 
et al., 2002). Oxidation by diamide is reversible through reducing agent DTT or BME 
(Ward et al., 2000). To further verify the oxidation-mediated down-regulation of ERα, 
the thiol-oxidant diamide was used. MCF7 cells were treated with increasing 
concentrations of diamide and the ERα protein level was assessed. Figure 23a shows 
that diamide decreased the level of ERα starting from 0.2 mM and became more 
pronounced at 0.5 mM. Next, we then tested the mRNA levels of ERα with 0.5 mM 
of diamide and found that the decrease in ERα mRNA level was also observed (Fig. 
23c). The results show that ERα expression is indeed regulated by a mechanism 
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Figure 23: Thiol-oxidant diamide induces down-regulation of ERα. a) MCF7 cells were 
seed for 2 days before being exposed to different concentrations of diamide 24 h. Cell extracts 
were analyzed by western blot. MCF7 cells were treated with 0.5 mM of diamide for 24 h 
cells extract analyzed by b) western blot and c) realtime PCR. Results shown are 















































3A.5 EFFECTS OF ERα DOWN-REGULATION ON ER RESPONSE GENES. 
It has been shown that in response to estrogen stimulation, ERα protein is rapidly 
down-regulated via proteosomal degradation pathway to limit the extent of the 
estrogen signaling (Tateishi et al., 2004; Alarid et al., 1999; Nawaz et al., 1999). 
Estrogen response genes were however up-regulated several folds. In this section, we 
evaluated the impact of ERα down-regulation by H2O2 on estrogen-dependent 
responses. 
 
3A.5.1  Down-regulation of ERα by H2O2 inhibits estrogen response 
element (ERE) activity 
In the first set of experiments, we studied the effects of H2O2 on the general 
transcriptional activity of ER. MCF7 cells were transiently transfected with a plasmid 
containing luciferase reporter gene whose expression is driven by an estrogen 
response element (ERE). Estrogen receptor, upon binding to estrogen will be recruited 
to the ERE and drive the transcription of the luciferase gene. The amount of luciferase 
was subsequently assessed and used to represent the level of ER activity in the cells. 
In the study, MCF7 cells transfected with ERE luciferase plasmid were estrogen-
deprived overnight after transfection by growing the cells in phenol-free RPMI 
supplemented with 10 % charcoal-stripped FBS (CS FBS). Cells were then treated 
with 100 µM of H2O2 for 16 h to down-regulate ERα. After H2O2 treatment, cells 
were incubated with 10 nM of E2 or DMSO control for 2, 4 or 6 h before harvesting 
for luciferase assay. Western blot analysis in Figure 24a shows that ERα expression 
level was decreased in the cells treated with 100 µM of H2O2 for 16 h. Notably, down-
regulation of ERα by H2O2 did not affect the basal activity of ERE (Fig. 24b). This is 








the presence or absence of ERα, there is minimum stimulation of ERE. However, 
when E2 was added to cells expressing ERα, there was a strong activation of ERE, 
about 12 folds increase in the activity at 6h (Fig. 24b). In comparison, H2O2-treated 
cells which have much lower levels of ERα had less than 3 folds increase in ERE 
activity in response to E2 stimulation. The results show that the down-regulation of 





*: p-value < 0.05 
Figure 24: H2O2 inhibits total ERE activity induced by E2. a) MCF7 cells were seeded for 
1 day before changing to phenol-free RPMI supplemented with 10 % charcoal-stripped FBS. 
Cells were treated with 100 µM H2O2 for 16 h and harvested for western blot analysis. b) 
MCF7 cells were seeded overnight and transfected with 1 µg of ERE luciferase plasmid 
together with 0.1 µg of renilla plasmid using SuperFect as described in the Materials and 
Methods section. Cells were recovered in phenol-free RPMI supplemented with 10 % 
charcoal-stripped FBS after 3 h of transfection. On day three, cells were treated with 100 µM 
of H2O2 for 16 h before exposure to 10 nM of E2 for 2, 4 or 6 h. Dual luciferase assay was 
carried out according to the Materials and Methods section. Results obtained are 
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3A.5.2  H2O2 down-regulates ERα response genes 
Progesterone receptor (PR) and c-Myc gene expression have been reported to be 
regulated by ERα (Kastner et al., 1990; Dubik and Shiu, 1988). To determine if the 
expression of these two genes are under the control of by ERα in the MCF7 cells, 
cells were estrogen-deprived by growing overnight in phenol-free RPMI 
supplemented with 10 % CS FBS. Lane 1 of Figure 25a shows that PR and c-Myc 
protein were hardly expressed in the absence of estrogen. When E2 was added to the 
cells for 24 and 48 h, PR and c-Myc protein expression were increased (Fig. 25a). The 
effects of E2 on these two proteins were investigated through a time course analysis. 
MCF7 cells were estrogen-deprived overnight before E2 was added for of 4, 8, 24 and 
48 h. The c-Myc expression increased rapidly upon addition of E2. The protein level 
increased from 4 h and was sustained up to 24 h after which the expression declined at 
48 h (Fig. 25b). On the other hand, PR protein expression responded slower to E2 
treatment. The protein became detectable only at 24 h and increased up to the 48 h 
time-point tested (Fig. 25b). These results show that PR and c-Myc are indeed ERα 
responsive genes. Next, we examined the effects of H2O2 on the level of PR and c-
Myc in MCF7 cells. Figure 25c shows that concentration-dependent down-regulation 
of ERα by H2O2 resulted in decreased expression of both PR and c-Myc. c-Myc 
decreased more than PR and this is most probably due to a longer half-life of PR as 
compared to c-Myc (Fig. 26a). 
To determine the effects of H2O2 on the ability of E2 to stimulate estrogen response 
genes, estrogen-deprived MCF7 cells were treated with 0, 100 and 200 µM of H2O2 
for 16 h and were given either 10 nM E2 or DMSO for another 4 h before harvesting. 
Western blot analysis shows that in the absence of E2, c-Myc protein level was low 
(Fig. 26b). Addition of E2 induced c-Myc expression in control cells; but was greatly 
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reduced in H2O2 treated cells (Fig. 26b). The results indicate that the down-regulation 








Figure 25: H2O2 decreases ERα response genes, PR and c-Myc expression. a) MCF7 cells 
were seeded overnight in complete medium. Cells were changed to phenol-free RPMI 
supplemented with 10 % charcoal-stripped FBS for another 2 days. Cells were exposed to 10 
nM E2 for 24 and 48 h. b) MCF7 cells were seeded overnight in complete medium. Cells 
were changed to phenol-free RPMI supplemented with 10 % charcoal-stripped FBS for 
another 2 days. Cells were exposed to 10 nM E2 for various time-points. c) MCF7 cells were 
seeded for 2 days before treated with various concentrations of H2O2 for 24 h. Cell extracts 


































Figure 26: H2O2 decreases the ability of estrogen to induce c-Myc expression. a) MCF7 
cells were seeded for 2 days before treated with 100 µg/ml of cycloheximide. Cells were 
harvested at various time-points after treatment. b) MCF7 cells were seeded for overnight in 
complete medium. Cells were changed to phenol-free RPMI supplemented with 10 % 
charcoal-stripped FBS for 24 h before treated with H2O2 for 16 h. Cells were then exposed to 
10 nM E2 for 4 h. Cell extracts were analyzed by western blot. Results shown are 



















3A.6 15-DEOXY-DELTA-12,14-PROSTAGLANDIN J2 (15D-PGJ2) DOWN-
REGULATION OF ERα IS VIA ROS 
We have shown in the previous sections that the addition of exogenous ROS such as 
H2O2 and peroxynitrite can down-regulate ERα expression. Next, we want study the 
physiological relevance of ROS in the down-regulating ERα, by treating the cells with 
an agent that is known to produce ROS intracellularly. The compound 15-Deoxy-
Delta-12,14-prostaglandin J2 (15d-PGJ2) is a natural ligand for peroxisome 
proliferator-activated receptor gamma (PPARγ), a member of the nuclear receptor 
family (Forman et al., 1995; Murphy and Holder, 2000). Activation of PPARγ is a 
multi-step process involving the binding of ligand to PPARγ, heterodimerization with 
retinoic X receptor and binding to PPARγ response element. 15d-PGJ2 was shown to 
down-regulate ERα via a PPARγ independent but proteosomal dependent pathway 
(Lecomte et al., 2008; Qin et al., 2003). Other than its role as a PPARγ ligand, reports 
have shown that 15d-PGJ2 induces ROS in cells when added exogenously (Kim et al., 
2008; Kim et al., 2009; Shin et al., 2009). Here, we ask the question whether ROS 
could be the intermediate that led to ERα down-regulation in MCF7 cells treated with 
15d-PGJ2. 
 
3A.6.1  Morphology and growth of MCF7 cells exposed to 15d-PGJ2 
We tested the effects of increasing concentrations of 15d-PGJ2 on the morphology 
and growth of MCF7 cells. Figure 27a shows the morphology of MCF7 cells treated 
with 15d-PGJ2 after 24 h. Cells looked slightly enlarged and sparse compared to 
untreated control. Next, MCF7 cells were incubated with increasing concentrations of 
15d-PGJ2 for 24 h and cell density was estimated by crystal violet staining. The time 
at which 15d-PGJ2 was added was regarded as time 0 h. Cell growth was expressed as 
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percentage relative to the time of treatment. 15d-PGJ2 exhibited a concentration-
dependent inhibition of cell growth. Density of cells treated with 0, 5, 10 and 20 µM 
of 15d-PGJ2 for 24 h was at 202, 166, 121, 120 % respectively, relative to the time 






*: p-value < 0.05 (relative to time of trigger) 
 
Figure 27: MCF cell survival upon 15d-PGJ2 treatment. MCF7 cells were seeded for 2 
days before treated with various concentrations of 15d-PGJ2 for 24 h. a) Morphology of the 
cells was captured under phase-contrast microscope at 10x magnifications. b) Cell density and 
survival were estimated by staining the cells with crystal violet 24 h after treatment. Results 
shown were obtained from the mean of 2 independent experiments +/- SE.  





































3A.6.2  15d-PGJ2 down-regulates ERα at the protein and mRNA level 
Next, we determined the effects of 15d-PGJ2 on the expression of ERα at 24 h after 
treatment. Western blot analysis showed that 15d-PGJ2 down-regulated ERα protein 
in a concentration-dependent manner. ERα protein level was decreased sharply with 
5µM of 15d-PGJ2 (Fig. 28a). At higher concentrations of 10 and 20 µM of 15d-PGJ2, 
ERα protein expression was completed abolished. Realtime analysis of ERα mRNA 
shows a decrease in the mRNA level (Fig. 28b). The transcript level of ERα was 
observed to be at 33, 5 and 10 % with 5, 10 and 20 µM of 15d-PGJ2 respectively after 
24 h of treatment. To determine whether the 15d-PGJ2-induced down-regulation of 
ERα was mediated by PPARγ, cells were pretreated with PPARγ antagonist GW9662 
(1 to 10 µM) before exposure to 15-PGJ2. GW9662 is a potent, irreversible and 
selective antagonist that prevents the activation of PPARγ by covalently modifying a 
cysteine residue in the ligand-binding site of PPARγ (Leesnitzer et al., 2002; Seargent 
et al., 2004). Results show that in cells co-treated with GW9662 and 15d-PGJ2, the 
reduction in the level of ERα protein still occurred as compared to those treated with 
15d-PGJ2 alone (Fig. 28c). The results suggest that the down-regulation of ERα 
















Figure 28: 15d-PGJ2 down-regulates ERα protein and mRNA levels. MCF7 cells were 
seeded for 2 days before treated with various concentrations of 15d-PGJ2 for 24 h a)  ERα 
protein expression was determined by western blot while b) mRNA level was determined 
with realtime-PCR. c) MCF7 cells were preincubated with various concentrations of GW9662 
for 30 min before treated with 10 µM of 15d-PGJ2. Results shown are obtained from the 
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3A.6.3  15d-PGJ2 produces ROS in MCF7 cells  
ROS produced by 15d-PGJ2 was measured by flow cytometry FITC channel using a 
redox sensitive dye CM-H2DCFDA which fluoresces under oxidation by intracellular 
H2O2 and other reactive species. Intracellular ROS were quantified by determining the 
mean of DCF fluorescence intensity. ROS level increased rapidly when MCF7 cells 
were treated with 10 µM of 15d-PGJ2. ROS could be detected as early as 1 h after 
treatment and the increase in ROS was sustained for up to 4 h of treatment (Fig. 29). 
Quantification of two experiments shows that 15d-PGJ2 induced an increase in 
intracellular ROS with an increase of 56 % at 1h, 43 % at 2 h, 102 % at 3 h and 65 % 
at 4 h relative to untreated control. 
The increased in the DCF fluorescence, a measurement of intracellular oxidation and 
ROS production, can also be represented as a shift in DCF fluorescence to the right of 
the x-axis of the Fluorescence-activated cell sorting (FACS) histogram. As a positive 
control, 1 mM of H2O2 was added to another set of MCF7 cells 1 h prior to harvesting 
of the cells. Figure 30a shows that both H2O2 and 15d-PGJ2 treatment caused the 
DCF fluorescence to shift to the right on the x-axis of the FACs histogram, indicating 
increase ROS production. The rightward shift caused by 15d-PGJ2 was more than the 
rightward shift induced by H2O2, which signifies that 10 µM of 15d-PGJ2 resulted in 
greater intracellular oxidation than 1 mM of H2O2 added extracellularly. 
Next, we tested the ability of antioxidant N-acetyl-cysteine (NAC) to scavenge the 
ROS produced by treatment with 15d-PGJ2. The cells were preincubated with 0 or 5 
mM of NAC for 2 h prior to treatment with 10 µM of 15d-PGJ2 for another 2 h. Flow 
cytometry result shows that preincubating the cells with 5mM of NAC caused the 
DCF fluorescence to shift to the left on the x-axis of the FACs histogram, indicating 
decreased ROS production (Fig. 30b). Figure 30c shows the summary of the DCF 
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mean data from three repeated experiments. This set of results shows that NAC 




*: p-value < 0.05 (relative to untreated control) 
 
Figure 29: 15d-PGJ2 produces ROS in MCF7 cells. MCF7 cells were seeded for 2 days 
before treated with 10 µM of 15d-PGJ2 for 1 to 4 h. ROS levels in cells were detected using 
flow cytometry with CM-H2DCFDA flurogenic probe according to the Materials and 
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Figure 30: NAC scavenges 15d-PGJ2-induced ROS. a) Cells were treated with 10 µM of 
15d-PGJ2 and 1 mM of H2O2 for 1 h. ROS levels in cells were detected using flow cytometry 
with CM-H2DCFDA flurogenic probe. b) Cells were preincubated with 0 or 5 mM of NAC 
for 2 h before treated with 15d-PGJ2 for 2 h. ROS levels in cells were detected using flow 
cytometry with CM-H2DCFDA flurogenic probe. c) Graphical representative of (b). Results 




















































3A.6.4  Scavenging of ROS by NAC restores cell growth and ERα 
expression 
To test if ROS was the intermediate involved in growth inhibition and the down-
regulation of ERα by 15d-PGJ2, NAC was used to scavenge the ROS produced by 
15d-PGJ2. Figure 31a shows the morphology of cells treated with 15d-PGJ2 with or 
without NAC preincubation. The cells preincubated with NAC and then treated with 
15d-PGJ2 have similar morphology and cell density compared to control cells. This 
shows that scavenging ROS by NAC could restore cell growth. In addition, ROS 
scavenging by NAC prevented 15d-PGJ2-mediated down-regulation of ERα protein 
(Fig. 31b), as well as mRNA level (Fig. 31c). 
In summary, 15d-PGJ2 induces repression of ERα expression at the protein and 
mRNA level. Large amount of ROS was produced early upon treatment and 
scavenging of the ROS could prevent decrease of ERα protein and mRNA level. 














*: p-value < 0.05  
 
Figure 31: Scavenging of ROS by NAC restores ERα expression. a) Cells were 
preincubated with either 0 or 5 mM of NAC for 2 h before treated with 10 µM of 15d-PGJ2 
for 24 h. a) Morphology of the cells were captured under phase contrast microscope. b) ERα 
protein level was analyzed by western blot. c) ERα mRNA level was measured using 
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Figure 32 summarized the findings regarding H2O2 down-regulation of ERα. We 
found that H2O2 represses ERα expression through a reversible oxidation pathway. 
Diamide, a thiol-oxidant could also inhibit ERα expression. Drugs that down-regulate 
ERα could do so via the production of H2O2 or other ROS. The suppression of ERα 
expression is reversible by preincubation with reducing agent DTT and by scavenging 
ROS. Down-regulation of ERα protein at 8 h was preceded by decrease in ERα 
mRNA levels at 4 h. The repression of ERα expression results in an inhibition of ERα 























CHAPTER 3B: RESULTS – REDOX REGULATION OF NHE1 
 
3B.1 DOWN-REGULATION OF NHE1 BY H2O2 
In this section, we investigated another gene that has been shown to be down-
regulated by H2O2. Previously, our lab has reported that H2O2 repress the activity of 
the 1.1kb mouse NHE1 promoter in L6 rat myoblast through an oxidation and 
caspase-dependent mechanism. In this section, we would like to determine the 
response element of H2O2 and address the mechanism involved in the down-
regulation of NHE1 promoter activity by H2O2. 
 
3B.1.1  Identification of crucial region in the promoter of NHE1  
We have previously established that NHE1 is a redox-regulated gene (Akram et al., 
2006; Kumar et al., 2007). Using L6 cells with a stably transfected full length 1.1kb 
of NHE1 promoter (L6 1.1kb cells) we were able to reproduce the results previously 
published. Figure 33 shows that the 1.1kb of NHE1 promoter activity was decreased 






Figure 33: H2O2 down-regulates NHE1 full length promoter activity. L6 myoblasts stably 
transfected with 1.1kb NHE1 promoter were subjected to various concentrations 10, 25, 50, 
100 and 200 µM of H2O2 for 24 h. Cells were harvested and assessed for NHE1 promoter 
activity using luciferase assay as described in Materials and Methods section. Results 
represent mean of four independent experiments done in duplicates +/- SE. 
 
In order to understand which region of the NHE1 promoter is important for its 
transcription, NHE1 promoter constructs with different 5’ end deleted were 
transfected into L6 cells together with a plasmid encoding for renilla as a transfection 
control. Figure 34a shows the different 5’ deletion constructs and their corresponding 
names. Figure 34b illustrates the basic principle of the luciferase assay. Briefly, the 
promoter of NHE1 is linked upstream of a luciferase gene. The plasmid construct will 
be introduced into the cells via transfection. Any signal that leads to an increase in 
NHE1 promoter activity will result in an increase of luciferase enzyme production, 
which can be quantitatively measured by luciferase assay (as described in Materials 





























































Wild type L6 cells were transfected with various 5’ deletion constructs of NHE1 
mouse promoter. The promoter activity of NHE1 for the different constructs was 
similar from 1.1kb up to 0.15kb (Fig. 34c). There was some increase in the promoter 
activity at the 0.18kb region suggesting that the region between 0.18kb and 0.15kb 
contains a possible enhancer element involved in the transcription of NHE1. The most 
striking feature was that removal of a stretch of 33 bp nucleotides from the 5’ end of 
the 0.15kb region resulted in an 85% decrease in the promoter activity. This indicates 
that the 33 bp region at the 5’ end of the 0.15kb promoter most likely contains 
important transcription factor binding site for NHE1 gene transcription in cells 
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Figure 34: 0.15kb promoter is basal promoter required for full NHE1 promoter activity. 
a) Different 5’ deletion constructs of mouse NHE1 promoter. b) Basic principle of luciferase 
assay. c) L6 wild type cells were transiently transfected with the pXP-1.1, pXP-0.9, pXP-0.2, 
pXP-0.18, pXP-0.15 and pXP-0.12 plasmids. Cells were co-transfected with renilla plasmid 
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3B.1.2  H2O2 down-regulates 0.15kb proximal NHE1 promoter activity 
3B.1.2.1 Regulation of NHE1 mRNA level by H2O2 in NIH 3T3 cells 
Having determined that the minimal response element of the NHE1 promoter that 
activates full activity lies on the 0.15kb promoter, we next use a cell line that have a 
stably transfected 0.15kb mouse NHE1 promoter (NIH 3T3 0.15kb cells) to assess if 
the down-regulation of NHE1 mRNA could be correlated with the inhibition of the 
0.15kb region of the promoter. 
First, we determine the effect of H2O2 on mRNA of NHE1 in NIH 3T3 0.15kb cells. 
Figure 35a shows that in 24 h, H2O2 down-regulated NHE1 mRNA transcript level to 
70 % and 50 % that of control in the presence of 35 µM and 50 µM of H2O2 
respectively. In a time course analysis of the effect of H2O2, we found that the level of 
NHE1 mRNA started decreasing at 15 h post treatment with 35 µM and 50 µM of 












































Figure 35: H2O2 down-regulates NHE1 mRNA in a concentration- and time-dependent 
manner. a) NIH 3T3 cells were treated with 25, 35 and 50 µM of H2O2 for 24 h and harvested 
for mRNA isolation. b) NIH 3T3 cells were treated with 35 and 50 µM of H2O2 for 5, 9, 15 
and 24 h. Cells were harvested for mRNA isolation. The level of NHE1 mRNA was 
determined from realtime PCR. Results shown are obtained from the mean of 3 independent 
experiments +/- SE. 
 
3B.1.2.2 Regulation of NHE1 0.15kb promoter by H2O2 in NIH 3T3 cells 
Next, we want to understand how the promoter activity of 0.15kb was affected by 
H2O2 treatment. Results show that H2O2 down-regulated NHE1 0.15kb promoter 
activity in a concentration-dependent manner, from 100 % to 80, 37, 19, 15 and 14 % 
for 10, 25, 35, 50 and 100 µM of H2O2 respectively (Fig. 36a). The promoter activity 
of NHE1 first decreased slightly at 1 h after H2O2 treatment, but it recovered at 3 h. 
The promoter activity started to decrease again at 9 h and the repression was sustained 
up to 24 h (Fig. 36b). To determine if the down-regulation of NHE1 0.15kb promoter 
activity by H2O2 is reversible, cells were allowed to grow for up to 72 h after H2O2 















































activity. The results in Figure 36c shows that activity of NHE1 promoter started to 
recover 48 h after treatment and continued to recover at 72 h. This set of results 
demonstrated that the 0.15kb NHE1 promoter is indeed down-regulated by H2O2 and 































































































































*: p-value < 0.05 (relative to no H2O2 control) 
 
**: p-value < 0.05 
 
Figure 36: H2O2 down-regulates NHE1 0.15kb promoter in a concentration- and time-
dependent manner. a) NIH 3T3 cells stably transfected with 0.15kb NHE1 promoter was 
treated with various concentrations of H2O2 for 24 h. b) NIH 3T3 cells stably transfected with 
0.15kb NHE1 promoter was treated with 50 µM of H2O2 for various time-points. c) NIH 3T3 
cells stably transfected with 0.15kb NHE1 promoter was treated with 50 µM of H2O2 for 24, 
48 and 72 h. Cells were assessed for NHE1 promoter activity using luciferase assay. Results 



























































3B.1.3  Oxidation is involved in the down-regulation of 0.15kb proximal 
NHE1 promoter activity and endogenous mRNA level by H2O2 
 
3B.1.3.1 H2O2 mediates down-regulation of 0.15kb NHE1 promoter activity 
and mRNA level through reversible oxidation 
Here, we determine the nature of the down-regulation of the 0.15kb promoter activity 
by H2O2. NIH 3T3 cells were preincubated with NAC, a direct ROS scavenger and 
precursor of GSH, for 2 h before treatment with H2O2 for another 24 h. Preincubation 
with NAC completely prevented the down-regulation of the 0.15kb promoter activity 
at all concentrations used (Fig. 37a). The mRNA level of NHE1 was also restored by 
NAC preincubation (Fig. 37b). Cells pretreated with reducing agent DTT have a 
concentration-dependent restoration of 0.15kb NHE1 promoter activity, starting from 
0.2 mM of DTT. DTT at concentration of 0.5 mM prevented the repression of 0.15kb 
NHE1 promoter activity by up to 80% and it also prevented the down-regulation of 
NHE1 mRNA level by H2O2 (Fig. 38a and  38b). We used another reducing agent 
BME to test the hypothesis that down-regulation of NHE1 promoter activity and 
mRNA level is indeed a reversible oxidation event. NIH 3T3 cells were preincubated 
with BME for 2 h before being treated with H2O2 for another 24 h. Figure 39a shows 
that BME prevented the repression of 0.15kb NHE promoter activity starting from 
0.5mM. Promoter activity of cells was 60, 90 and 100 % for cell pretreated with 0.5, 1 
and 2 mM of BME respectively. The mRNA level of NHE1 treated with 1 mM of 
BME was prevented from down-regulated by H2O2 (Fig. 39b). 
Taken together, this set of data showed that the down-regulation of 0.15kb NHE1 
promoter activity and NHE1 mRNA level is a reversible oxidation event which can be 





*:p-value< 0.05 (Relative to H2O2 treated cells without NAC) 
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Figure 37: Scavenging ROS with NAC prevents H2O2-induced down-regulation of 
0.15kb NHE1 promoter activity and NHE1 mRNA level. a) NIH 3T3 cells stably 
transfected with 0.15kb NHE1 promoter was preincubated with various concentrations of 
NAC for 2 h before treated with 50 µM H2O2 for 24 h. Cells were harvested for NHE1 
promoter activity using luciferase assay. b) NIH 3T3 cells were preincubated with 5 mM of 
NAC for 2 h before treated with 50 µM of H2O2 for 24 h. Cells were harvested for realtime 























































































































Figure 38: Reducing agent DTT prevents H2O2-induced down-regulation of 0.15kb 
NHE1 promoter activity and NHE1 mRNA level.  a) NIH 3T3 cells stably transfected with 
0.15kb NHE1 promoter was preincubated with increasing concentrations of DTT for 2 h 
before treated with 50 µM of H2O2 for 24 h. Cells were harvested for NHE1 promoter activity 
using luciferase assay b) NIH 3T3 cells were preincubated with 0.5 mM of DTT for 2 h 
before treated with 50 µM of H2O2 for 24 h. Cells were harvested for realtime PCR analysis. 
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Figure 39: Reducing agent BME prevents H2O2-induced down-regulation of 0.15kb 
NHE1 promoter activity and NHE1 mRNA level. a) NIH 3T3 cells stably transfected with 
0.15kb NHE1 promoter was preincubated with increasing concentrations of BME for 2 h 
before treated with 50 µM of H2O2 for 24 h. Cells were harvested for NHE1 promoter activity 
using luciferase assay. b) NIH 3T3 cells were preincubated with 1 mM of BME for 2 h before 
treated with 50 µM of H2O2 for 24 h. Cells were harvested for realtime PCR analysis. Results 











































































































3B.1.3.2 Thiol-oxidant diamide mimics the effects of H2O2 to down-regulate 
the 0.15kb NHE1 promoter activity and mRNA expression level 
To further verify the oxidant-mediated down-regulation of NHE1, the thiol-oxidant 
diamide was used. Figure 40a showed a concentration-dependent decrease in 0.15kb 
NHE1 promoter activity which starts from 150 µM of diamide. Promoter activity 
decreased to 60 % and 30 % that of control when 200 and 250 µM of diamide was 
used respectively. In the presence of 200 µM diamide, the endogenous mRNA level 






































































*:p-value< 0.05  
 
Figure 40: Thiol-oxidant diamide down-regulates NHE1 0.15kb promoter activity and 
NHE1 mRNA level. a) NIH 3T3 cells stably transfected with 0.15kb NHE1 promoter was 
treated with increasing concentrations of diamide for 24 h. Cells were harvested for NHE1 
promoter activity using luciferase assay. b) NIH 3T3 cells were treated to 200 µM of diamide 
for 24 h. Cells were harvested for realtime PCR analysis. Results showed are obtained from 






















































3B.1.4  Peroxynitrite down-regulates 0.15kb NHE1 promoter activity 
Peroxynitrite is a strong oxidant and can react directly with the electron-rich groups 
such as sulfhydryls, iron-sulfur centers and zinc-thiolates (Crow et al., 1995; Kuhn et 
al., 1999; Soum et al., 2003). Peroxynitrite has been shown to inhibit gene expression 
by inhibiting activation of NFκB (Soum et al., 2003). Here, we tested whether 
extracellularly added peroxynitrite could also down-regulate the activity of 0.15kb 
NHE1 promoter. Figure 41 shows a concentration repression of this promoter activity. 




*:p-value< 0.05 (Relative to no peroxynitrite treated control) 
 
Figure 41: Peroxynitrite down-regulates 0.15kb NHE1 promoter activity. NIH 3T3 cells 
stably transfected with 0.15kb NHE1 promoter was treated with various concentrations of 
peroxynitrite for 24 h. Cells were harvested for NHE1 promoter activity using luciferase 



































































3B.1.5  Role of caspases in H2O2-mediated down-regulation of 0.15kb 
NHE1 proximal promoter activity 
In the report previously published by our lab (Kumar et al., 2007), caspase activation 
was shown to be crucial for the sustained down-regulation of the 1.1kb NHE1 
promoter activity. Next, we ask if the activation of caspases is required for the down-
regulation of 0.15kb NHE1 promoter activity. The caspase activities upon treatment 
with H2O2 in NIH 3T3 0.15kb cells were first investigated. Cells treated with 25, 35 
and 50 showed increased caspase 2 and 3 activities (Fig. 42a). With 50 µM of H2O2, 
activity of caspase 2 was increased by 5 folds compared to untreated cells while 
activity of caspase 3 was increased by 16 folds. Although caspase 9 activity was also 
detected, it was at much lower level than caspase 2 and 3. Caspase 6 and caspase 8 
were not activated at all. We proceeded to determine the temporal activation of 
caspases. NIH 3T3 0.15kb cells were treated with 50 µM of H2O2 for 3, 5, 9, 12, 24 
and 48 h, capase activities in the cells were assessed. The results show that caspase 2 
and 3 were activated as early as 9 h and the activation was sustained for up to 24 h 
(Fig. 42b). After 48 h, caspase 2 and 3 activities returned to that of control cells where 










Figure 42: H2O2 treatment activates caspase 2 and 3 in NIH 3T3 cells. a) NIH 3T3 cells 
were treated with various concentrations 25, 35 and 50 µM of H2O2 for 24 h before harvested 
for caspase assay. b) NIH 3T3 cells were treated with 50 µM of H2O2 for various time points 
ranging from 3 h to 48 h and harvested for caspase assay. Cell lysates were assayed for 
caspase 2, 3, 6, 8 and 9 activity using caspase fluorogenic substrates of caspases.  Results 
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As the activation of caspase was shown to be important in the sustained down-
regulation of the full length 1.1kb NHE1 promoter activity (Kumar et al., 2007), we 
tested if caspase activation is also required for the inhibition of 0.15kb NHE1 
promoter. NIH 3T3 0.15kb cells were preincubated with general caspase inhibitor 
zVADfmk for 2 h followed by treatment with 50 µM of H2O2 for another 24 h. The 
cells were then harvested for caspase activity assay and luciferase assay. Figure 43a 
shows that preincubation of cells with zVADfmk was able to completely inhibit the 
activation of caspase 2 activity induced by H2O2 treatment. Caspase 3 activity was 
also completely inhibited with zVADfmk (Fig. 43b). Having established that 
zVAdfmk completely inhibits caspase 2 and caspase 3 activities, we the assessed the 
effect on the 0.15kb NHE1 promoter activity. Figure 43c shows that the inhibition of 
caspase activity by zVADfmk could not prevent H2O2-induced down-regulation 
0.15kb NHE1 promoter. The data suggests that while 1.1kb NHE1 promoter required 
the activation of caspases to have sustained down-regulation of its activity, this was 
not the case for 0.15kb promoter. 
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Figure 43: Pan caspase inhibitor zVADfmk does not prevent H2O2-induced down-
regulation of the 0.15kb NHE1 promoter. NIH 3T3 stably transfected with 0.15kb NHE1 
promoter was preincubated with 100 µM of pan caspase inhibitor zVADfmk for 2 h before 
treated with 50 µM of H2O2 for 24 h. Cells lysates were analyzed for a) caspase 2 activity and 
b) caspase 3 activity using caspase fluorogenic substrates of caspases. c) Cell lysates were 
assessed for NHE1 promoter activity using luciferase assay. Results shown are obtained from 
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3B.1.6  15d-PGJ2 down-regulates 0.15kb NHE1 promoter activity and 
NHE1 mRNA level via ROS production 
In the previous chapter of this thesis, we showed that 15d-PGJ2 down-regulated ERα 
protein and mRNA expression via ROS production. Here, we ask if 15d-PGJ2 could 
also inhibit 0.15 kb NHE promoter activity in a ROS-dependent manner. NIH 3T3 
0.15kb cells were treated with different concentrations of 15d-PGJ2 for 24 h, after 
which the NHE1 promoter activity was assessed. Figure 44a shows that 0.15kb NHE1 
promoter activity decrease from 100 % to 70 % and 34 % when the cells were treated 
with 10 and 20 µM of 15d-PGJ2 respectively. At the mRNA level, 20 µM of 15d-
PGJ2 reduced the amount of NHE1 mRNA by 50 % in 24 h when compared to 



































































*:p-value < 0.05  
 
Figure 44: 15d-PGJ2 down-regulates 0.15kb NHE1 promoter activity and NHE1 mRNA 
level. a) NIH 3T3 stably transfected with 0.15kb NHE1 promoter were treated with various 
concentrations of 15d-PGJ2 for 24 h. Cells were harvested for NHE1 promoter activity using 
luciferase assay. b) Cells were treated with 20 µM of 15d-PGJ2 for 24 h. NHE1 mRNA level 
was determined by realtime-PCR. Results shown are obtained from mean of 2 independent 
experiments +/- SE. 
 
The increased in the DCF fluorescence, a measurement of intracellular oxidation and 
ROS production, can be represented as a shift in DCF fluorescence to the right of the 
x-axis of the FACS histogram. The 15d-PGJ2 caused the DCF fluorescence to shift to 
the right on the x-axis of the FACS histogram. Increase in intracellular ROS was 
detected at 2 h and 4 h after drug treatment (Fig. 45a and 45b). The rightward shift 
produced by 15d-PGJ2 was comparable to the rightward shift obtained when cells 
were incubated with 1 mM of H2O2. This indicates that the ROS produced by 15d-












































Figure 45: 15d-PGJ2 produces ROS in NIH 3T3 cells. NIH 3T3 0.15kb cells treated with 
20 µM of 15d-PGJ2 for a) 2 h and b) 4 h. ROS levels in cells were detected using flow 










Next, we asked if the ROS produced is responsible for the repression of 0.15kb NHE1 
promoter activity by 15d-PGJ2. To test this hypothesis, antioxidant NAC was used in 
the following experiment to scavenge the ROS produced by 15d-PGJ2. The cells were 
preincubated with 0 or 5 mM of NAC for 2 h prior to treating the cells with 20 µM of 
15d-PGJ2 for another 2 h. Cells were then assessed for DCF fluorescence. Figure 46a 
showed that 15d-PGJ2 caused a right-ward shift on the x-axis of the FACs histogram, 
indicating increased ROS production. Preincubation of NAC prior to 15d-PGJ2 
addition shifted the graph back to the left on the x-axis of the FACs histogram, 
signifying a decrease in ROS production. The graph on Figure 46b summarized the 
effects of NAC on ROS production upon addition of 15d-PGJ2. This set of results 
show that NAC preincubation prevented ROS from being elevated in the cells treated 
with 15d-PGJ2. The outcome of scavenging ROS with NAC was that it indeed 
prevented the down-regulation of 0.15kb NHE1 promoter activity by 15d-PGJ2. As 
shown in Figure 46c, the 0.15kb NHE1 promoter activity decrease by 80 % in cells 
treated with 15d-PGJ2 alone. However, upon pretreatment with NAC this decrease in 
NHE1 promoter activity was prevented. In a nutshell, the data suggests that similar to 
what was previously shown in section 3A.6 on the mRNA expression of ERα, the 
down-regulation of 0.15kb NHE1 promoter activity by 15d-PGJ2 was associated with 
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*: p-value < 0.05 
 
Figure 46: Scavenging ROS produced by 15d-PGJ2 with NAC restores 0.15kb NHE1 
promoter activity. a) NIH 3T3 0.15kb cells were preincubated with 0 or 5 mM of NAC for 2 
h before treated with 20 µM of 15d-PGJ2 for 2 h. ROS levels in cells were detected using 
flow cytometry with CM-H2DCFDA flurogenic probe. b) Graphical representation of (a). c) 
NIH 3T3 0.15kb cells were preincubated with 0 or 5 mM of NAC for 2 h before treated with 
20 µM of 15d-PGJ2 for 24 h. Cells were harvested for NHE1 promoter activity using 





























































3B.1.7  H2O2 down-regulates NHE1 expression in MCF7 breast cancer 
cells 
Since NHE1 is often up-regulated in tumor cells and has been shown to be important 
in tumorigenesis, we next tested if the H2O2-mediated inhibition of NHE1 expression 
also occurs in cancer cells. Using MCF7 as a model, NHE1 mRNA level was 
determined after H2O2 treatment. Treating MCF7 cells with 200 µM of H2O2 reduced 
the mRNA level of NHE1 by 40% (Fig. 47a). Similarly, diamide could down-regulate 
the mRNA transcript of MCF7. An 80 % reduction in the mRNA level of NHE1 was 
observed in diamide treated cells (Fig. 47b). This set of results show that, similar to 

















































*: p-value < 0.05 
 
Figure 47: H2O2 and diamide down-regulate NHE1 mRNA level. a) MCF7 cells were 
treated with 200 µM of H2O2 for 24 h before harvested for realtime-PCR analysis. b)  MCF7 
cells were treated with 0.5 mM of diamide for 24 h before harvested for realtime-PCR 
analysis. Results are representative or mean of 3 independent experiments +/- SE. 
 
Different 5’ deletion constructs of the mouse NHE1 promoter was transfected into 
MCF7 to determine the important region for NHE1 promoter activity (Fig. 48a). The 
mouse promoter activity of NHE1 is similar to the full length 1.1kb promoter up to 
the 0.15kb region. When the 5’ 33bp fragment was removed from the 0.15kb region, 
it resulted in an 80% decrease in promoter activity (Fig. 48b). This shows that the 33 
bp region of DNA contained important transcription binding site for NHE1 gene 
expression in MCF7 cells. The result was similar when we used the human NHE1 
promoter (Fig. 48c). The promoter constructs of the human NHE1 gene was linked to 
a Chloramphenicol Acetyl Transferase gene (CAT) instead of luciferase gene. The 






















































statistical difference (Fig. 48d). Subsequent deletion of the 5’ end of the promoter 
resulted in a significant decrease in promoter activity.  
Multiple sequence alignment of the 0.15 kb promoter sequence of various animal 
species shows a high conservation of the entire region (Fig. 48e). This evolutionary 
conservation suggested that important and common transcription factors bind to this 





































































Figure 48: 0.15kb region of NHE1 promoter is highly conserved and important for 
NHE1 transcription. a) Different 5’ deletion constructs of mouse NHE1 promoter. b) MCF7 
cells were transiently transfected with different 5’ deletion constructs of mouse NHE1 
promoter. Cells were co-transfected with renilla plasmid for normalization. Results are 
obtained from the mean of 4 independent experiments +/- SE. c) Different 5’ deletion 
constructs of human NHE1 promoter.  d) MCF7 cells were transiently transfected with the 
human NHE1 promoter plasmids -1374/+16, -252/+16 and -92/+16. Cells were co-transfected 
with renilla plasmid for normalization. CAT assay was carried out to assess the promoter 
activities. Results are obtained from the mean of 3 independent experiments +/- SE. e) NHE1 
promoter sequence from various species was extracted from Pubmed database and underwent 
multiple sequence alignment using ClustalW function in Jarview software. Results shown are 

























































Next, we ask if the stretch of 33 bp region at the 5’ end of the 0.15kb NHE1 promoter 
is the H2O2 response element in MCF7. Since this short region of the mouse promoter 
and the human promoter are 85 % similar, these promoter regions would most likely 
bind to similar transcription factors (Fig. 49a & 49b). Oligonucleotides corresponding 
to this region of 0.15kb human NHE1 promoter were synthesized for the subsequent 
EMSA experiment. MCF7 nucleus extract was pretreated with various concentrations 
of H2O2 for 20 min before it was allowed to bind to the 40 bp oligonucleotides. Figure 
49c shows that binding of transcription factors to the oligonucleotides decreased with 
increasing concentrations of H2O2. This could be reversed by adding DTT after H2O2 
had been allowed to oxidize the nuclear extracts (Fig. 49d). Taken together, the results 
showed that the 33 bp of DNA sequence at the 5’ end of the 0.15kb of NHE1 













Figure 49: H2O2 prevents binding of transcription factor(s) to NHE1 promoter region. a) 
40 bp of region from 5’ 0.15kb of NHE1 promoter in mouse and human. Underlined sequence 
represents exact 33 bp region between 0.15kb and 0.12kb of NHE1 promoter. b) Alignment of 
the mouse and human 40 bp region from 0.15kb of NHE1 promoter c) MCF7 nuclear extract 
was preincubated with various concentrations of H2O2 for 20 min before the mixture were co-
incubated with oligonucleotides that correspond to the NHE1 human 40 bp region for another 
20 min. EMSA was then carried out according to the Materials and Methods section. d) 
MCF7 nuclear extract was preincubated with various concentrations of H2O2 for 20 min 
before DTT was added to the mixture for another 20 min. The mixture was finally co-
incubated with oligonucleotides that correspond to the NHE1 human 40 bp region for 20 min 
before EMSA was carried out as described in the Material and Methods section. 
H2O2 mM













































3B.2 TRANSCRIPTION FACTOR INVOLVED IN H2O2 DOWN-
REGULATION OF NHE1 EXPRESSION 
 
3B.2.1  Analysis of the region between 0.15kb and 0.12kb of NHE1 
promoter. 
Previously in this section, H2O2 was shown to down-regulate 1.1kb NHE1 promoter 
activity (Fig. 33) and the important region for NHE1 transcription was located in a 33 
bp stretch of nucleotides at the 5’ end of 0.15kb NHE1 promoter (Fig. 34c). This 
0.15kb NHE1 promoter activity is regulated by H2O2 in a reversible oxidative manner 
(Fig. 37 – Fig. 39) and the binding of transcription factors to this short region were 
also shown to be redox regulated (Fig. 49c and Fig 49d). Figure 50 is a diagram 
illustrating the idea behind the down-regulation of NHE1 by H2O2. Firstly, H2O2 
enters the cell and oxidize transcription factor(s) or co-factor(s) involved in the 
transcription of NHE1 gene expression. This then leads to the down-regulation of the 
promoter activity and inhibition of NHE1 mRNA synthesis. 
 
 
Figure 50: Redox regulation of NHE1 transcription at the 0.15kb NHE1 promoter. 
Diagram showing how H2O2 targets transcription factor of NHE1 leading to down-regulation 








3B.2.1.1 Bioinformatics software used to predict transcription factors binding 
to the 40 bp of the 0.15kb NHE1 promoter 
In this section, bioinformatics was used to identify the transcription factors that might 
potentially bind to the 33 base-pair nucleotides at the 5’ end of 0.15kb NHE1 
promoter. We extended the search to 40 base-pair nucleotides at the 5’ end so as to 
not exclude factors that might be binding to the boundary nucleotides. Table 1 shows 
a list of bioinformatics software that was used to predict transcription factors binding 
to the 40 bp of DNA sequence. 
AliBaba 2 is a tool for prediction of transcription factor binding sites by context 
dependent matrices generated from TRANSFAC 3.5 public sites (Grabe, 2002). 
ConSite is a user-friendly, web-based tool for finding cis-regulatory elements in 
genomic sequences. Predictions are based on the integration of binding site prediction 
generated with high-quality transcription factor models and cross-species comparison 
filtering (phylogenetic footprinting) (Sandelin et al., 2004). ConSite uses the JASPAR 
database, an open-access and non-redundant collection of curated profiles (Sandelin et 
al., 2004). 
TESS is a web tool for predicting transcription factor binding sites in DNA sequences. 
It can identify binding sites using site or consensus strings and positional weight 
matrices from the TRANSFAC, JASPAR, IMD, and CBIL-GibbsMat database 
(Schug, 2008).  
Patch is a search data base for potential transcription factor binding sites with the 
pattern search program using TRANSFAC 6.0 public sites (contributed by Jochen 




Table 1: Software used in the analysis of the 40 bp of 0.15kb NHE1 promoter. 
 
Transcription factor prediction software Database used 
AliBaba 2 TRANSFAC v3.5 
ConSite JASPAR 




Patch TRANSFAC v6.0 
 
 
3B.2.1.2 Transcription factors predicted to bind to the 40 bp of 0.15kb NHE1 
promoter 
As shown in Table 2, AP2, SP1 and COUP were predicted to bind to the 40 bp of 
NHE1 promoter region by at least two of the transcription factor prediction software. 
The predicted sites of transcription binding are shown in Figure 51. The binding of 
AP2 to DNA is flexible and the consensus sequences reported for AP2 are GCC N3 
GGC, GCC N4 GGC and GCC N3/4 GGG (Mohibullah et al., 1999). However, the 
possible AP2 binding sites predicted by the various software did not match the above 
AP2 consensus sequence. This could be due to the flexibility of AP2 binding sites 
found in various targeted genes. Indeed, Dyck have found the site GGCGACAGGG 
on the NHE1 promoter to be an AP2 binding site (Dyck et al., 1995). The consensus 
sequence of SP1 is GGGCGG or its variants (Silverman and Drazen, 2000; Honda et 
al., 1997). Two possible SP1 binding sites were found on the 40 bp of NHE1 
promoter region: GGGCGA and GGGCCG. A potential COUP binding site 
(GTGTCA) was also found on the 40 bp sequence. This predicted site differs from the 















Table 2: Transcription factors predicted to bind to the 40 bp nucleotide sequence of 
0.15kb NHE1 promoter. 
 
Transcription factor predicted Software used 
AP2 Data from Dyck, ConSite, Patch, AliBaba 2 and TESS 
SP1 AliBaba 2 and Patch 









Figure 51: Predicted transcription factor binding sites. Predicted binding sites for a) AP2, 
b) SP1 and c) COUP transcription factor. 
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3B.2.2  Transcription factor AP2, SP1 and COUP 
3B.2.2.1 AP2 
AP2 or Activating Protein 2 is a family of transcription factors that consist of 5 
members in human and mice namely AP2α, AP2β, AP2γ, AP2δ and AP2ε. All AP2 
proteins share a highly conserved helix-span-helix dimerization motif at the carboxyl 
terminus, followed by a central basic region and a less conserved domain rich in 
proline and glutamine at the amino terminus (Eckert et al., 2005). The proteins are 
able to form hetero- as well as homodimers. The helix-span-helix motif together with 
the basic region mediates DNA binding and the proline- and glutamine-rich region is 
responsible for transactivation. AP2 has been shown to be flexible in its binding to 
DNA sequence. It has been shown to bind to GCCN3GGC, GCCN4GGC and 
GCCN3/4GGG (Mohibullah et al., 1999; Hilger-Eversheim et al., 2000). Other than 
the consensus sequence, AP-2 proteins have been shown to bind to a range of G/C-
rich elements with variable affinities (Mitchell et al., 1987). AP2 is involved in cell 
proliferation and differentiation (Duan and Clemmons, 1995; Gaubatz et al., 1995; 
Newman et al., 2000) 
AP2 was reported to bind to the proximal promoter end at −95 to −111 bp from the 
start site of mouse NHE1 promoter (Dyck et al., 1995). Deletion of distal promoter 
sequence up to AP2 binding site decreases promoter activity by 25% in both NIH 3T3 
and p19 embryonal carcinoma (Dyck et al., 1995; Dyck and Fliegel, 1995). Deletion 
of the AP2 site abolishes most of the promoter activity, suggesting that the AP2 site is 
important in the transcription of NHE1. 
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 3B.2.2.2 SP1 
SP1 or Specificity Protein 1 is a transcription factor found ubiquitously expressed in 
mammalian cells. It belongs to the Specificity Protein/Krüppel-like Factor (SP/KLF) 
transcription factor family, which is characterized by the highly conserved DNA 
binding domain with three adjacent Cys2His2-type zinc fingers (Suske et al., 2005). 
SP1 binds to GC rich region on gene promoters (Briggs et al., 1986). There are more 
than 12,000 sites in the human genome found to be SP1 binding sites and these sites 
are associated with various genes involved in almost all cellular processes (Cawley et 
al., 2004). SP1 also transactivates synergistically with a large variety of transcription 
factors by binding DNA cooperatively or by recruiting the basal transcription 
machinery synergistically (Wierstra, 2008). So far, SP1 have not been shown to be a 
transcription factor for NHE1. 
 
3B.2.2.3 COUP-TF 
COUP-TF or Chicken ovalbumin upstream promoter transcription factor belongs to 
the orphan subfamily of the nuclear receptor superfamily of steroid/thyroid hormone 
receptor. There are 2 COUP genes, COUP-TFI and COUP-TFII. Members of the 
nuclear receptor superfamily share similar structures such as N-terminal ligand-
independent activation domain, a highly conserved DNA binding domain (DBD), a 
hinge region and a ligand binding domain (LBD) (Tsai and O'Malley, 1994). COUP-
TFs bind to a consensus sequence of (A/G)G(G/T)TCA (Guo et al., 2001). They are 
involved in regulation of embryonic development and neuronal cell fate determination 
(Tsai and Tsai, 1997). 
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The COUP-TFs have been reported to be involved the transcription of mouse NHE1 
at the distal end of NHE1 promoter (Fernandez-Rachubinski and Fliegel, 2001). Study 
showed that nucleotides at -829 to -824 are critical for COUP-TF binding. 
 
3B.2.2.4 AP2 and SP1 are redox regulated 
AP2 had been reported to be oxidizable by H2O2 and diamide, which inhibited its 
DNA binding activity to synthetic AP-2 oligonucleotides (Huang and Domann, 1998). 
The oxidation of AP2 is reversible by reducing agents such as DTT and BME. The 
mechanism of action might be via the oxidation of reactive cysteine residues in the 
AP2 DNA binding domain. 
SP1 has also been reported to be a redox regulated gene. It was found that thioredoxin 
alone, or in conjunction with the full thioredoxin system can increase SP1 DNA 
binding activity in vitro to oligonucleotides containing the SP1 consensus sequence 
(Bloomfield et al., 2003). Another report showed that when young mouse nuclear 
extracts were treated with H2O2, there was a drastic decrease in the SP1 DNA-binding 
activity which can be restored by the treatment with high concentrations of DTT 




3B.2.3  Investigation of AP2 as transcription factor for NHE1 
Based on the fact that AP2 has been shown to be redox regulated and found to bind to 
the 33 bp region at the 5’ end of 0.15kb NHE1 promoter (Dyck et al., 1995; Huang 
and Domann, 1998), we hypothesize AP2 to be the target transcription factor involved 
in H2O2-induced down-regulation of 0.15kb NHE1 promoter. H2O2 could oxidize AP2 
and prevent it from binding NHE1 promoter, thus resulting in the down-regulation of 
promoter activity and NHE1 mRNA level. In order to test this hypothesis; we first 
need to know which isoform of AP2 is present in NIH 3T3 cells.  
Mouse AP2 expression plasmid for each of the five AP2 isoforms and the empty 
plasmid were obtained from Dr. Bruce D. Gelb, Center for Molecular Cardiology, 
Mount Sinai School of Medicine, USA. The plasmids were transfected individually 
into NIH 3T3 cells. Cells transfected with the empty plasmid have no AP2 isoform 
over-expressed, but contains the endogenous AP2 isoform. As the AP2 cDNA have 
been cloned into pCDNA6V5His plasmid containing a V5 epitope tag, we can detect 
over-expression of the isoforms using V5 specific antibody in western blot. Figure 
52a shows that the different isoforms of AP2 have been expressed in NIH 3T3 cells. 
To determine which isoform is present endogenously, we transfected another set of 
NIH 3T3 cells with the plasmids and analyzed the mRNA expression using realtime-
PCR. Five TaqMan probes which detect specific AP2 isoforms were obtained. For 
each of the TaqMan assay using a specific AP2 isoform probe, the sample from the 
cells over-expressing the particular isoform, and sample from the empty plasmid 
expressing cells were assayed. The AP2 plasmid-transfected sample acts as the 
positive control for that particular isoform being detected. The cells transfected with 
the empty plasmid acts as the test of which isoform of AP2 is endogenously present. 
Figure 52b to Figure 52f show the amplification plots of realtime-PCR assay detecting 
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for AP2α to AP2ε mRNA respectively. Specific AP2 isoform mRNA was detected 
from the positive control sample in the individual assay, but no signal was picked up 
from the empty plasmid sample except in AP2α assay. This set of data suggests that 










































Figure 52: AP2α isoform is present in NIH 3T3 cells.  NIH 3T3 cells were transfected with 
6 µg of either pCDNA 6.1 empty vector, AP2α, AP2β, AP2γ, AP2δ or AP2ε using SuperFect 
according to protocol in the Material and Methods section. Cells were harvested for a) 
western blot analysis or b) AP2α mRNA, c) AP2β mRNA, d) AP2γ mRNA, e) AP2δ, and f) 



























































































































To determine if AP2α is indeed expressed in NIH 3T3, anti-AP2α antibody was used 
to probe for AP2α protein in western blot. AP2α siRNA was used to knockdown 
AP2α to ensure the specificity of the antibody used. Figure 53a shows that AP2α is 
expressed exclusively in the nucleus with very little to no AP2α in the cytosol. The 
siRNA targeting AP2α was able to knockdown AP2α protein. Transfection of the V5-
tagged AP2α in to NIH 3T3 resulted in an increase in AP2α protein detected by the 
AP2α antibody. Silencing of AP2α also resulted in the disappearing of the band (Fig. 
















Figure 53: AP2α is present in the nucleus in NIH 3T3 cells. a) AP2α in NIH 3T3 was 
silenced with various concentration of AP2α siRNA using Lipofectamine RNAiMAX reagent 
as described in the Materials and Methods section. Cells were harvested 48 h post transfection 
and fractionated into cytosolic and nuclear fraction using NE-PER kit as described in the 
Materials and Methods section. b) NIH 3T3 cells were over-expressed with 6 µg of either 
empty vector pCDNA 6.1 or AP2α. AP2α of another set of cells were silenced with 10 nM of 
AP2α siRNA or control siRNA. Cells were harvested 48 h post transfection and nucleus was 
isolated using NE-PER kit. 
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Having established that AP2α is expressed in NIH 3T3, the effects of over-expressing 
AP2α on NHE1 expression was examined. First, the amount of plasmid required to 
achieve good expression of AP2α was optimized. NIH 3T3 cells were transfected with 
2, 4 or 6 µg of either empty plasmid or AP2α plasmid for 48 h before harvesting for 
western blot analysis. As shown in Figure 54a, 2 µg of AP2α plasmid hardly 
increased the level of AP2α in the cells while 4 and 6 µg of the plasmid gave large 
increase in AP2α expression. However, at the protein level, NHE1 was not increased 
both at the pre-mature form or the mature form at 48 h post-transfection. In order to 
determine when AP2α start to be expressed, 6 µg of AP2α plasmid was transfected 
into NIH 3T3 cells and harvested at 24, 48 and 72 h post transfection. From Figure 
54b, it was observed that at 24 h, the cell were already expressing high level of AP2α 
protein and it remained high up to 48 h before it started declining at 72 h post-
transfection. Since the cells have already been expressing high level of AP2α from 24 
h to 48 h, NHE1 would have been given the time to be expressed. However, NHE1 
protein expression remained similar to that of empty plasmid up to 72 h post-
transfection. The 0.15kb NHE1 promoter was checked for any increase in activity. 
Figure 56c represented over-expression control for Figure 54d and 54e. No increase in 
the 0.15kb promoter activity was observed when AP2α was over-expressed (Fig. 56d). 
Although there was a slight increase in the level of NHE1 mRNA, it was statistically 













































































































Figure 54: Over-expressing AP2α does not affect NHE1 expression. a) NIH 3T3 cells 
were transfected with 2, 4, or 6 µg of empty vector or AP2α plasmid overnight as described in 
the materials and methods section. Cells were harvested 48 h post-transfection. b) NIH 3T3 
cells were transfected with 6 µg of empty vector or AP2α plasmid overnight and harvested at 
24 h, 48 h or 72 h post-transfection. Cell lysates were analyzed by western blot. NIH 3T3 
cells were transfected with 6 µg of empty vector or AP2α plasmid overnight and harvested at 
48 h post transfection. Cell lysates were analyzed by c) western blot, d) luciferase assay for 
NHE1 promoter activity and e) realtime PCR for NHE1 mRNA. Results shown are obtained 




























































































It was showed in Figure 54 that over-expression of AP2α protein did not lead to an 
increase in the amount NHE1 protein, mRNA level or the 0.15kb NHE1 promoter 
activity. However, it is possible that other AP2-like proteins might be involved in the 
transcription of NHE1. To test the hypothesis, a dominant negative form of AP2α 
(AP2∆) which has the activation domain deleted (residues 31-117) was used. This 
form of AP2 is able to bind to the AP2 consensus sequence but is not capable of 
recruiting other co-activators for transcription. When the dominant negative AP2 sits 
on the NHE1 promoter, other AP2-like transcription factors would not be able to bind 
to the DNA sequence. This should result in a decrease in NHE1 transcription. Figure 
55a shows that the transfection of AP2∆ was efficient for 2, 4 and 6 µg of plasmid 
tested. Using 6 µg of AP2∆, we tested the expression of AP2∆ and NHE1 over 72 h. 
AP2∆ was expressed from 24 h and the level remained high up to the 72 h tested (Fig. 
55b). The level of NHE1, both immature and mature forms, were however unaffected 
by the over-expression of AP2∆. In addition, the 0.15kb NHE1 promoter activity was 
also similar to that of the empty plasmid control (Fig. 55d). Along the same line, the 

















































































































Figure 55: Over-expressing AP2 dominant negative does not affect NHE1 expression. a) 
NIH 3T3 cells were transfected with 2, 4, or 6 µg of empty vector or AP2∆ plasmid overnight 
as described in the materials and methods section. Cells were harvested 48 h post-transfection. 
b) NIH 3T3 cells were transfected with 6 µg of empty vector or AP2∆ plasmid overnight and 
harvested at 24 h, 48 h or 72 h post-transfection. Cell lysates were analyzed by western blot. 
NIH 3T3 cells were transfected with 6 µg of empty vector or AP2∆ plasmid overnight and 
harvested at 48 h post transfection. Cell lysates were analyzed by c) western blot, d) luciferase 
assay for NHE1 promoter activity and e) real-time PCR for NHE1 mRNA. Results shown are 

























































































Over-expression of AP2α has no effect on either the level of protein or mRNA of 
NHE1 or on the promoter activity of NHE1. This could be due to the efficient 
transcription by endogenous AP2α or insufficient cofactors required to increase 
transcription. However, the expression of dominant negative AP2 was also unable to 
affect NHE1 transcription. This led us to speculate that AP2 or AP2-like transcription 
factor are in fact not involved in transcription of NHE1. To test this hypothesis, the 
endogenous AP2α was silenced using siRNA and its effects on the level of NHE1 
protein and mRNA, and 0.15kb NHE1 promoter activity was examined. Figure 56a 
shows the efficient silencing of AP2α where more than 90% knockdown was 
observed. Protein level of NHE1 remained unchanged. The mRNA level of NHE1 
when AP2α was silenced was the same as that of control cells (Fig. 56b). The 0.15kb 
NHE1 promoter was also unaffected by the depletion of AP2α in the cells (Fig. 56c). 
Finally, to show that AP2α is not involved in the down-regulation of NHE1 by H2O2, 
we silenced AP2α and treated the cells with H2O2 for 24 h. Results showed that the 
promoter activity of AP2α depleted cells was still down-regulated when treated with 
H2O2 (Fig. 56d). This set of data confirmed that the target of H2O2 is a transcription 
factor other than AP2α. 
From the bioinformatics analysis, SP1 and COUP have been identified as potential 
transcription factor for NHE1 in addition to AP2. It would be interesting to investigate 
if they are indeed able to regulate transcription of NHE1. Of particular interest would 
be SP1, as it was been reported to be a redox-regulated gene. Future work would 
involve verifying SP1 as the transcription factor for NHE1 and determining what role 



















































































































Figure 56: Silencing AP2α does not affect NHE1 expression. AP2α in NIH 3T3 was 
silenced with 10 nM AP2α siRNA or control siRNA. Cells were harvested at 48 h post 
transfection and cell lysates were analyzed by a) western blot, b) real-time PCR for NHE1 
mRNA and c) luciferase assay for NHE1 promoter activity. d) AP2α in NIH 3T3 was silenced 
with 10 nM AP2α siRNA or control siRNA and cells were treated with 50 µM of H2O2 at 24 h 
post-transfection for another 24 h. NHE1 promoter activity using luciferase assay was 
assessed. Results shown are obtained from the mean of 3 independent experiments +/- SE. p-
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CHAPTER 4: DISCUSSION 
4.1 REDOX REGULATION OF ERα  
Recent world estimate revealed that breast cancer is the most common cancer that 
affects women (Jemal et al., 2009), and it is the leading cause of death in women 
between the ages of 35 and 45 (Stoica et al., 2000). Of all the breast cancer patients, 
approximately 60% of them are ERα-positive and their tumor growth is often 
stimulated by estrogen through ERα (Dickson and Lippman, 1988; Jacquemier et al., 
1990). Other than being an important prognosis marker that correlates with better 
survival rate, ERα is also the target of endocrine therapy (Stoica et al., 2000). The 
clinical relevance of ERα makes it an important target to study. Although research on 
ERα has been ongoing for the past 30 years, there are aspects of the receptor which 
have not been fully explored. One such aspect that we have identified is the regulation 
of ERα by ROS. 
ROS have been found to be up-regulated and implicated in the pathogenesis of a 
variety of diseases including breast cancer. Many anti-tumorigenic drugs have also 
been shown to produce ROS. While ERα transcriptional activity has been reported to 
be redox regulated, the effects of ROS on the expression of ERα remain poorly 
understood. Intrigued by this gap in knowledge, we set out to investigate the 
mechanistic role ROS, in the form of H2O2, on the expression and function of ERα. 
The findings of this study provide new insights to ERα signaling and give rise to new 




4.1.1 Regulation of ERα expression and function by oxidative stress 
4.1.1.1  ERα protein expression is specifically targeted by H2O2/ ROS 
ERα signaling can be controlled at the expression level or at the level of its role as a 
transcription factor that binds ERE. Our experimental data provided evidence that 
ERα expression, but not ERβ expression, is a target of H2O2-meditated down-
regulation in MCF7 breast cancer cells. The down-regulation of ERα protein can be 
observed as early as 8 h after H2O2 treatment. And it occurs regardless of the 
availability of estrogen. This indicates that estrogen does not participate in the 
suppression of ERα by H2O2. H2O2 was also shown to down-regulate ERα protein in 
T47D, another breast cancer cell line, which suggest that H2O2-mediated suppression 
of ERα is a general phenomenon in ERα-positive breast cancer cells.  
Our data is in contrast with another report which looked into the response of ER to 
oxidative stress. Tamir et al did not find a down-regulation of ERα when MCF7 or 
T47D were treated with H2O2 but instead found an up-regulation of ERβ (Tamir et al., 
2002). The discrepancy in the results is most likely due to the difference in the 
concentration of H2O2 used in the two systems. The authors of that paper used a very 
low concentration of 2.5 µM of H2O2 whereas we found that suppression of ERα 
expression occurs only when the cells are exposed to at least 50 µM of H2O2. It 
should be noted that the concentrations of H2O2 (100 and 200 µM) used in our present 
study was considered to be sub-lethal levels (Barnouin et al., 2002). In alignment with 
our findings, another research using glucose oxidase system which produces H2O2 in 
the medium, reported down-regulation of ERα in 24 h (Weitsman et al., 2009). 
However, the amount of H2O2 the cells were exposure to in Weitsman’s study was not 
specified, as glucose oxidase system produces H2O2 in a continuous manner with the 
amount of H2O2 produced dependent on the units of enzyme used. Although it was 
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not known how ERα was down-regulated by glucose oxidase, proteosomal 
degradation was suggested as its mechanism of action. This hypothesis was tested by 
us and was found to be incorrect in our system. 
Apart from H2O2, peroxynitrite was shown to be able to down-regulate ERα protein 
expression. Therefore, the down-regulation of ERα might be a general phenomenon 
that can be mediated by different species of ROS. It remains to be tested whether 
other species of ROS such as superoxide and hydroxyl radical are able to repress ERα 
expression. Through these findings, we propound that chemotherapeutic agents that 
produce H2O2 or ROS might also be able to down-regulate ERα in breast cancer cells.  
 
4.1.1.2  ERα mRNA level is regulated by H2O2: A novel finding 
ERα expression can be regulated at the level of protein degradation (Wijayaratne and 
McDonnell, 2001; Wang et al., 2009), transcription (Huang et al., 2006; Sundar et al., 
2008) and mRNA stability (Saceda et al., 1998; Kenealy et al., 2000; Ing and Ott, 
1999). We tested the hypothesis that the down-regulation of ERα by H2O2 is due to 
proteosomal degradation, by inhibiting proteosome with MG132. However, inhibition 
of the proteosome was unable to restore ERα protein level. Having ruled out increased 
ERα protein degradation as the mechanism of ERα down-regulation by H2O2, we 
moved on to examine the abundance of ERα mRNA in H2O2 treated and untreated 
cells. The data showed that the ERα mRNA level was drastically decreased as early as 
4 h upon treatment with H2O2. This finding is significant as it is the first study to 
demonstrate that ERα mRNA level is decreased in response to H2O2 treatment. In 
addition, it is very likely that the observed down-regulation of ERα protein by H2O2 
was a result of the decrease in ERα mRNA level. 
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Besides ERα, H2O2 has also been shown to decrease the mRNA of other genes. One 
group which studied the effect of oxidative stress on the plasma membrane Ca2+ 
extrusion systems in hippocampal neurons found that Na+/Ca2+ exchangers were 
significantly down-regulated at the mRNA level after 2-3 h exposure to 300 µM H2O2 
(Kip and Strehler, 2007). Along the same line, the mRNA level of CdK2 is decreased 
after oxidative stress in human diploid fibroblasts exposure to 150 µM of H2O2 
(Frippiat et al., 2003). Furthermore, H2O2 could partially block the mRNA expression 
of CD28 in Jurkat T cells (Ma et al., 2003).  
The down-regulation of ERα mRNA could be the result of either of the following two 
possible mechanisms or a combination of both the mechanisms. The first mechanism 
is that H2O2 suppresses the transcription of ERα. Apart from the basal transcription 
machinery, genes recruit sequence specific transcription factors to sit on the 
enhancer/silencer region of DNA adjacent to the regulated genes to promote or silence 
gene expression. These transcription factors often have activation domains that will 
recruit other co-regulators to help in regulation transcription (Latchman, 1997). The 
timing and amplitude of gene transcription depend on the type of transcription factors 
and co-regulators being recruited. H2O2 could be targeting the specific transcription 
factor or co-regulator involved in the transcription of ERα. This can happen via direct 
oxidation of these proteins, causing them not to bind to the DNA or not being able to 
be recruited to promote transcription (Ammendola et al., 1994; Huang and Adamson, 
1993; Huang and Domann, 1998; Liang et al., 1998).  The transcription factor or co-
regulators could also be degraded in response to oxidative stress. With the ERα gene 
containing at least 7 promoters, the transcriptional regulation of ERα is highly 
complex (Kos et al., 2001). Additional experiments such as cloning of these 
166 
 
promoters would be needed to determine if H2O2 down-regulate ERα through 
decreasing its transcriptional activity. 
The turnover of the mRNA also plays an important role in the control of gene 
expression. In mammalian cells, the abundance of a particular mRNA can fluctuate 
drastically following a change in the mRNA half-life, without any alteration in 
transcription rates (Ross, 1995). Another possible mechanism that leads to decreased 
in ERα mRNA level is through decrease in the stability of the synthesized mRNA. 
The half-life of ERα mRNA was previously determined to be 4-5 h (Saceda et al., 
1998; Kenealy et al., 2000). Treating cells with E2 causes the half-life of ERα mRNA 
to drop from 4 h to 40 min. Similarly, Trichostatin A and 5-Aza 2'deoxycytidine can 
also decrease ERα mRNA and protein levels by decreasing ERα mRNA stability 
(Pryzbylkowski et al., 2008). An mRNA with a shorter half-life will be less abundant 
at any given time, leading to lower translation and decreased protein expression.  
 
4.1.1.3  The transient nature of H2O2-induced down-regulation of ERα 
expression 
The down-regulation of ERα protein and mRNA level was not permanent but 
transient where the suppression lasted up to 24 h or 48 h depending on the 
concentration of H2O2 the cells were exposed to. This is not surprising as the data 
showed that the growth of the cells was inhibited by H2O2 but the cells were not dying. 
These findings are reminiscent of 1α,25-dihydroxyvitamin D inhibition of ERα 
transcription. ERα mRNA level was first down-regulated 5 h after 1α,25-
dihydroxyvitamin D treatment and subsequently returned to that of untreated cells 
after 24 h (Swami et al., 2000). Such reversible down-regulation and subsequent re-
expression of protein was also observed in the regulation of Bcl-xL expression by 
167 
 
H2O2 in cardiac myocytes (Valks et al., 2003). Bcl-xL in H2O2 treated cardiac 
myocytes was down-regulated in the first 6 h of treatment. The protein was 
subsequently re-expressed through the increase in mRNA level.  
The signaling mechanism that resulted in the down-regulation of ERα was not 
permanent due to the treatment being a one-time exogenous addition. Thus, whatever 
molecules that were affected by H2O2 treatment will return to their basal state after 
some time. Higher concentration of H2O2 elicited a greater response in the cell 
signaling pathway, resulting in a strong down-regulation and took longer for ERα to 
be reexpressed. For example, H2O2 might oxidize the transcription factor of ERα 
preventing it from binding to the ERα promoter thereby inhibiting ERα transcription. 
This oxidized transcription factor might return to its original reduced state through the 
cell’s antioxidant system after some time. Alternatively, the transcription factor might 
get degraded upon H2O2 treatment but new transcription factor would be formed to 
replace the degraded one. As such, ERα transcription would be restored and new ERα 




4.1.1.4  Functional consequences of ERα down-regulation 
4.1.1.4.A ERα-regulated genes response 
The down-regulation of ERα expression can have different functional outcomes. For 
example, the binding of E2 to ERα has been shown to decrease the level of the 
receptor through proteosomal degradation, while ERα response genes expressions are 
increased. On the other hand, hypoxia also down-regulates ERα via proteosomal 
degradation, however, the ER responsive gene, PS2, was found to be down-regulated 
together with the loss ERE-driven reporter transcription (Stoner et al., 2001). 
Consistent with the hypoxia treatment, H2O2 suppression of ERα expression led to the 
disruption of the estrogen responsiveness. This is observed in the loss of ERE-driven 
reporter plasmid transcription. In addition, PR and c-Myc were shown to be estrogen 
responsive genes and the down-regulation of ERα by H2O2 resulted in the decrease of 
their gene expression. Similarly, ERα down-regulation affected E2 signaling by 
decreasing E2-mediated c-Myc expression. Defective ERα DNA-binding activity has 
been found in up to one-third of all ERα-positive breast cancers and is correlated with 
absence of PR expression (Scott et al., 1991). Taken together, our results indicated a 
functional ERα in the MCF7 cell line used and the down-regulation of ERα by H2O2 
led to a loss of E2 responsiveness. 
H2O2 was shown to decrease ERα but not ERβ, therefore, E2 should still be able to 
stimulate ERE through ERβ. On the contrary, the ERE activity in H2O2 treated, ERα 
depleted cells were much lower compared to untreated cells upon E2 stimulation. This 
observation indicates that the ERβ activity upon E2 treatment is low in MCF7 cells 
and most of the estrogen-responsiveness is mediated through ERα. The lower 
transactivation ability of ERβ has also been highlighted by several groups both on 
synthetic and endogenous genes (McInerney et al., 1998; Cowley and Parker, 1999).  
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4.1.1.4.B Growth inhibition 
It is well documented that the lost of ERα results in growth arrest of breast cancer 
cells (Lu et al., 2003; Chow et al., 2004; Sundar et al., 2008). In conjunction with the 
suppression of ERα expression, the growth of MCF7 was significantly inhibited by 
H2O2 treatment. It is likely that the observed anti-proliferative effect of H2O2 on 
MCF7 cells is a functional consequence of ERα down-regulation involving the loss of 
estrogen-mediated signaling. In breast cancers, over-expression of ERα is commonly 
found and has been linked to enhanced proliferation and resistance to apoptosis. ERα 
does so by promoting cells in G0 phase to enter the cell cycle and hastening the G1 to 
S phase transition (Prall et al., 1997; Foster et al., 2001). ERα upon binding to 
estrogen, also stimulates the expression of c-Myc which is a powerful oncoprotein 
involved in cell proliferation, differentiation and apoptosis (Dubik and Shiu, 1988; 
Osborne et al., 2004). Tolhurst et al recently provided evidence that ERα over-
expression led to ligand-independent expression of the estrogen-regulated genes PR 
and pS2, and growth in the absence of estrogen (Tolhurst et al., 2010).  
A few reports have shed light that the ratio of ERα: ERβ is important in controlling 
estrogen regulated proliferation in estrogen responsive cells (Covaleda et al., 2008; 
Treeck et al., 2010). For instance, the ratio of ERα: ERβ expression is higher in breast 
tumors than in normal tissues due to lower expression of ERβ in tumor cells 
(Lazennec et al., 2001). This high ERα: ERβ ratio found in breast cancer cells 
corresponded to a highly proliferative state (Frech et al., 2005). Conversely, low ERα: 
ERβ ratio found in normal mammary cells and in cancer cells made to over-express 
ERβ, correlated with an anti-proliferative state and an induction of terminal 
differentiation (Förster et al., 2002; Ström et al., 2004; Paruthiyil et al., 2004; Frech et 
al., 2005). Treatment of cells with H2O2 decreases the levels of ERα while the levels 
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of ERβ remained unchanged. This resulting low ERα: ERβ ratio could also have 
contributed to the anti-proliferative state in H2O2-treated cells. 
 
4.1.2 Oxidation as the mechanism mediating H2O2-induced down-regulation of 
ERα 
In the present study, pretreatment of the cells with reducing agent DTT prevented the 
down-regulation of ERα by H2O2. Thus, the results suggest that H2O2 induced the 
down-regulation of ERα through a reversible oxidation mechanism in MCF7 cells. 
Our data with diamide mimicked the effects of H2O2 which indicates the involvement 
of thiol oxidation of cysteine residue that might be present in molecules required for 
ERα expression. Others have shown that a number of signaling molecules, including 
receptors (Suc et al., 1998; Liu et al., 1999; Uchida et al., 1999) and downstream 
elements such as G-proteins (Mallis et al., 2001), kinases (Ward et al., 1998; 
Gopalakrishna and Jaken, 2000), phosphatases (Mahadev et al., 2001) and 
transcription factors (Choi et al., 2001) are regulated by reversible oxidation of critical 
cysteine residues (Eaton et al., 2003). 
H2O2 could affect the signaling cascade of kinases and phosphatases, leading to 
alteration of phosphorylation status and activity of cellular proteins such as 
transcription factors and RNA stabilizing factors. For instance, upon treatment of cells 
with H2O2, the small GTPase Ral is activated. Resulting from this is a JNK-dependent 
phosphorylation of FOXO4 transcription factor which leads to the nuclear 
translocation and activation of FOXO4 (Essers et al., 2004). On the other hand, 
mRNA stabilizing factor, HuR has been shown to be regulated by PKCα-dependent 
phosphorylation. This posttranslational modification of HuR by phosphorylation 
represents a critical feature for HuR shuttling from nucleus to cytosol to increase 
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COX-2 mRNA stability (Doller et al., 2007). H2O2 can either activate or inactivate 
PKCα depending on the concentration of the oxidant (Gopalakrishna and Anderson, 
1989; Abdala-Valencia and Cook-Mills, 2006). In the down-regulation of ERα 
expression, one possible scenario is that H2O2 could affect the balance of the kinases 
and phosphatases activities in the cell, leading to the inactivation of transcription 
factors or RNA stabilizing factors involved in the expression of ERα. This would 
decrease the steady-state ERα mRNA level in the cell. 
H2O2 could also oxidize the critical cysteine residues on the DNA-binding domain of 
transcription factors, abolishing their DNA-binding abilities. Indeed, oxidation of 
transcription factors provides a direct regulation of transcription of a particular gene. 
For example, H2O2 and diamide were found to abolish the DNA-binding activity of 
heat-shock transcription factor through oxidizing critical residues within the DNA-
binding domain. This oxidation can be reversed by DTT and Trx (Jacquier-Sarlin and 
Polla, 1996). Although the hypothesis remains to be tested, it is possible that H2O2 
targets the DNA binding domain of transcription factors regulating ERα transcription, 
resulting in the loss of ERα promoter activity. Along the same lines, AP2γ has been 
reported to be a transcription factor for ERα that trans-activates the ERα gene in 
hormone-responsive tumors (deConinck et al., 1995; McPherson et al., 1997; 
McPherson and Weigel, 1999; Schuur et al., 2001; Woodfield et al., 2007). SP1, 
together with USF-1 and ERα, have also been shown to be essential for ERα gene 
transcription (deGraffenried et al., 2002; deGraffenried et al., 2004). As mentioned in 
section 4.3.2.4 of the results section, both AP2 and SP1 had been shown to be redox-
regulated transcription factors. The oxidation of these transcription factors has also 
been found to be reversible by DTT treatment. Therefore, further research is warrant 
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to establish if these transcription factors are involved in H2O2-mediated down-
regulation of ERα. 
 
4.1.3 Significances of ERα as a redox regulated gene 
4.1.3.1  Potential clinical relevance 
Resistance to apoptosis is a major hindrance in the treatment of cancer, and 
proliferative factors such as ERα play an important role in this resistance (Lee and 
Nam, 2008). The use of Selective Estrogen Receptor Modulators (SERMs), 
particularly tamoxifen, which competes with E2 in binding to ERα have proven to be 
effective in the treatment of breast cancer (Gronemeyer et al., 2004). However, 
resistance to tamoxifen is a major obstacle in the management of breast cancer. 
Intrinsic resistance occurs in approximately 40 % of ERα-positive tumors where the 
cancer cells fail to initially response to tamoxifen treatment. Acquired resistance can 
occur when changes in ERα signal transduction pathways convert inhibitory SERM 
ERα complex to a growth stimulatory signals. (Jordan, 2004). Alterations in signal 
transduction pathways which lead to ligand-independent activation of ERα via 
phosphorylation can also be involved in tamoxifen resistance (Pearce and Jordan, 
2004). Most resistant breast tumors remain ERα-positive and frequently respond to 
alternative endocrine treatment, indicative of a continued role for ERα in breast 
cancer cell proliferation (Ali and Coombes, 2000). The problem of resistance has 
resulted in the search for and the development of diverse therapies designed to inhibit 
ERα action. 
The mechanism underlying many chemotherapeutic agents and ionizing radiation on 
tumor cell kill is the production of ROS leading to oxidative stress (Wang and Yi, 
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2008). The data presented in this study showed that ROS is able to down-regulate 
ERα expression in breast cancer cells. The ability of ROS to suppress total ERα in the 
cancer cells is superior to tamoxifen’s action of just blocking the binding of estrogen 
to the receptor, since depletion of ERα reduces both ligand-dependent and ligand-
independent activation ERα activity. The regulation of ERα expression by ROS 
provides an alternative approach to target the proliferative actions of ERα in breast 
cancer cells. One application of our findings is to target the expression of ERα though 
agents that produces ROS intracellularly in tumor cells.  
It was suggested that cancer cells are more vulnerable to oxidative stress because they 
function with a heightened basal level of ROS mediated signaling. Other than 
decreasing the level of functional ERα as shown in this study, ROS can induce lipid 
peroxidation, DNA damage, and protein oxidation (Schumacker, 2006). ROS have 
been shown to target several proteins that are important in cell signaling events, 
including those involved in cell death or survival, i.e., NFκB, AP-1, H-Ras, MAPK, 
IP3 kinase, PKC-ε, Ras, p53, HIF-1, ASK-1, Bcl-2, caspases, JNK and p38 MAPK 
(Gibellini et al., 2010). Furthermore, ROS were reported to induce apoptosis by 
triggering mitochondrial permeability transition pore opening and release of 
proapoptotic factors (Brenner and Grimm, 2006). Due to their multiple effects 
affecting cell survival, ROS producing agents might be more efficacious than 
conventional ERα targeting drugs such as aromatase inhibitor and fulvestrant in 





4.1.3.2  Inducing down-regulation of ERα through ROS producing agents 
Many of the factors shown to down-regulate ERα have been reported to produce ROS 
in cells. Table 3 shows compounds that have been found to down-regulate ERα and 
the proposed mechanism of down-regulation. Artemisinin and oligomines have been 
found to down-regulate ERα by inhibiting the promoter activity of ERα. Tumor 
necrosis factor α (TNFα), epithelial growth factor (EGF), arsenic trioxide, genestein, 
resveratrol, and 1α, 25-dihydroxyvitamin D could suppress ERα at the mRNA level. 
(-)-Epigallocatechin-3-gallate (EGCG) inhibits ERα function while 15d-PGJ2 down-
regulates ERα through the proteosomal degradation pathway. All the compounds 
mentioned above have been demonstrated to produce ROS in cells. However, the link 
between the down-regulation of ERα and ROS by these agents has never been 
explored.  
In this thesis, the mechanism of how 15d-PGJ2 down-regulate ERα and its 
relationship with ROS was investigated. Previously, ERα was shown to be down-
regulated via proteosome-dependent pathway upon treatment with 15d-PGJ2 (Qin et 
al., 2003). However, in that study, the restoration of ERα by MG132 was only 50 % 
even after using high concentration of the inhibitor. Therefore, proteosomal 
degradation alone cannot fully account for how ERα was down-regulated by 15d-
PGJ2. Our research indicates that the mRNA of ERα was drastically reduced in 24 h 
after 15d-PGJ2 treatment. This is the first report to show that ERα mRNA level is 
affected by 15d-PGJ2. Thus, in addition to the protein degradation, 15d-PGJ2 can also 
down-regulates ERα at the mRNA level. As the mRNA of ERα was almost 
completely down-regulated at 24 h, we propose that the down-regulation of ERα at 
the transcript level is the mechanism which maintains low ERα protein level at later 
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time-points while proteosomal degradation could be responsible for the early down-
regulation of ERα. 
15d-PGJ2 is a natural agonist of PPARγ which binds to PPARγ, resulting in the 
heterodimerization with retinoic X receptor and binding to PPARγ response element. 
This could lead to either the up-regulation or down-regulation of target gene 
expression (Fuenzalida et al., 2007; Burgermeister et al., 2003; Kumar et al., 2009). 
One obvious question when using 15d-PGJ2 is whether the effects that we observed 
on ERα were due to the genomic regulation by the activation of PPARγ. Utilizing the 
computational analysis tool, Peroxisome Proliferator Response Element (PPRE) 
Search program (Kumar et al., 2009), we looked for potential PPRE on the ERα 
promoter A, a promoter selectively engaged by breast cancer cells (Grandien et al., 
1995). The results in Appendix A show that there are two potential PPARγ binding 
sites on the ERα promoter. It is plausible that 15d-PGJ2 affects the expression of ERα 
by activating PPARγ to repress the promoter activity of ERα. However, the down-
regulation of ERα still occurred in the presence of PPARγ antagonist, GW9662. It is 
known that 10 µM of GW9662, the maximum concentration used in our study, is 
sufficient to completely block 15d-PGJ2-induced PPRE-driven luciferase activity in 
MCF7 cells (Wang et al., 2006). And toxic effects were observed when GW9662 was 
used at a higher concentration (Seargent et al., 2004). In line with our findings, 
Lecomte et al also reported that PPARγ was not directly involved in the down-
regulation of ERα by 15d-PGJ2 (Lecomte et al., 2008). Three PPARγ antagonists 
(T0070907, BADGE and GW9662) failed to block the suppression of ERα expression 
induced by PPARγ ligands. Silencing of PPARγ in MCF7 also could not prevent ERα 
down-regulation mediated by 15d-PGJ2, thus, demonstrating a PPARγ-independent 
mechanism (Lecomte et al., 2008). 
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In fact, we found that the effects of 15d-PGJ2 on ERα were mediated through 
intracellular ROS production. The level of ROS was increased dramatically in cells 
treated with 15d-PGJ2 and this is consistent with previous reports (Kim et al., 2008; 
Kim et al., 2009; Shin et al., 2009). Scavenging the ROS with NAC restored the ERα 
protein and mRNA level completely, implicating ROS to be the critical intermediate 
involved in the down-regulation of ERα by 15d-PGJ2 in our system. The ROS 
produced by 15d-PGJ2 has been suggested to be generated through mitochondria and 
NADPH oxidase activation (Shin et al., 2009). The use of catalase could abolish 15d-
PGJ2-induced production of ROS, which implicates H2O2 as the ROS generated (Shin 
et al., 2009). In addition to ROS, RNS was also significantly elevated with 15d-PGJ2 
treatment (Lim et al., 2007). In the current study, the mechanisms for ROS production 
and the type of ROS produced by 15d-PGJ2 are not explored; further research to 
clarify these questions would be required. Suffice to say, H2O2 has been shown to be 
produced in 15d-PGJ2 treated cells (Shin et al., 2009), and therefore, it could 
potentially be the ROS mediating the down-regulation of ERα in our system. 
In summary, our results have demonstrated that ROS produced by drug treatment 
could indeed lead to the down-regulation of ERα. 15d-PGJ2 is able to inhibit breast 
cancer cell growth and suppress ERα expression through ROS production. Other have 
also found 15d-PGJ2 to be effective in killing various cancer cell types, i.e., leukemia 
cells, prostate cancer cells, thyroid papillary cancer cells, colorectal cancer cells, 
glioma cancer cells and oral squamous cell carcinoma cells (Butler et al., 2000; 
Nikitakis et al., 2002; Chen et al., 2002; Cho et al., 2006; Shin et al., 2009). Taken 
together, these observations suggest that 15d-PGJ2 could be a promising 
chemotherapeutic agent in the treatment of breast and other cancers. 
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4.1.4 ROS-induced suppression of ERα gene expression: Possible development 
of ERα-negative breast cancer phenotype 
The majority of literature suggested that most breast cancers, including ER-negative 
breast cancers, arose from ER-positive or otherwise estrogen-responsive progenitor 
cells (Allred et al., 2004). Many breast cancers lost their ERα expression during the 
progression of the cancer, and become ERα-negative. The transition from ERα-
positive to ERα-negative phenotype has been thought to be through various pathways. 
One important way that ERα-negative breast cancer could arise is through 
hypermethylation of CpG island on ERα gene promoter (Leader et al., 2006). In ERα-
negative breast cell lines, DNA methyltransferase 1 (DNMT1) level and activity are 
increased between 2 to 10 folds. This is in conjunction with high levels of methylation 
observed in these cells (Ottaviano et al., 1994). Treatment of these cells with 
inhibitors of DNA methyltransferases, such as 5-azacitidine or decitabine, could elicit 
re-expression of functional ERα protein (Oh et al., 2001). 
Another way to suppress ERα expression is the activation of histone deacetylases 
(HDAC) which remove acetyl groups from lysine residues on histones H3 and H4. 
This results in the formation of a compact structure that diminishes gene activity 
(Pinzone et al., 2004). Treating ERα-negative cells with trichostatin A, an HDAC 
inhibitor, resulted in re-expression of ERα mRNA in these cells in a time- and 
concentration-dependent manner (Yang et al., 2000). 
The hyperactivation of MAPK can also lead to loss of ERα in breast cancer cells (Oh 
et al., 2001). Here, ERα-negative cells were found to have high levels of growth 
factor receptors such as epidermal growth factor receptor or c-erbB-2 which are 
down-stream targets of Raf-1. Inhibiting Raf signaling via treatment with the MEK 
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inhibitors PD 098059 or U0126 resulted in re-expression of ERα in these ERα-
negative cells. 
Interesting, we showed that chronic exposure of ERα-positive cells to H2O2 could lead 
to a sustained low expression of ERα. The ROS production system and antioxidant 
defense of cancer cell are often deregulated, leading to the increase of ROS in cancer 
cells as compared to normal cells. The increase of ROS in cancer cells is thought to be 
involved in the tumor initiation, promotion and metastasis (Wang and Yi, 2008). On 
the other hand, further aberrant de-regulation of the ROS production system in the 
cells could increase the amount of ROS in the cells such that it becomes detrimental. 
Treatment of cancer cells with chemotherapeutic agents could also expose the cells to 
higher amount of ROS (Pelicano et al., 2003; Zhou et al., 2003; Goto et al., 2003; 
Inayat-Hussain et al., 2002). Such chronic increase of ROS in breast cancer cells 
could inhibit cell growth, down-regulate ERα expression and deprive cells of 
proliferative estrogenic signaling pathway. However, due to high adaptability and fast 
mutation rate of cancer cells, a sub-population of them might accumulate enough 
changes in their cellular signaling pathways to overcome the limitations and take 
advantage of the elevated ROS level. This group of cells would be ERα negative and 
capable of growing in the absence of estrogen.  
One example to illustrate this idea is through the fulvestrant-resistance model. 
Fulvestrant is a drug used in the treatment of breast cancer where it depletes the cell 
of ERα by inducing rapid degradation of the receptor (Dauvois et al., 1992). Like 
chronic treatment of cells with ROS, chronic treatment of cells with fulvestrant leads 
to low expression of ERα. One report has shown that breast cancer cells treated with 
fulvestrant grew significantly slower then untreated cells in the initial stage. However, 
after a three month period of growth suppression, these ERα-negative cells began to 
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proliferate in fulvestrant at rates similar to those of untreated wild-type cells 
(McClelland et al., 2001). These cells were found to have increased expression of a 
number of components involved in the EGFR/MAPK signaling pathway which 
allowed them to grow even in the absence of ERα and estrogen. 
Our data suggest that chronic increase of intracellular ROS could be a plausible 
mechanism for breast cancer cells to loss their ERα expression and become estrogen 
independent during tumor progression. Through acquiring additional survival 
mechanisms, such cells can thrive in an ERα-negative state and will no longer be 





4.2 REDOX REGULATION OF NHE1  
It has been demonstrated that cellular redox status plays a role in maintaining 
intracellular pH (Pervaiz and Clément, 2002). Increase of H2O2 in the cell leads to 
intracellular acidification and apoptosis in tumor cells (Clément et al., 1998). NHE1 is 
an important exchanger involved in pHi homeostasis. In addition, NHE1 has been 
shown to facilitate tumor development and maintain tumorigenic phenotype (Reshkin 
et al., 2000). In recent years, we have identified regulation of NHE1 gene expression 
as a possible mechanism involved in ROS-mediated regulation of tumor cell’s 
response to apoptosis (Akram et al., 2006). Further studies have shown that H2O2 
mediates down-regulation of 1.1kb mouse NHE1 promoter via an oxidative and 
caspase dependent mechanism (Kumar et al., 2007). In the present study, we provide 
more evidence to show that H2O2 is the signaling molecule that induces repression of 
NHE1 gene transcription. 
 
4.2.1 H2O2 regulates an important region of NHE1 promoter 
Our results showed that the 0.15kb region of NHE1 promoter was the minimal region 
required for full transcriptional activity in both rat L6 myoblast and human MCF7 
cells. This is reminiscent of previously published data where deletion of NHE1 
promoter up to the 0.15kb region resulted in 25 % decrease in total promoter activity 
in NIH 3T3 cells (Dyck et al., 1995). As shown by us and others, removing the 33 bp 
of DNA from the 0.15kb NHE1 promoter decreased the promoter activity drastically 
(Dyck et al., 1995; Dyck and Fliegel, 1995). In addition, we found high conservation 
between the 0.15kb region of the NHE1 proximal promoter amongst various species. 
This evolutionary conservation highlights the importance of this region for the 
transcription of NHE1 and this region is likely to be regulated by similar set of 
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transcription factors. In this regard, Façanha et al have compared 500 bp of the 
porcine NHE1 promoter sequence with NHE1 promoter of different species. The 
similarity between the porcine, human, rabbit and mouse NHE1 promoter was 78, 76 
and 75 % respectively (Façanha et al., 2000). In line with our conclusion, the authors 
deduced that broadly similar regulatory mechanisms for NHE1 transcription exist 
amongst the different mammalian species.  
 
4.2.1.1   Pattern of regulation 
As the 0.15kb of NHE1 promoter is important for the transcription of NHE1, its 
inhibition suggests that H2O2 is targeting crucial transcription factor of NHE1. H2O2 
was shown to down-regulate the activity of the 0.15kb NHE1 promoter region sharply 
at a low concentration of 50 µM after 24 h. The suppression of 0.15kb NHE1 
promoter activity occurs in two phases. First, there was a slight inhibition at 1 h post 
treatment followed by a return to basal state steadily up to 5 h. The promoter activity 
then decreased from 5 h onwards until 24 h. Cellular antioxidants act as reducing 
agents and protect the cell from damage induced by oxidative stress. An example of 
such antioxidant is GSH. With the help of various GSH peroxidases, GSH functions 
as a major thiol antioxidant to detoxify peroxides (Fratelli et al., 2005). The decrease 
of the promoter activity in 1 h may represent the initial oxidation of transcription 
factor at the 0.15kb promoter. As the amount of ROS introduced is not too high, the 
oxidized proteins could be quickly reversed back by antioxidant systems in the cells. 
However, H2O2 can activate other signaling cascade to result in a second round of 
ROS production which our lab has recently found to be peroxynitrite (Chang, 
unpublished data). Indeed, when exogenous aqueous peroxynitrite was added to the 
cells, 0.15kb NHE1 promoter was down-regulated. Other than NHE1, peroxynitrite 
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has been shown to down-regulate neutrophil surface expression of L-selectin and up-
regulate expression of CD11b in a concentration-dependent fashion (Zouki et al., 
2001).  
 
4.2.1.2  Oxidative nature of H2O2 in suppressing gene expression 
Using thiol antioxidants (NAC), as well as chemical reducing agents, DTT and BME, 
we investigated the nature of H2O2-mediated suppression of 0.15kb NHE1 promoter 
activity. Preincubation of cells with ROS scavenger NAC and reducing agents, DTT 
and BME, prevented the inhibition of 0.15kb NHE1 promoter activity by H2O2. The 
results demonstrate the presence of an oxidation phase in the regulation of NHE1 
transcriptional activity mediated by H2O2. This is similar to our previous study on the 
full length 1.1kb NHE1 promoter, and it suggests that the same transcription factor is 
targeted by H2O2 in the two promoters (Kumar et al., 2007). The data with thiol-
oxidizing agent diamide showed that it mimicked the effect of H2O2 in suppressing 
the 0.15kb promoter activity. Indeed, our experimental data indicates that the 
inhibition of NHE1 promoter activity could involve the oxidation of thiol moiety of 
cysteine residue that might be present in the transcription factors necessary for NHE1 
expression.  
The reversible oxidative inactivation of transcription factors has been proposed to be 
important in cellular response to oxidative stress. Other than the transcription of 
NHE1, human cytochrome P450 1A1 (CYP1A1) gene expression has also been 
reported to be down-regulated by H2O2 (Morel and Barouki, 1998). The transcription 
factor of CYP1A1, nuclear factor I (NFI), contains redox-sensitive cysteine residue at 
the DNA-binding domain which renders it liable to oxidative inhibition by H2O2 
(Morel and Barouki, 2000). It has been suggested that intracellular GSH-dependent 
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pathway could reactivate the DNA-binding activity of NFI proteins during oxidant 
stress through the reduction of oxidation-sensitive cysteine residue on NFI 
(Bandyopadhyay et al., 1998). Our results show that the down-regulation of the 
0.15kb promoter activity by H2O2 lasted for 24 h, after which it started to recover. 
This could signify the reversal of the thiol oxidation of NHE1 transcription factors by 
cellular antioxidant system or new transcription factors being made to replace those 
that were degraded. 
 
4.2.2 Targeting NHE1 expression through ROS-producing agents 
Our lab has previously published that 15d-PGJ2 down-regulated human NHE1 
expression in a PPARγ-dependent manner (Kumar et al., 2009). From computational 
analysis tool, Peroxisome Proliferator Response Element (PPRE) Search, human 
NHE1 promoter was predicted to contain 2 PPARγ binding sites. Using the same 
program, mouse NHE1 promoter was not found to contain any PPRE (Appendix B). 
Interestingly, our experimental data showed that 15d-PGJ2 at 20 µM could down-
regulate NHE1 0.15kb promoter activity. It is logical to believe that the repression of 
the mouse NHE1 promoter activity is PPARγ independent. Indeed, ROS was 
subsequently found to mediate the down-regulation of the promoter activity. Our 
finding is in line with other studies which have documented that many effects of 15d-
PGJ2 is independent of its receptor PPARγ, but rather rely mainly on intracellular 
ROS produced (Kim et al., 2008; Kim et al., 2009; Shin et al., 2009; Lecomte et al., 
2008). For example, the addition of 15d-PGJ2 to rat vascular smooth muscle cells 
resulted in up-regulation of heme oxygenase-1 (HO-1) which cannot be blocked by 
PPARγ antagonist GW9662. Instead, NAC could inhibit the up-regulation of HO-1 
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induced by 15d-PGJ2 completely; suggesting a ROS-mediated activation of HO-1 
expression (Lim et al., 2007). 
Although our previously published data did not implicate ROS as a mechanism for 
NHE1 down-regulation by 15d-PGJ2, we are finding evidences that ROS is produced 
and could also be involved in the down-regulation of NHE1 in human breast cancer 
cells (Zhou, unpublished data). Along the same lines, resveratrol, a polyphenolic 
compound found in red wine, has recently been reported to regulate the expression of 
NHE1 by repressing its promoter activity (Jhumka et al., 2009). H2O2 was found to be 
produced in cells treated with resveratrol and is critical for the suppression of NHE1 
gene expression. Taken together, treatment of cells with ROS-producing agents could 
be an effective strategy to target the expression of NHE1.  
Over-expression of NHE1 has been shown to facilitate tumor development and 
maintenance of tumorigenic phenotype. The down-regulation of NHE1 could sensitize 
human breast cancer cells to drug-induced apoptosis (Kumar et al., 2009). Therefore, 
transcriptional repression of NHE1 could potentially be a promising approach to 
breast cancer therapy. Using 15d-PGJ2, the expression of NHE1 would be suppressed 
through both PPARγ-dependent and ROS-dependent mechanisms. It could also 
decrease the ERα expression through ROS, thus, diminishing the proliferative actions 
of estrogen. The ROS produced by 15d-PGJ2 can induce apoptosis in cancer cells that 
are already stressed by elevated oxidative cellular environment. ROS could also 
regulate various survival proteins such as Akt and JNK so that the cells are geared 
towards growth arrest and finally apoptosis (Shin et al., 2009). As 15d-PGJ2 targets 
multiple survival pathways in the cancer cells; the likelihood of tumor cells 
developing resistance to it would be reduced. As such, 15d-PGJ2 may be a good 
candidate for used as an adjuvant in chemotherapy. 
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4.2.3 AP2 is a transcription factor of NHE1: True or false? 
Out of the three possible transcription factors identified by the bioinformatics 
software as possible transcription factor for NHE1, AP2 was selected for further 
investigation. One main reason was because AP2 has been shown to bind to the 
0.15kb NHE1 promoter in vitro (Dyck et al., 1995; Yang et al., 1996). The second 
reason being AP2 has been reported to be a redox regulated protein where H2O2 could 
inhibit its DNA-binding activity to AP2 consensus sequence ((Huang and Domann, 
1998). Consistent with Huang and Domann’s study, our results also indicate that 
reversible thiol oxidation of a transcription factor could be responsible for the 
inhibition of NHE1 gene expression upon treatment with H2O2. As AP2 has only been 
shown to bind to NHE1 promoter in vitro we sought to determine if AP2 is indeed the 
transcription factor for NHE1 in vivo in NIH 3T3 mouse embryonic cells stably 
expressing 0.15kb of NHE1 promoter. 
Through mRNA detection, AP2α was found to be the only AP2 isoform expressed in 
NIH 3T3 cells. However, when AP2α was knocked down in the cells by up to 90%, 
there was no change in the NHE1 promoter activity, mRNA expression level and 
protein level. Even when AP2α was knocked down, H2O2 could still suppress the 
NHE1 0.15kb promoter activity. Over-expression of AP2α also resulted in no change 
in the NHE1 protein, mRNA level and promoter activity. These data strongly suggest 
that AP2α is not the transcription factor for NHE1 and it is not the target of H2O2-
mediated down-regulation of the 0.15kb promoter activity in our system. Supporting 
our data that AP2 is not the transcription factor for NHE1 in vivo comes from a study 
which examines NHE1 protein expression in transgenic mice lacking AP2α. In it, 18-
day-old AP2α heterozygote mice show no significant changes in NHE1 expression in 
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heart, lung, liver, kidney and brain, while AP2α null mice showed a large increase in 
NHE1 protein expression in the brain (Rieder and Fliegel, 2003). 
 
The discrepancy between our data and the data from Dyck et al could due to 
differences in methods used to address the role of AP2 in NHE1 transcription. While 
our experiments were conducted within live cells, most of the experiments showing 
AP2 as the transcription factor for NHE1 in Dyck’s study were in vitro setups. Using 
EMSA, Dyck showed that purified human AP2α and NIH 3T3 nuclear extract could 
bind to the DNA within the 33 bp region between the 0.15kb and 0.12kb of the NHE1 
promoter. Although this method could provide evidences that a specific protein can 
bind to a specific sequence of DNA in certain conditions, the limitation of EMSA as a 
technique for representing DNA–protein interactions in vivo, is that the physiological 
conditions will not be identical to those used in vitro (Smith and Humphries, 2009). 
EMSA also does not take into account of the chromatin structure and the various 
modifications that take place on the DNA which could enhance or repress 
transcription of a particular gene. In order to supplement the EMSA data, a Chromatin 
immunoprecipitation (ChIP) assay would be the next logical step. The assay uses 
specific antibody that recognizes the transcription factor of interest to pull down all 
DNA sequences that the transcription factor is binding to in the cell. Polymerase chain 
reaction (PCR) is then carried out to determine if the transcription factor binds to the 
specific DNA of interest. Having confirmed that a particular transcription factor binds 
to a certain stretch of promoter region in vivo, silencing of the transcription factor 





The present study has revealed that AP2 might not be the transcription factor 
responsible for the transcription of NHE1. This is a significant finding as it means that 
the transcription factor crucial for NHE1 expression is still not discovered. Using 
bioinformatics, SP1 and COUP were identified as possible transcription factor 
candidates that sit on the 33 bp of DNA between the 0.15kb and 0.12kb of NHE1 
promoter. Attempts have been made to verify SP1 as the transcription factor for 
NHE1 since it has also been shown to be a redox regulated gene. However, different 
sets of siRNA purchased from 2 different companies failed to knockdown gene 
expression of SP1 (Appendix C). Therefore, future work should focus on getting 
effective siRNA for SP1 and COUP to verify if these 2 transcription factors are 
factors binding to the 33 bp 5’ region of 0.15kb NHE1 promoter.  
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4.3 ERα AND NHE1: TWO IMPORTANT MEDIATORS OF CANCER 
CELL SURVIVAL 
ERα and NHE1 are proteins that have distinct functions in the cells. ERα is a 
transcription factor that mediates the effects of estrogen while NHE1 is a pH regulator.  
Although seemingly unrelated, these two proteins play important roles in the survival 
of tumor cells. ERα contribute to tumor cell survival by increasing cell proliferation 
rate through shortening the overall cell cycle time, and enhancing tumor cell’s 
resistance to chemotherapeutic drugs (Teixeira et al., 1995). NHE1 plays a role in 
tumor cell survival by maintaining an alkaline intracellular pH which is unsuitable for 
apoptosis to occur. Tumor cells also exploit the permissive effect of NHE1 on cell 
proliferation where the constitutive activity of NHE1 allows cancer cells to progress 
through cell cycle faster. Thus, both ERα and NHE1 promote cancer cell survival by 
increasing cell proliferation and preventing apoptosis. 
 
4.3.1 H2O2 regulates ERα and NHE1 in similar ways  
In this study, the regulation of ERα and NHE1 by H2O2 were found to be similar in 
various aspects and they are summarized in Table 4. First, both of the genes are 
down-regulated at the mRNA level. The down-regulation of NHE1 mRNA was due to 
H2O2 suppression of NHE1 promoter activity. While it is unclear whether the down-
regulation of ERα mRNA is due to suppression of promoter activity or destabilization 
of the mRNA, it is known that redox sensitive transcription factors are involved in 
ERα transcription. Therefore, it is plausible to think that ERα promoter activity could 
also be suppressed by H2O2. Although the target of H2O2 that leads to the repression 
of these two genes might or might not be the same molecule, it is clear that thiol 
oxidation is involved in the down-regulation both genes. Thus, the target would 
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contain reactive cysteine that is oxidizable by diamide. The oxidative repression of 
these two genes is reversible by reducing agent DTT. In the absence of reducing agent, 
the gene expression is inhibited for 24 h, and started to recover by 48 h. In addition, 
caspase was found not to be involved in the regulation of these two gene expression 
by H2O2. Finally, both genes expression were suppressed by 15d-PGJ2 and this down-
regulation is mediated through ROS production in the cells. 
As proteins important in cancer survival, ERα has long been the target of endocrine 
treatment in breast cancer therapy (Jordan, 2004), while NHE1 has been proposed to 
be a potential chemotherapeutic target (Liu et al., 2008; Lauritzen et al., 2010). It is 
interesting that the expression of these two proteins is regulated by H2O2 in a similar 
manner. These results provide new insight into the mechanistic action of H2O2 on 
gene down-regulation and suggest that H2O2 responsive genes are regulated via 
common signaling pathways. Moreover, our research has given evidences that ROS-
producing chemotherapeutic agents could be used to target ERα and NHE1 expression 
together to negate the survival advantage mediated by these two proteins. Clinically, a 
drug with such combinatorial effects could be use as an adjuvant to enhance the 
efficacy of currently available cancer treatments. 
Table 4: Similarities between the down-regulation of ERα and NHE1 expression by 
H2O2. 
 ERα NHE1 
Down-regulation at mRNA 





Can be thiol-oxidized Yes Yes 




Caspase not involved in 
down-regulation 
Yes Yes, in 0.15kb promoter 
Down-regulated by 15d-




4.3.2 Relevance of ERα and NHE1 expression as prognosis markers in breast 
cancer. 
Over 60 % of patients who have breast cancer express ERα and this group of patients 
generally has better prognosis than the patients who do not express ERα. In addition 
to ERα, we propose that that NHE1 expression level might be a potential prognosis 
marker for breast cancer patients. Some preliminary results from our lab suggest that 
NHE1 expression level is increased in breast cells that are cancerous but not yet 
aggressive. However, the aggressive tumor cells have very low levels of NHE1 
compared to both non-tumorigenic cells and non-aggressive cancer cells.  Appendix D 
shows the results comparing the non-tumorigenic breast cells (184A1 and MCF10A), 
the non-aggressive breast cancer cells (MCF7, SK-BR3, BT-474 and HCC-90) and 
the aggressive breast cancer cells (MDA-231 and BT-594). Supporting this is clinical 
data from 97 patients who have breast cancer (Appendix E). These patients were 
followed up over a median of 6.4 years and study showed with statistical significance 
that those who have high level NHE1 protein in their tumor fared better in terms of 
survival than those who have low level NHE1 expression. When we factor in the ERα 
status of these patients we found that ERα-positive, NHE1-positive patients seemed to 
fare better then ERα-negative, NHE1-negative patients. However, due to the small 
sample size the results are not yet statistically significant. 
Studies have shown that NHE1 is important in the initiation and progression of cancer. 
However, no report had yet associated the decrease in NHE1 with increased 
aggressiveness of breast cancer. Therefore, more research should be conducted to 
further verify the findings and understand the etiology for the loss of NHE1 in 




4.4 FUTURE WORK 
4.4.1 To determine if H2O2 affect the stability of ERα mRNA 
To further understand the molecular mechanism by which H2O2 suppress the gene 
expression of ERα, it is crucial to determine what causes the ERα mRNA level to 
decrease upon treatment. As mentioned in the discussion section, it could be a result 
of either suppression of transcription or increased mRNA instability. Knowing at 
which level ERα expression is being affected would provide new directions for future 
research on H2O2-mediated ERα suppression. Due to the complexity of ERα 
transcriptional regulation, it would be logical to approach this question by addressing 
the mRNA instability of ERα after H2O2 treatment. Through the process of 
elimination, if the mRNA stability of ERα is found not to be affected by H2O2, one 
could deduce that H2O2 targets the transcription of ERα instead. 
Attempts were made to determine if there is any changes in the mRNA stability upon 
H2O2 treatment using classic transcription inhibitor Actinomycin D and 5,6-dichloro-
1-ß-D-ribobenzimidazole (DRB). However, the MCF7 cells used in this study was 
insensitive to treatment with the transcription inhibitors. When used alone or in 
combination, Actinomycin D and DRB could not block the transcription of ERα in 
MCF7 (results not shown). Thus, because of experimental constraint, we were not 
able to determine if the down-regulation of ERα mRNA level was due to a change in 
the half-life of the mRNA. To overcome this limitation, other methods of measuring 
mRNA half-life could be utilized. One way is to employ other pharmacological 
inhibitor such as α-Amanitin which binds to RNA polymerase II and III, preventing 
incorporation of new ribonucleotides into newly synthesized RNA (Cassé et al., 1999; 
Gong et al., 2004). Another approach would be to use pulse chase method where 
radioactive nucleotides are incubated with cells to allow for incorporation of these 
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nucleotides into the RNA. The time-dependent decay of newly synthesized mRNA 
would then monitored (Ross, 1995; Chen et al., 2009). 
 
4.4.2 To investigate the mechanism of ROS-producing compounds in 
suppression of ERα expression  
In this study, we have shown that 15d-PGJ2 inhibits ERα expression through ROS 
generation. In order to further explore the pathway leading to this inhibition, the 
mechanism for ROS production by 15d-PGJ2 in MCF7 cells could be determined. 
Although mitochondria and NADPH oxidase activation have been shown to be the 
source of ROS produced by 15d-PGJ2, it has not been proven in our system. Thus, 
specific inhibitors of the mitochondria complexes and NADPH oxidase could be 
tested for their effects on 15d-PGJ2-induced ROS generation in MCF7 cells. The 
findings obtained could help to ascertain if 15d-PGJ2 produces ROS through similar 
mechanisms in different cell types. In addition, the nature of ROS produced by 15d-
PGJ2 in MCF7 cells should also be investigated. The information derived from this 
work could be used to validate our hypothesis that H2O2 is involved in 15d-PGJ2-
mediated down-regulation of ERα expression. 
Other than 15d-PGJ2, many compounds have been identified to down-regulate ERα 
and shown to produce ROS (Table 3). Further experiments would be needed to test if 
these agents also suppress ERα expression via ROS production. Should it be found 
that ROS is the main mechanism involved in the inhibition of ERα expression by 
these agents, it would provide supporting evidence that redox-regulation of ERα 




4.4.3 To identify the transcription factor that regulates NHE1 transcription 
From the current research, AP2 was found not to be the transcription factor of NHE1. 
As the 0.15kb NHE1 promoter is important for the transcription of NHE1, it would be 
of scientific merit to investigate the transcription factor that binds to this region. This 
work could yield new information for NHE1 transcriptional regulation and allow us to 
further validate the target involved in H2O2-mediated suppression of NHE1 promoter 
activity. 
Other than verifying SP1 and COUP as transcription factors for NHE1 0.15kb 
promoter, another method to identify the transcription factor binding to the 33 bp 
region would be to conduct a protein-DNA binding by streptavidin-agarose pull down 
followed by identification using mass spectrometry (MS). In this method, 
oligonucleotides labeled with biotin are allowed to bind with nuclear extracts. The 
protein complex together with the oligonucleotides is pulled down using streptavidin-
agarose beans. The complexes are subsequently dissociated and the individual 
constituents are resolved by SDS–PAGE and revealed by staining. Proteins are then 
be subjected to limited proteolytic cleavage and analyzed by matrix-assisted laser 
desorption ionization-time of flight (MALDI-TOF) MS. Peptide mass fingerprinting 
in this way allows identification of proteins by comparison with simulated digests of 
expressed protein databases (Drewett et al., 2001). The advantage of this method is 
that no prior knowledge of what might bind to the oligonucleotides is required. It is 
also able to resolve and identify proteins in the complexes that are too large to be 
resolved using EMSA. However, ChIP assay would still be required to confirm the 




4.5 MODEL AND CONCLUSION 
 
 
Figure 57: Model of the down-regulation of ERα and NHE1 by H2O2. 
 
Taken together, our findings provided a new perspective to ERα as a redox-regulated 
protein. Previous research had shown that the ERα DNA-binding is subjected to redox 
modulation. The current study places the gene expression of ERα itself to be targeted 
by H2O2 and potentially by other reactive species. The similarities in the regulation of 
ERα and NHE1 by H2O2 suggested that there might be a common pathway in the 
control of gene expression by H2O2. Further examination of the mechanisms leading 
to the down-regulation of ERα mRNA level would provide better comprehension of 
how H2O2 represses gene expression. The discovery that AP2 is not the transcription 
factor for NHE1 is a major finding that would challenge the scientific community’s 
understanding of NHE1 transcriptional regulation. Thus, it is paramount to investigate 


















emerging evidences are showing that a number of anticancer agents function through 
the production of reactive species such as H2O2 to kill or suppress tumor cells growth. 
Increase of ERα and NHE1 levels in breast cancer have been shown to be involved in 
carcinogenesis and tumor growth. The targeting of ERα and NHE1 expression 
together by ROS could represent a novel approach to shut down breast cancer cells’ 

































Appendix A: PPRE present in human ERα promoter A.  a) 1kb sequence of human ERα 







































































Appendix B: PPRE present in human and mouse NHE1 promoter.  a) 1.4kb sequence of 
human NHE1 promoter. b) Results of bioinformatics analysis of human NHE1 promoter 
using PPRE Search software. c) 1.1kb sequence of mouse NHE1 promoter. d) Results of 






Appendix C: siRNA from two companies failed to knockdown SP1 protein expression. 
SP1 in MCF7 was silenced with various concentration of SP1 siRNA from Santa Cruz and 
Dharmacon using Lipofectamine RNAiMAX reagent as described in the Materials and 







Appendix D: NHE1 levels in different breast cell lines. NHE1 level of different breast cell 






































































































• MCF7 – non-aggressive 
• MDA-MB-231 – aggressive
• SK-BR3 – non-aggressive 
• BT474 – non-aggressive 
• BT549 - aggressive
• HCC70 – non-aggressive 
• MCF10A – non-tumorigenic 








Appendix E: The expression level of NHE1 in tumor tissues is associated with clinical 
outcome. a) Overall survival curves between patients expressing NHE1 and patients not 
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